❌

Reading view

The astonishing toll of America’s food stamp cuts

A child helps load boxes at a California food bank.
A child helps load boxes at a California food bank in January 2026.  | Paul Bersebach/MediaNews Group/Orange County Register via Getty Images

As we head into Thanksgiving, a holiday dedicated to abundance and sharing, millions of Americans are struggling to afford groceries. Children, in particular, are at risk, their parents forced to choose between listening to their baby cry because they’re hungry or watch them shiver because they can’t pay for heating as the weather turns cold.

Many of us have felt the costs of everyday life getting steeper, squeezing people at the gas pump and the grocery store. But some folks are facing not only inflation but the loss of government benefits: Federal assistance for food has been drying up since the Republicans’ One Big Beautiful Bill Act passed last year. According to the estimates from the left-leaning Center on Budget and Policy Priorities, about 5.5 million people have fallen off of the Supplemental Nutrition Assistance Program (or SNAP) between the law’s passage in July 2025 and July 2026 — a 13 percent decline in just one year. About 2 million of the people who lost benefits are children. At this point, SNAP participation has reached a 17-year low, the lowest it’s been since the Great Recession, and not because people don’t need it.

It is as acute of an affordability crisis as any that Americans are facing right now. Nearly 1 in 4 US adults experienced food insecurity in 2025, according to the Urban Institute; 8 percent said in a recent federal survey that their household often or sometimes did not have enough to eat. When people struggle to afford food, they get desperate: Parents start skipping meals so their kids can eat, they delay turning on their furnace when temperatures drop, they can’t afford gas or other basic household needs.

“People are struggling, and we hear that and see that specifically in what is supposed to be an emergency food system, food pantries. They are reporting that they are seeing more people now than the pandemic. It’s not in a good place for families,” Gina Plata-Nino, director of SNAP policy and advocacy at the Food Research & Action Center, told me. “Every family is really feeling this — and what’s supposed to be a buffer when people hit a hard time is being taken away.”

While Democrats spent more time on the campaign trail talking about the OBBBA’s Medicaid cuts, some of them also criticized the GOP for gutting food stamps. In announcing his bid to be House speaker, Rep. Hakeem Jeffries (D-NY) said Democrats should restore SNAP’s funding during their first 100 days in power. A bipartisan deal has been percolating to delay some of the cuts and stem the bleeding.

Congress says they want to address this burgeoning hunger crisis. Now is their chance.

How Trump and the GOP cut food assistance for millions

When writing the OBBBA, Republicans wanted to prioritize cutting down on social services and alleged “fraud, waste, and abuse,” so they passed several measures meant to restrict SNAP eligibility and limit funding for the program.

The law forced more adults to comply with the program’s onerous work requirements, raising the age of people expected to work from 55 to 64 for childless adults. More parents of younger children were also required to meet certain job-related standards in order for their families to continue getting assistance. The law also required states to contribute funding for the program for the first time if their enrollment “error” rates are too high, which has pushed states to require people to reapply for benefits. It also placed new restrictions on how the assistance money could be spent (rolling back previous allowances for utility and internet costs) and, in a sop to the GOP’s anti-immigration hardliners, the law cut eligibility for migrants who aren’t in the US permanently, even if they are here legally.

“Democrats will scream ‘cuts,’ but what they’re really defending is a wasteful program that discourages work, mismanages billions, and traps people in dependency,” House Speaker Mike Johnson said in a statement last June. He put it even more bluntly in an interview with Face the Nation: “We have not cut SNAP.”

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

And yet, millions of people have dropped from the program’s rolls since the OBBBA became law — again, including as many as 2 million children — and not because they were committing fraud or were too lazy to find work. In some states, the decrease has been very steep: Arizona saw its SNAP participation decline by roughly 50 percent in one year. Another nine states — Florida, Illinois, Indiana, Louisiana, Kansas, Nebraska, Nevada, Oklahoma, and Texas — have had their programs’ enrollment drop by more than 20 percent since last summer.

Not all of this decline can be blamed on the Republican bill; even the left-leaning CBPP acknowledges that enrollment had already started to fall before Trump signed it as pandemic-era provisions expired and the economy improved. 

But the rate of decrease has been accelerating in the year-plus since the OBBBA passed, as states crack down on enrollment in order to minimize their cost-sharing responsibilities under the law’s new rules. The legislation penalizes states for paying too much in benefits, and also paying too little, and also if there are any clerical errors in a person’s application. So, for those reasons, states have a strong incentive to simply force everyone to redo the paperwork — and we know from prior experience that more paperwork means more people who should be eligible losing their benefits.

“I think that the thing that is contributing most to the acceleration in the declining enrollment are state-level policy changes related to the cost shift and getting their payment error rate under control,” Lauren Bauer, a fellow of economic studies at the Brookings Institution, told me. It has “prompted states to really tighten their belts and start making it much harder to get on the program, even for people who otherwise would be eligible in the absence of this policy change.”

The new work requirements and other eligibility restrictions have also begun to take effect nationwide, and experts therefore expect the enrollment trends to get worse; Arizona, with its 50-percent decline in SNAP enrollment, could be a preview of what’s to come across the country. 

“I do think that we are in the middle of this story… [This could be] the worst-case scenario of states learning from each other,” Bauer told me, “where Arizona starts telling everybody how they’re doing it and we see catastrophic declines in enrollment among people who otherwise should be eligible because everyone is so scared.”

How bad it gets remains to be seen. But what’s clear at this point is that enrollment has not been shrinking because fewer Americans need this food assistance, as Diane Schanzenbach of Georgetown University wrote for Econofact.

As CBPP’s analysts wrote in their own review of the data: “It’s very unlikely that reduced need is driving the decline in SNAP participation.” Instead, people are getting removed because they have trouble with the paperwork, or they may not even know they need to fill out new paperwork, or the state’s social services office may be inundated with a backlog of applications to check. As more people depend on the gig economy to make ends meet, they may be working unusual hours that make it more difficult to prove they meet the new requirements. 

“What [the One Big Beautiful Bill Act] has done is that it has increased the time tax on families and the red tape,” Plata-Nino said.

And because children only receive assistance through their parents — as opposed to getting it directly, like they do with survivor benefits after a parent dies — kids are particularly vulnerable to losing access because their parent has lost access.

All this means that people are going into credit card debt just to pay for their basic household needs, or are simply going without. “We hear from families who don’t turn on the heat, who only take one bath a week, that only the baby gets warm water, and even in the winter, they’re getting cold water,” Plata-Nino said. “We hear from families who turn on the heating plates to warm up their house because they don’t have it. It really is incredibly challenging.”

And if more people are struggling to afford food because they no longer receive government assistance, that is going to have consequences for their long-term health. One metaanalysis of the relationship between food insecurity and adverse health outcomes found that not having assured access to food was associated with 22 different negative health effects, including stress and depression, poor sleep, diabetes and hypertension, and anemia. 

Kids experience a wide range of negative physical and mental health effects from hunger, which can impact their development for years. And while they have historically been able to rely on getting at least one good meal at school, declining SNAP enrollment also means fewer free school lunches through community eligibility, Bauer said.

“People do turn to the charitable sector. They do turn to friends and family. But there is a reduction in the quantity and quality of food that you intake, and there are consequences to that,” Bauer said. “In terms of your health, both mental and physical, as well as other outcomes — especially for children, in terms of school attendance and school performance.”

In other words, the situation for SNAP is dire as Democrats are coming into power. What now?

What Congress could do to make food more affordable

If there is any good news, it’s that Democrats’ enormous wins in the 2026 midterms are motivating lawmakers to do something about the looming SNAP cuts, potentially even before the new year. Democrats and even some Republicans have been discussing a delay in the new state cost-sharing requirements as part of the larger “farm bill” that Congress wants to pass. And in the past two weeks, a few key elected officials on the right have indicated that they might be willing to agree to Democrats’ preferred two-year delay; House Agriculture Committee chair Glenn Thompson (R-PA) said he is open to negotiating with Dems.

“Every indication is that both sides want to get this done in lame-duck,” Bauer told me. “What the Democrats are going for is a two-year delay to never doing this. That would be the hope.”

The idea is that the two-year delay could, in theory, turn into a permanent one if Democrats can win the White House in the 2028 election and keep control of Congress. Even if the two parties agreed on a two-year delay in the lame duck, Democrats could still include a full repeal of the OBBBA’s SNAP cuts as part of their budget reconciliation bill next year. President Donald Trump won’t sign that bill even if the Democratic-controlled Congress passes it, but Dems could take the opportunity to show voters they are following through on their campaign promises and do a dry run for a bill that could actually become law in 2029.

In theory, if Democrats fully control the government in a couple years, they could not only reverse the GOP’s food-stamp cuts but expand the program. Bauer said they could look at how to make benefits more generous for people and make more people eligible to receive them. And in the long term, a healthier economy that actually lifts up working-class folks is the best way to help people get off government programs; adding a time tax that penalizes the people who really depend on these benefits to get by just ends up pushing them further into poverty.

“People don’t want to be on SNAP,” Plata-Nino said. “They’re just trying. They just don’t make enough because the government has failed in providing those things where people can have enough money to just live on.”

That is still a ways off. For now, the dramatic decline in SNAP enrollment is an emergency happening in slow motion, one that could make the holiday season more stressful and expensive for millions of Americans. But we aren’t powerless: Each of us can call our House representative or senator and urge them to do something about food assistance. And if you have the means, you can donate money to your local food bank and make sure they are well stocked for the winter months ahead. (Recurring donations are ideal, if you can manage it.)

Those are makeshift solutions. A long-term fix to America’s hunger crisis will require Congress to step up and do something.

  •  

The US has officially lost control of measles

A healthcare worker takes down signs at a Maryland vaccine clinic.
A healthcare worker takes down signs at a Maryland vaccine clinic. | Sarah L. Voisin/The Washington Post via Getty Images

This year, the United States has recorded more measles cases — 5,739 as of Tuesday, November 17 — than in the past 25 years combined. There are active outbreaks in New York, Pennsylvania, and across the Midwest. At least eight people have died with measles infections in the US.

None of this is supposed to happen in the 21st century. In 2000, the United States declared that measles had been eliminated. For years, the extremely rare cases the US saw were from people who contracted the virus in another country and brought it back to America; we didn’t have to worry about measles spreading naturally in our communities.

But that’s no longer true. The Pan American Health Organization, which works with the countries in the Western Hemisphere on ongoing public health threats as well as emergency response, made it official Monday after the annual meeting of its measles and rubella elimination commission: The United States’ measles elimination status has been revoked. The virus is once again endemic in America.

It is an international embarrassment for a country that until very recently was the world’s unquestioned global health leader. And for doctors here in the US who have been practicing for decades, it’s an almost-unthinkable development, putting American lives needlessly at risk. The death of a 7-month-old baby in New York state, who was too young to be vaccinated, has made the consequences of the country’s collective failure hauntingly clear. 

“It’s very, very, very surreal,” Dr. Barbara Keber, a family physician in Long Island, New York, told me last week. She’s been practicing medicine for 45 years and is old enough to have gotten measles herself when she was a child. But it was never something she’d had to deal with during her professional career — until now.

“When I had it, my sister had it, my best friend had it — that’s how I saw measles,” she said. “Then it disappeared, and I never saw it as a practicing physician until more recently.”

The reversal has been dramatic. In 2024, there were just a couple hundred measles cases in the US, nothing out of the ordinary. But last year, there were more than 2,000 measles cases and three deaths, and then both of those figures more than doubled in 2026. This year started with a brutal outbreak in South Carolina, and it is winding down with Pennsylvania in crisis and New York state reporting its first measles death in more than 30 years.

It’s impossible to talk about the recent rise of measles without talking about vaccine skepticism. Fears that childhood immunizations cause autism have been growing for years (reminder: they don’t), and the rise of US health secretary Robert F. Kennedy Jr. and a vast network of anti-science activists and politicians has led to widespread distrust in medical science and doctors since the pandemic began. As a result, fewer and fewer American kids are being given their measles shots. Nationwide, the measles vaccination rate is 92.4 percent among kindergarteners, down from 95 percent before the pandemic, which is the threshold public health experts say is necessary to stop the virus from spreading locally. And in some places, the decline has been more severe: In one Texas school district where measles ran wild last year, less than 50 percent of schoolchildren were vaccinated.

Over the past two years, I have spoken with doctors working on the front lines of these outbreaks to better understand what it’s like to face measles, often for the first time, and what they hear from their patients in the midst of an outbreak. I’ve taken away three lessons from those conversations, which serve as both an explanation of how we got here and a guide for what to expect as we try to find our way out of this crisis.

1. Small communities can be the kindling for measles outbreaks

One clear pattern has emerged across the recent outbreaks: They are often sparked in insular communities where anti-vaccine attitudes — sometimes the result of sincerely held religious reliefs — are widespread.

In New York and Pennsylvania right now, for example, measles has taken hold in Amish and Mennonite communities. Last year’s outbreak in Texas started in a Mennonite community as well. A charter school in South Carolina where less than 20 percent of kids were vaccinated against measles was the epicenter of that state’s outbreak. This is a pattern that predates our current measles explosion: When New York endured an isolated outbreak in 2019, it was concentrated in the Hasidic Jewish communities north of New York City.

Even in states like New York, where state officials have actually tried to strengthen school vaccine requirements, some parents in these communities have opted to homeschool their kids; they don’t have to follow those mandates. And when they do go out into the world, where more children may be vaccinated on average, they are increasingly likely to encounter another kid who is also unvaccinated as more families overall opt out of those shots.

That’s the recipe for these massive outbreaks: A lot of unvaccinated kids in one group get infected and then, as they move around the community, they come into contact with those other kids, who are also unprotected.

“These are groups that we have to work very carefully with because they have their religious beliefs. When you speak to them about vaccines, they’re just going to tell you no,” Keber told me. “But the issue there then becomes, well, they might not be being exposed during the school day, but they go and play baseball and they do dance and they do other activities where they’re mixing with other kids.”

In some of these communities, skepticism has remained stubbornly high even in the aftermath of an outbreak. But some people do take the threat of measles more seriously after people get sick around them. Keber told me that fear is not really the most effective message for convincing previously skeptical people to get themselves or their children vaccinated; relationship building over time — even if it takes a couple of conversations — is more effective.

“We’re not trying to scare people. That doesn’t really help anything,” Keber said. “If they get to trust the physician, that’s the biggest bang for the buck. This is somebody that you trust with the health of yourself and your family.”

2. Doctors are still figuring out how to deal with measles in the wild

Measles may be one of the most well-known diseases given its high infectiousness and signature rashes, but because it had been eliminated for so long, many doctors have had only an academic understanding of the virus — at least until these past few years.

“Almost no physicians that are currently practicing medicine have ever seen measles,” Keber said.

When I spoke last year to Dr. Ada Stewart, a family physician in Columbia, South Carolina, who has been practicing medicine for more than 20 years, she told me the same thing. At the time, she and her colleagues were reviewing their old medical school materials to make sure they knew all the signs and symptoms.

“We learned those things in medical school, but we never saw it,” Steward said. “We never had to worry about seeing it.”

When both doctors and patients are a step behind because they’re unfamiliar with measles, the virus can flourish. As Keber told me, somebody who’s not immune to measles has a 90 percent chance of catching it if they are exposed. And people can be contagious up to four days before the telltale skin rashes appear.

The early symptoms can resemble lots of other conditions: high fever, cough, runny nose, or red, watery eyes. Until very recently, Americans and their doctors didn’t have to worry whether those might be signs of a measles infection. But now they do.

“That makes it a little more dangerous than some other things where you know right away if somebody’s sick,” Keber said.

3. It’s going to take a long time to get measles under control

One of the observations that has stuck with me most came from Dr. Andrew Carroll, a family physician in Chandler, Arizona, a suburb outside of Phoenix. He told me there were two groups of people who seemed most fearful about measles when it began to spread locally: The older generation, who remembered what the disease was like, and the youngest patients for whom it was an entirely foreign and frightening pathogen. 

The people in the middle, who grew up at the time the US was successfully stamping out measles and knew it only as a public health victory, were less bothered. It is one of the great dilemmas in public health: When you eradicate a disease, people become less concerned about it — and that can create the conditions for its return. We’re seeing that with measles: a swath new parents, for whom the virus was never a serious worry, are choosing not to vaccinate their own children, and that has helped the virus to surge back.

“It only takes one generation to forget the progress we’ve made on certain things — and one of those is measles,” Carroll told me. “Twenty-five years ago, we were a measles-free nation. Now we’re back one generation later because we forgot how terrible it was.”

And that may mean that, ultimately, it will take another generation coming of age and having their own kids — who, having been chastened by the outbreaks we’re experiencing right now, help vaccination rates recover to the point that we can eliminate measles a second time. 

“We’re going through a cycle, and there will be casualties. There will be needless deaths and illnesses,” Dr. Jason Terk, a pediatrician in north Texas, told me last year. “I think that the only generation that is going to learn from this will be maybe the next one.”

  •  

How the 7 healthcare workers who just got elected to Congress plan to fix our broken system

New members of Congress on Capitol Hill.
Newly elected members of Congress on Capitol Hill. | Andrew Harnik/Getty Images

Last week’s blue tsunami carried a lot of white coats: At least seven newly elected Democrats have medical degrees or nursing careers. Pediatrician Annie Andrews of South Carolina scored one of the most shocking Senate victories of election night for Democrats, while Abdul El-Sayed (who earned a medical degree before working in public health) won the all-important Michigan Senate race. In the House, Democrats will soon welcome pediatrician Richard Pan of California, emergency room physician Amish Shah of Arizona, surgeon Adam Hamawy of New Jersey, emergency nurse Mitchell Berman of Wisconsin, and oncology nurse practitioner Kristina Knickerbocker of Ohio.

Like many Democrats, these candidates campaigned on lowering costs, expanding health coverage, and confronting the drugmakers and healthcare corporations that they accuse of putting profits ahead of patients. They have endorsed big ideas to make healthcare better, from a public insurance option to Medicare-for-all, alongside targeted changes to drug prices and health insurance denials.

With President Donald Trump still in the White House, Democrats’ healthcare agenda faces obvious obstacles in the short term. But I spoke with Pan and Shah this week to learn how they hope to influence the healthcare conversation in Washington going forward. 

They may be politicians, but they have seen America’s broken healthcare up close. They’re hoping to help some of their new colleagues, who may not have those same experiences and may be prone to thinking of policy issues in abstract terms, understand the urgency and the human toll of our messed-up medical system. And as lawmakers try to come up with solutions to fix those problems, they’ll be there to make sure those policies actually make sense in practice.

“For us, these policy discussions are not abstract,” Pan said. “As a practicing physician, I know what it’s like to be on the front lines and have to look a patient in the eye and even tell them that, well, these programs either exist or don’t exist, and we’re not going to be able to get you help. And those are the types of things I have to deal with each time I see a patient.”

What practicing medicine teaches you about politics

The new members will join a small but notable group of providers-turned-politicians: The Congressional Doctors Caucus, founded last year, had six Democratic members before last week’s midterms. Shah, who previously served in the Arizona legislature, told me that he believed his medical career had given him a valuable outlook for thinking about how to serve in political office.

“The core function of practicing medicine is to care for people,” Shah said. “The same should really be true about politics.”

He’s experienced the shocking inequities of US healthcare, and seen its impact on people’s well-being, firsthand. Earlier this year, Shah said, an uninsured woman came into his emergency room department with an allergic reaction. His team treated her successfully. But she was worried about the bill, asking if she might have to pay a $10,000 charge after she was discharged. And Shah told me that he had to be honest with her that she might.

That’s when he learned that his patient was her family’s breadwinner — and that she actually worked in a nearby emergency department. Somebody who helped provide emergency care to others couldn’t afford it herself.

“It’s a tragedy that those of us who actually go out to help others and be part of the team that saves lives can be left without insurance,” Shah said.

Pan, a former California state senator, described a similar experience while treating kids in primary care. He has seen all the ways US health care is lacking: children who don’t get the mental health support they need to excel in school, families that struggle to afford stable housing or find healthy food. His ability to help depended on decisions made well outside his examination room.

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

“These are all things that certainly have potential policy solutions, but it’s not just theoretical,” he told me. “It is very real and tied to very specific patients that I’ve seen.”

But while these experiences have made them eager to change things, the newly elected physicians are also mindful about how proposed changes could disrupt ongoing patient care. Pan said he wants to push his colleagues about both the intended and unintended consequences or new policies: Who will get help? What happens to people whose needs don’t fit neatly into boxes? As any doctor will tell you, every patient is unique.

That’s especially true for people with chronic conditions, he said, who may have spent years finding the right doctors and treatments. Lawmakers have to strike a balance: identifying ideas that will improve the health system in the long term, without jeopardizing the care that people need right now.

Shah said he hopes his experience as a physician can help Congress find a middle ground between the patients demanding reform and the providers who are wary of big changes. After decades in medicine and a stint in the state legislature, he knows the different players and their concerns.

“I speak the language of healthcare,” he said. “I’ve earned the trust of a lot of those stakeholders that I will not take an axe to the system, but rather reform it in a way that really improves it and centers the patient. So that gives me a unique ability to improve this at the congressional level.”

What the new doctors and nurses want to change

These Democratic doctors, like their party’s leaders, have a clear No. 1 priority when they take office next year: reversing the $1 trillion in Medicaid cuts that Republicans passed as part of the One Big Beautiful Bill Act in 2025.

“Given all the damage the Republicans did in the past two years, first we got to triage to stop the bleeding,” Pan told me. He wants to repeal the OBBBA’s Medicaid work requirements, restore the lapsed Affordable Care Act tax credits that helped reduce premiums for millions of Americans, and protect Medicare payments. Those were common themes across these physician-politicians: Andrews, Berman, and El-Sayed endorsed the same policies as part of their campaign platform, while Knickerbocker likewise pledged to protect Medicaid, Medicare, the ACA, and children’s health coverage.

Beyond reversing the Republican cuts, the newcomers want to cover more people, though they have different ideas about how to do it.

“You have these real stories that then drive the legislation, and give you the ideas to solve the problems for people.”

Amish Shah, emergency room physician elected in Arizona

Shah said he supports letting people buy into Medicare. Andrews, Berman, Knickerbocker, and Shah have also endorsed a public option: a government-backed health insurance plan that would compete with private plans. El-Sayed and Hamawy, meanwhile, say they favor Medicare-for-all, guaranteeing comprehensive coverage without premiums or out-of-pocket costs.

“I want to see every United States citizen covered, and I’d like to see the premiums drop,” Shah said.

But even the people who have health insurance often struggle to pay for medical care. Andrews, Berman, El-Sayed, and Hamawy have all proposed expanding the government’s negotiation of prescription drug prices. Andrews and Berman want to extend Medicare’s $35 insulin cap to private insurance. Andrews, Berman, and Hamawy also want to crack down on private equity ownership and consolidation among healthcare providers.

Perhaps unsurprisingly, these doctors were not afraid to get into the weeds of healthcare policy on the campaign trail. Andrews’s detailed plans include limits on some hospital prices and changing Medicare payments so the same service costs the same regardless of where it is performed. Berman’s agenda draws on his own nursing experience: He wants nurses to help set staffing standards, more funding for nursing education, and enhance workplace safety for medical workers, a goal he shares with Shah. In Arizona, Shah worked on protections for healthcare workers, and he wants Congress to focus on the problem too.

Pan also wants to figure out how to restore trust in public health after two years of US Health Secretary Robert F. Kennedy Jr. undermining faith in vaccinations and other medical science. He helped write California laws tightening exemptions from school vaccination requirements; in Congress, he wants stronger oversight of the administration’s healthcare agencies, including probing any possible corruption, and stronger protections for scientific decision-making. He told me that lawmakers may want to consider creating new safeguards into law so future administrations have less latitude to overhaul public health policy.

“The American people need accurate information from their government,” Pan said. “We might want to rethink how to put better guardrails so that someone like an RFK Jr. in the future couldn’t…basically upend everything.”

Andrews and Shah have also placed a lot of emphasis on fixing prior authorizations, one of the most common frustrations for patients and providers alike.

Shah recalled that he once met a Republican constituent who said he was completing prior authorization paperwork on behalf of the doctor treating his son, who had muscular dystrophy, because the doctor’s office was overwhelmed. He was shouldering an absurd administrative burden as a layperson, just so his child could get the care he needed. 

And so, Shah worked on legislation to streamline the prior authorization process. A 2021 law standardized prior authorization forms and limited their length to two pages, excluding supporting medical documentation. He sees his state work as a possible model for federal legislation.

“We really need to start looking at these denials,” he said. He wants more scrutiny of decisions that are later overturned and of automated and increasing AI-driven systems that reject people’s claims without meaningful review.

It’s another example of how these freshman members will be ready to dive into the weeds of fixing healthcare. The question will be whether the new lawmakers can translate their direct experience with patients’ frustrations into changes that make getting healthcare care easier.

“You have these real stories that then drive the legislation,” Shah said, “and give you the ideas to solve the problems for people.”

  •  

HIV was supposed to kill them. Now they could help scientists find a cure.

an illustration of three people in a dark landscape standing around a point of light

Paul Boakye was 22 when he was diagnosed with HIV. It was winter 1986, five years after the world first became aware of the deadly disease that would become known as acquired immune deficiency syndrome (AIDS). After receiving the news, Boakye was certain he was going to die young. “I distinctly remember a doctor telling me that I probably wouldn’t live to see 30,” he said. 

Years passed, and Boakye watched as both his former partner and many of his friends died of complications from HIV, which infiltrates immune cells and weakens the body’s defenses. During the early days of the HIV pandemic, a diagnosis was essentially a death sentence. Without getting treatment, HIV infections can eventually develop into AIDS — the stage in which a person’s immune system has deteriorated to the point that they become vulnerable to typically harmless infections and rare cancers. Once AIDS manifests, life expectancy drops to just a few years. 

But Boakye was an exception. 

Now four decades after his diagnosis, at age 63, he remains symptom-free. He is one of the rare people with HIV whose immune systems can fight off the virus without treatment. These individuals, known as “elite controllers,” make up less than 0.5 percent of those who get infected with HIV.

For many scientists, this group of people provides a roadmap for a so-called functional cure, a state akin to cancer remission, where the infection is under control, but not completely eliminated. 

A cure for HIV is still much needed. In 2025, approximately 1.2 million people around the globe became newly infected and around 570,000 died from HIV-related causes. Today’s clinicians now have an arsenal of effective medications to both prevent and treat HIV infections. “There are a lot of tools to fight HIV, but it’s also evident that this is not enough,” said Asier Saez-Cirion, leader of the Viral Reservoirs and Immune Control Unit at the Pasteur Institute in Paris. 

Transmission electron micrograph of HIV-1 virus particles (teal) from infected H9 cells, produced in cell culture. The particles exhibit two stages of replication: the two Arcs are immature particles budding from the plasma membrane of the cell, and the center spherical particle is a mature form in extracellular space.

To keep HIV as a survivable disease, people with the virus must take treatments for life, which brings up widespread issues of cost and access. When those become a barrier, it ends up costing lives. But researchers have been working on deciphering the lasting secrets of elite controllers like Boakye, in hopes of one day developing a functional cure for millions more people living with HIV. This work has led to many new strategies for fighting the virus — and several new treatments are now being evaluated in clinical trials. 

The elite controllers of HIV 

Joel Blankson, an associate professor of medicine specializing in infectious diseases at the Johns Hopkins University School of Medicine, remembers when he encountered an HIV elite controller for the first time. It was 1998, and a woman had come to the clinic after testing positive for HIV. That test result showed that her immune system had encountered the virus and produced antibodies to fight it. 

But further tests revealed something baffling. Normally, as an HIV infection progresses, the virus infiltrates key immune cells, known as CD4 T cells, hijacking their internal machinery to make more copies of itself, and killing the host cells in the process. This patient, however, had no detectable levels of virus in her blood and appeared to have a healthy number of CD4 T cells. “That was fascinating,” Blankson said, since clinicians at the time did not think that could be possible. 

Starting in the 1990s, researchers in the US and elsewhere in the world started documenting such cases. A few years earlier, Bruce Walker, a physician-scientist and director of the Ragon Institute of Mass General Brigham, MIT, and Harvard, had been similarly astounded by a patient who had been HIV positive for 16 years with no signs of disease. “I thought initially he couldn’t possibly be infected because everybody we saw had progressive illness,” Walker said. 

For any virus, whether it’s HIV or influenza or Covid-19, people have a range of responses — some people become severely ill while others may have no symptoms at all. But HIV is exceptionally good at evading the immune system’s defenses, so the research community was glad to see that there were some people who seemed to be able to naturally fight off HIV. “It was particularly exciting to see that they were able to maintain this control in the long term,” Saez-Cirion said. 

So the natural question was: What made these people different from those who became severely ill from HIV? 

Some researchers hypothesized that these elite controllers had been infected by a defective version of HIV. Early evidence appeared to support this claim: In 1992, researchers described a small group of long-term, symptom-free HIV-positive individuals who had all been inadvertently infected through blood transfusions from an asymptomatic individual. The transfusions had occurred in 1985, before blood was routinely screened for HIV. Both the donor and the recipients harbored a strain of the virus with genetic mutations that hindered its ability to replicate. 

But this incident turned out to be the exception. Later studies found that most people who survived for many years without disease progression did not carry weakened versions of HIV. For example, when Blankson and his colleagues isolated HIV from elite controllers’ cells, they found that the virus was able to multiply effectively in a lab dish just as well as the virus from people who became ill from HIV. And when they used the virus from these elite controllers to infect mice engineered to have human-like immune systems, the pathogen was still able to spread through the animals with ease. All of this suggested there was something unique not about the infecting strain of the virus but instead about these individuals’ immune systems. 

As the tests for detecting the virus in blood samples improved, researchers found that there were even different levels of how much some people could control the virus. There were, for example, “viremic controllers,” who are often defined as those with less than 2,000 copies of HIV within a milliliter of blood, and “elite controllers” who have less than 50. For comparison, a typical HIV-positive person can have anywhere from tens of thousands to more than 1 million HIV particles in a milliliter of blood, depending on the stage of their infection.

More recently, another group of intriguing patients has emerged: post-treatment controllers, who, after taking antiretroviral treatment for many years, become capable of controlling HIV without medication..This group is giving even more hope that controllers may hold a clue to finally creating a lasting cure for the disease. 

Unraveling the mechanisms of elite control 

Once people who seemed to be beating back HIV on their own began to emerge, researchers went searching for more of them. Eventually, several research teams were able to assemble large cohorts of these patients: Walker and his colleagues, for instance, found around 1,000 elite controllers to begin to study them en masse to search for trends.  

Some of the earliest studies looked into elite controllers’ genetics. Using a technique known as genome-wide association, which involves screening the genetic material of many people for links to disease, scientists discovered that a large proportion of elite controllers possessed variants of genes that code for structures responsible for presenting antigens — the fragments of viruses and other substances that immune cells use to detect pathogens. 

Researchers have drawn inspiration from these studies to develop new strategies for fighting HIV.

This led scientists to zero in on cytotoxic T cells, immune cells that zero in on these fragments to identify foreign and infected cells to attack. In elite controllers, these cellular soldiers appeared to be exceptionally good at seeking out and eliminating HIV. How these individuals’ immune responses accomplish this has been a matter of intense investigation: Some researchers, such as Mark Connors, an HIV researcher at the US National Institute of Allergy and Infectious Diseases, and his team have found that elite controllers’ cytotoxic T cells increase the production of a specific molecule that pokes holes in infected immune cells to kill them — something that the same type of cells in other HIV-positive people are unable to do. Other groups, such as Walker’s team, have found that cytotoxic T cells are able to launch highly specific attacks on vulnerable regions within the virus’s structure. 

Over the years, scientists have found that there is likely no one-size-fits-all explanation for why elite controllers’ immune systems are such formidable opponents for HIV. Studies have also found that these individuals also appear to possess exceptionally robust natural killer cells, which are immune foot soldiers that are some of the first to find and kill invading pathogens. 

Other investigations have looked beyond specific cells to the aftermath of an elite controllers’ immune response. Xu Yu, an HIV researcher at the Ragon Institute, along with Walker and their colleagues, have found that immune systems of some elite controllers keep HIV locked away in so-called gene deserts, where it is unable to make more copies of itself — an essential task for the virus’ success. 

Yu says that this is likely the result of unusually strong immune surveillance. Elite controllers’ immune systems were likely able to kill off the cells in which the virus had integrated itself into parts of the genome to multiply. This left only those cells with ineffective viruses behind. How the immune system actually does this remains a mystery, but according to Yu, it’s likely that multiple parts of controllers’ immune systems work together to launch particularly powerful responses. 

In addition to uncovering how, exactly, the immune system accomplishes this feat, Yu is also hoping to replicate this process in people who aren’t elite controllers. The good news is, evidence so far suggests that this may indeed be possible: In a 2023 study with eight people who had been on long-term anti-retroviral therapy, Yu’s team found that it was also possible for non-elite controllers to lock HIV away in these gene deserts — but only after more than two decades of treatment. 

The next step is to determine how to make people reach this state faster, so that they can one day stop needing treatment altogether, Yu says.

Researchers have drawn inspiration from these studies to develop new strategies for fighting HIV. Several are currently being tested in people with the virus. Walker’s team, for example, has developed a trial vaccine designed to train a person’s T cells to attack the most vulnerable parts the viruses’ structure — both as a way of preventing and of treating infection, in an early-stage trial. Saez-Cirion and his team have several ongoing trials, including one effort that involves administering immunotherapy in combination with antiretrovirals in people with newly diagnosed infection to try to coax their immune systems into developing the potent immune response found in elite controllers. 

The elite road to a cure? 

Experts are generally reluctant to say that elite controllers — even those who have lived symptom-free for decades — are “cured” of HIV. The main reason is that HIV is notorious for hiding in so-called reservoirs, cells in which HIV lingers without replicating. 

The virus in these reservoirs escapes detection from a person’s immune system and from current HIV medicines. From here, it can then become active after remaining quiet for years. Because HIV infects immune cells, which travel all around the body, the virus can hide in deep tissues, such as the brain, that are extremely difficult to probe in living people. 

And there are documented cases of the virus eventually breaking through an elite or viremic controller’s immune defenses, kick-starting disease progression — even if they have lived symptom-free for years or decades. It’s still unclear what factors determine when that point will come. So, many controllers are also on antiretroviral therapy.

There are, however, two elite controllers who are widely considered to be cured. One is the “Esperanza patient,” named after the Argentinian city where she lived, for whom researchers analyzed more than a billion cells and found no intact HIV. And the other, Loreen Willenburg, a Californian woman, kept the virus at bay for more than three decades without treatment — even while receiving immune-suppressing treatment for lung and brain cancer. Before she died in April, Willenburg donated her body to science; Yu and her colleagues have been carefully analyzing autopsy samples to determine whether there are intact viruses hidden somewhere within her body. 

But these are the incredibly rare known examples among the 92 million people who have acquired HIV since the virus was first described. So even the elite controllers must stay vigilant for the virus’s reemergence. Boakye regularly gets his blood screened to make sure that HIV has not begun to spread. Today, he lives in the UK working as a playwright, and he remains active and healthy — and HIV remains undetectable in routine tests, even after four decades without treatment.

For years, he has tried to enroll in a study in hopes of helping scientists understand how his immune system has managed to fight HIV all these years, and last year, he became involved in three research projects. One of these is at the Ragon Institute, where Yu’s team analyzed more than 1 million cells in Boakye’s blood and found only a tiny number of HIV fragments — and only one that appears to be intact. Whether this fragment is capable of replicating remains unknown.

“They believe that my immune system is ignoring all the defective fragments and just controlling the one fragment that could replicate,” Boakye said. How his immune system does this is still a mystery, but Boakye hopes that by studying him and other elite controllers, scientists will be able to reverse engineer new treatments. 

While a cure for HIV remains elusive, this research is bringing us closer than ever to that goal. There are multiple trials trying to mimic the responses found in elite controllers around the world, and the results of these efforts will emerge over the next five years or so, which is quite an exciting prospect, Saez-Cirion said. “We need additional tools that will allow people to live with HIV but without antiretrovirals. And if we can cure it — even better,” Saez-Cirion said.

  •  

Robots could transform breast surgery forever

An illustration of a person pulling their hospital gown aside to reveal a mastectomy scar. Beneath their other hand, part of their breast is glowing with a ripple effect.

“Wait, I can feel that?” Ami Brasure remembers thinking.

For most of us, the experience that dazzled her couldn’t be more ordinary: You’re standing around, maybe in your kitchen or living room, drinking something a little too carelessly, and before you know it, the liquid is dribbling down your chin and trickling down your chest — and you can feel it. It’s a familiar sensation (in this case, perhaps an embarrassing one). But for Brasure, a 50-year-old retail sales manager from the Washington, DC, area, it was life-affirming. 

At the time, she was recovering from a double mastectomy in the wake of a stage one breast cancer diagnosis. She vividly remembers the chill from her spilled drink as it snaked its way inside the compression garment she was wearing as part of her recovery process. The sudden dampness came as a shock — not because it was unpleasant, but because she never expected to feel anything in that area at all, certainly not so soon after surgery. 

Key takeaways

  • Every year, hundreds of thousands of women in the United States are diagnosed with breast cancer and undergo mastectomies that can leave them with little to no feeling in their chests.
  • In December 2025, the FDA cleared the da Vinci single-port surgical system for robot-assisted breast cancer surgery, specifically nipple-sparing mastectomies.
  • Some surgeons are embracing this new technology because it offers a smaller, hidden scar and a clearer view inside the breast. Some patients also report better sensation in the chest area afterward.
  • But critics say that there isn’t conclusive long-term evidence yet that robotic nipple-sparing mastectomies are as good as open mastectomies at making sure the cancer doesn’t come back, even if they are technically safe to perform.

As Brasure knew, many people who get mastectomies are left with little to no feeling in their chests. That loss of sensation can affect a patient’s psychological well-being, sometimes actively alienating them from their bodies as they adjust to life after treatment. 

“Every patient will have their own surgical goals. And mine was to look and feel as close as I did to how I looked and felt before I went into that operating room,” Brasure told me.

So when Dr. Lucy De La Cruz, chief of breast surgery at MedStar Georgetown University Hospital, offered Brasure the chance to be the hospital’s first patient to undergo a surgery that deployed a new robotic nipple-sparing mastectomy technique, she was enthusiastic. Especially because it was a procedure that some surgeons and studies have suggested leads to better preservation of feeling. 

Using a robot to aid a mastectomy is not entirely novel — surgeons around the world have been experimenting with this technique for the past decade. 

But what is new is that De La Cruz’s novel surgical plan combined several procedures into one operation. Using the da Vinci single-port robotic surgical system, she removed the breast tissue while preserving the nipples and skin. In the same operation, her team checked the lymph nodes, reconstructed the breasts with implants, and reconnected the nerve to the nipples to help restore sensation. In most robotic nipple-sparing mastectomies, the surgical incision is made along the armpit or the side of the chest. But here, De La Cruz and her team did everything through a single, 4-centimeter incision on each breast, naturally hidden under its fold. The hidden surgical scar and shorter recovery period, along with the possibility of having sensation back in her breasts post-surgery, were alluring for Brasure.

Normally, surgeons performed nipple-sparing mastectomies through more conventional “open” techniques, typically through a long incision at the bottom of the breast. It is a technically challenging operation. Breast tissue extends all the way up to the collarbone, and surgeons have to reach it through a tight space with limited visibility, relying on their hands and eyes to look and feel their way around the breast. An assistant often uses large metal retractors to lift the skin around the incision to keep the area exposed and visible. 

The procedure also carries a known risk of injury to the skin and nipple, sometimes severe enough that patients can lose the nipple and surrounding skin. These challenges led some surgeons to explore whether a robot-assisted surgery could help mitigate certain risks of open nipple-sparing mastectomies. But it was only in December 2025 that the Food and Drug Administration specifically cleared the use of the da Vinci single-port machine to perform mastectomies in the United States. 

And at least for Brasure, it seems to have made all the difference, helping her feel better connected to her body after a procedure that might, under other circumstances, have left her with a radically altered sense of it.

In theory, robotic nipple-sparing mastectomies sound like an amazing example of where surgical technology can take us. The American Cancer Society estimates that, in 2026, about 321,910 new cases of invasive breast cancer will be diagnosed in women. Many women opt for mastectomies not just as an active cancer treatment but also preventatively to reduce their risk, especially when they have a BRCA mutation — which indicates a very high likelihood of developing breast cancer — or a family history of the disease. A surgery with the potential to preserve more sensation, leave fewer surgical scars, and allow patients to recover more quickly promises to be a boon to women’s health. 

Instead, robotic nipple-sparing mastectomies have proved extraordinarily divisive among oncological surgeons. Some, including De La Cruz, have embraced them. Others worry that the technology has gotten ahead of the evidence, especially on one of the most important measures in cancer treatment: making sure that the cancer doesn’t come back.

The case for robotic mastectomies

Maleeha Aziz, a 33-year-old deputy director at an abortion fund in the Dallas-Fort Worth area, grew up around breast cancer. 

Aziz was 3 years old when her mother was first diagnosed. As a child, even though she couldn’t completely understand what was happening, she remembers her mother slowly losing her luscious, thick hair and how she could no longer pick Aziz up after the double mastectomy surgery. 

It was clear that there was a family history, and Aziz felt like the cancer wasn’t skipping a single person. Her nani, or maternal grandmother, and her aunt had been diagnosed with ovarian and breast cancer, respectively. But the last straw was when her 32-year-old cousin — as close to her as a sister — received a stage three breast cancer diagnosis while she was pregnant. 

Having seen the ravages of the disease firsthand and knowing from genetic testing in her early 20s that she was a BRCA carrier, Aziz ultimately decided that it would be better to get a preventative double mastectomy and reduce her cancer risk rather than live with pervasive anxiety from screening to screening. 

“Preventative care is not radical. What is radical is to get cancer,” she told her family when they worried that it was an unnecessary medical intervention. A preventative mastectomy can lower the risk of breast cancer by close to 90 percent. 

Aziz, like Brasure, was keen on sensation preservation. She remembered hating the numbness on her abdomen after her C-section delivery when she had her daughter, and couldn’t imagine the same around her breasts. 

So in 2023, at the age of 29, Aziz opted for a preventative robotic nipple-sparing mastectomy at the University of Texas Southwestern Medical Center as part of surgical oncologist Dr. Deborah Farr’s study on the feasibility of using the da Vinci single-port machine to perform the procedure. Farr was one of the few who were approved by the FDA to research and perform the robotic nipple-sparing mastectomy before it was officially cleared in 2025. More than three years later, Aziz has no regrets about her decision, especially since she has “pretty decent sensation” in her breasts, unlike her cousin who underwent a traditional mastectomy.

Aziz isn’t alone in her desire to preserve sensation in her breasts. 

Breast cancer, like all cancers, can prove to be a psychological malady as surely as it is a physical one. Body image is about much more than just appearance, said Danielle Saff, an oncological social worker at CancerCare, a nonprofit providing support and counselling for people diagnosed with cancer. Body image is also about familiarity with one’s body, connections and sensations. 

Saff told me that she often encounters patients who feel guilty for caring about things like how their breasts will look or how their body will change, fearing that such considerations are trivial when their lives are on the line. But patients must be allowed to ask these questions, Saff said, because they are important to their life after treatment. 

“When treatment ends, [that] doesn’t mean that one’s life goes back to quote unquote normal,” Saff said. “There’s so much adjustment that happens and so much grief throughout the process.”

Losing sensation in the breasts or nipples can also affect how some patients experience intimacy, Saff said, because the surgery can affect how they feel about their changed bodies. 

But for De La Cruz, however, sensation preservation goes beyond helping patients still enjoy intimacy after mastectomies — it is also about safety. What if boiling water splashes on you while you’re cooking or you accidentally hit yourself with a curling iron while doing your hair in the bathroom, she noted by way of example. Being able to feel external stimuli like pain, heat, cold, or pressure on your body is key to protecting it. 

How robotic surgery works

In a robotic mastectomy, the surgeon sits at a console a few feet away from the patient and controls every movement of the machine’s instruments with their hands. The da Vinci single-port robot, the version cleared for nipple-sparing mastectomies, has one arm that enters the body through a single small incision usually along the side of the chest or, in some cases, in the fold beneath the breast. The arm has three multi-jointed instruments at one end, which the surgeon can use to bend, grasp, and dissect breast tissue, nerves, and blood vessels much like they would with their wrists and fingers in a traditional non-robotic (“open”) surgery. Usually, a plastic surgeon is also in the operating room ready to begin reconstruction once the cancer is removed.

Because these robots also have an endoscope — a medical device with an attached light used to look inside body cavities — the interior of the breast is visible to the surgeon in great three-dimensional detail and size on a display screen outside the body. This makes it much easier for surgeons to navigate complicated tissue and nerve structures once they have been properly trained on the robot.

Aziz’s surgeon, Farr, a surgical oncologist who specialises in breast cancer at the University of Texas Southwestern Medical Center, believes that the robotic nipple-sparing mastectomy is essentially the same as the open one, but with much better control and visibility. 

At UT Southwestern, she often taught doctors how to perform procedures like the open nipple-sparing mastectomy.

“It is a procedure that is technically challenging for breast surgeons, and it’s really difficult for us to teach because really the only person who can see anything is the operating surgeon,” she said, adding that it’s difficult to communicate the steps and what the trainee should be doing if they can’t see inside the body.

In a traditional mastectomy, the surgical cut is held physically open with instruments called retractors, which can cause considerable physical trauma and pressure in the area around it. By contrast, in robotic surgery, carbon dioxide gas is used to open up the space in a much gentler manner. Farr believes that reduced trauma to the skin and better visualization of structures (and hence increased ability to avoid critical nerves) in robot-assisted surgery could be the reason that some patients report more sensation after nipple-sparing mastectomies performed with the da Vinci single-port machine. 

Notably, in her own patients, she did not see a difference in pain or other recovery metrics for those who opted for robotic surgery compared to those who opted for an open surgery instead. That makes sense to her because, as far as she’s concerned, she is doing the same surgery, open or robotically, just using a different tool. 

Nevertheless, the enhanced three-dimensional visualization, better likelihood of preserving breast sensation, and the ability to more easily teach the operation to trainees make it worthwhile for her to continue practicing and studying robotic nipple-sparing mastectomies.  

Why is the procedure so divisive?

Despite all of that — the potential for patients and the advantages for surgeons alike — robotic nipple-sparing mastectomies remain controversial. 

Surgeons we spoke to who remain cautious about adopting robotic nipple-sparing mastectomies are worried about one thing in particular: No study has yet shown clinical evidence that, in the long term, the patients who have undergone robotic nipple-sparing mastectomies have the same cancer survival outcomes as compared to open nipple-sparing mastectomy patients. 

Their fear appears to have a valid basis. 

In the United States, robot-assisted or laparoscopic surgery began to be broadly adopted around 2006 as a minimally invasive method to perform radical hysterectomies, a surgery in which the uterus, cervix, both ovaries and fallopian tubes, and nearby tissues are removed, usually as a treatment for early-stage cancers. There was limited research at the time to show that doing it this way produced long-term survival outcomes for patients that were equivalent to open radical hysterectomies — the existing, accepted standard of care.  

Then, a randomized controlled trial published in 2018 found that patients who underwent the minimally invasive version of the radical hysterectomy had lower rates of disease-free survival as well as overall survival. In other words, the more traditional, non-robotic approach was better for patient health in the long term. The researchers note that the study was not designed to establish what is causing this result and that it is still unclear.    

While robot-assisted hysterectomies may or may not be the most appropriate analog for nipple-sparing mastectomies, it remains true that it is a robotic procedure that received widespread attention, was adopted quickly, and ultimately seems to have had worse outcomes.    

In fact, the FDA referenced that radical hysterectomy study when it published two warnings in 2019 and 2021, cautioning against the practice of robotic breast surgery without a proper randomized controlled trial with long-term evidence on cancer metrics. The FDA asked that anyone experimenting with robotic nipple-sparing mastectomy should do so only within the boundaries of a clinical trial that it approved. 

Soon after, Intuitive — the company that manufactures the single-port da Vinci machine — sponsored a randomized controlled trial that was set to wrap up in 2031 and even published data from the initial 74 participants this year. It concluded that using the da Vinci single-port machine was feasible for robotic nipple-sparing mastectomies and that its safety was comparable to the open procedure in terms of early outcomes after the surgery and the ability to neatly remove tumors. It is worth noting that the robot-assisted surgery takes longer than the open one — so the patient spends more time under anesthesia — but the researchers largely attributed that to the unfamiliarity of surgeons with robotic surgery. They believed that operating time would reduce with better training and exposure to the machine. 

The researchers themselves acknowledge that published results from this study were focused on safety and early post-surgical outcomes, and they say that long-term oncological outcomes will likely be published later. The study was also statistically underpowered due to the small number of participants — enrollment of patients was stopped after FDA clearance was granted in December 2025. 

In a written statement to Vox, an Intuitive spokesperson said, “Da Vinci SP’s clearance for NSM was supported by a robust evidence package for this indication, including a U.S. randomized controlled trial comparing da Vinci SP with open surgery and global evidence from some of the regions where da Vinci SP was already approved for NSM — Europe, Japan, Korea and Taiwan.” They added that the FDA cleared the device after stringent review of the evidence. 

The company also said that patient safety is their top priority and noted that they will continue generating evidence for both short- and long-term outcomes in patients undergoing robotic nipple-sparing mastectomy using the da Vinci single-port machine globally.

The FDA cleared the da Vinci single-port for use in nipple-sparing mastectomies under what’s known as the 510(k) process, which is used for “low to moderate risk” devices if they are “substantially equivalent” to another device that has already been cleared by FDA before. In a written statement to Vox, the FDA said that the clearance reflects their evaluation of the evidence submitted by Intuitive and available scientific evidence under the “applicable regulatory framework.”

“Importantly, the clearance is based on the device’s use as a surgical tool, meaning the sponsor demonstrated that the device can be used safely as a tool in performing nipple-sparing mastectomy procedures,” said the FDA. “This differs from evaluating the device as a potential treatment for cancer, which would require evidence supporting its effectiveness in treating the disease.”

In other words, the FDA found that the device was safe for surgery, but it withheld judgment on whether performing robotic nipple-sparing mastectomies with the da Vinci single-port surgical system would lead to optimal cancer outcomes. In their statement, the FDA also said that they would continue keeping an eye on it (along with other devices they have cleared) and may take additional regulatory action if patient safety is affected. 

Despite the initial data and what Farr describes as “favorable” evidence from studies outside the United States, some critics strongly believe that no conclusive long-term evidence is available to show that robotic mastectomies are at least as effective as open mastectomies in treating cancer. 

Dr. Laurie Kirstein, surgical oncologist at Memorial Sloan Kettering Cancer Center, said that most of the studies done to date establish that robotic nipple-sparing mastectomies are technically safe, which is the first level of evidence needed to evaluate whether they can be more widely performed. For example, such studies consider metrics like whether patients experience bleeding complications or abnormal levels of skin or tissue death called necrosis. 

But, she also notes, the evidence still doesn’t move beyond that to establish strong cancer outcomes, either because the clinical studies are not designed to test for those outcomes or because there isn’t data on long-term outcomes from a randomized controlled trial in a well-defined patient population. 

“After a mastectomy, you’re only going to be getting a physical exam twice a year, right? So there’s no imaging screening,” Kirstein said. “So the mastectomy has to be good enough oncologically to reduce the amount of breast tissue left behind, and that has to be done and proven without a shadow of a doubt, and unfortunately right now those studies don’t exist.” 

What Kirstein is getting at is that the mastectomy surgery, which removes most or all breast tissue, is meant to be the ultimate safeguard. Once the patient undergoes that procedure, regular breast cancer screenings like mammograms generally stop, unless the doctor or patient feels something is abnormal, and the patient is instead monitored through physical exams. If any breast tissue is accidentally left behind, it could be harder to catch a cancer recurrence early. 

In contrast, people who opt for a lumpectomy — a surgery to remove breast tumors while preserving the remainder of the breast tissue — keep getting regular breast image screenings. That’s why surgeons are asking for irrefutable proof that the robotic approach removes the breast tissue just as thoroughly as open surgery does. In the absence of that certainty, some worry that the possibly more selective excisions in robot-assisted surgery may leave an opportunity for cancer to spring up, possibly unmonitored.  

A medical catch-22

Bringing exciting new medical technologies to the market in a responsible manner almost inevitably invites a paradox of sorts. Irrefutably showing that a new surgery is at least equivalent to existing methods and safe, requires performing it on real patients to gather data. And yet without data, there is considerable risk in subjecting patients to it.  

Clinical trials are meant to resolve that tension by testing a new technique under close oversight before it becomes routine. In this case, though, the FDA cleared the robot before Intuitive’s trial was complete, and the trial stopped enrolling patients soon after.

“I truly believe it is a better surgery when done properly,” Farr said. “It was a blessing and a curse that it was approved when it was.” 

For years, only her own study team could use the robot for these surgeries. Now she can teach it to her residents, fellows, and surgeons around the country. But once a device is cleared, “there’s really no further regulation in terms of who can do it and who can’t,” she said. That decision now rests largely with hospitals and with patients. 

Dr. Rosa Hwang, a surgical oncologist at the University of Texas MD Anderson who worked on Intuitive’s US trials, said surgeons will need dedicated training to learn how to perform robotic nipple-sparing mastectomies safely. She chooses her own robotic nipple-sparing mastectomy patients carefully. 

“I err on the side of being conservative for the robotic nipple-sparing mastectomy,” she said. Someone who might be a reasonable candidate for an open nipple-sparing mastectomy, for example, isn’t automatically one for the robotic version.

Farr said that she can understand why critics are skeptical about the existing data on robotic nipple-sparing mastectomies and while she believes the surgery needs more study, she doesn’t think that’s a reason to abandon it. She believes that criticism is healthy for the field, ultimately helping surgeons learn more and better test for the best outcomes.  

“I have a lot of respect for the people who have criticized me,” Farr said. “The response to critics,” she said, “should be not with defense but with data.”

If there is one thing that surgeons on both sides of the robotic mastectomy debate agree on, it’s that patients are asking for this. For women like Brasure and Aziz, beating breast cancer or avoiding it altogether was never the only goal. They also wanted to come out the other side living normal, safe lives in bodies that still felt like their own. The robot may or may not turn out to be the best way to get there — only long-term data will tell. But what’s already clear is that for many women, sensation is no longer an afterthought.

“Nothing feels the same,” Aziz said, “but I have feeling pretty much everywhere, and I feel good.”

  •  

A million people could gain health insurance in Texas after Democrats’ shocking win

Gina Hinojosa speaks to supporters.
Gina Hinojosa speaks to supporters as she is announced as the next governor of Texas on election night, November 3, 2026. | Mikala Compton/The Austin American-Statesman via Getty Images

On election night in Texas, the impossible became possible. Democrats won the governor’s seat for the first time since the 1990s and appear to be on their way to securing control of the state House too. Those massive, unexpected wins have now opened the window for a major policy change that has long been closed: expanding Medicaid to more than a million low-income Texans.

The Affordable Care Act offers generous funding for states to expand Medicaid eligibility to 133 percent of the federal poverty level, which is about $21,000 for one person or $44,000 for a family of three. But the Supreme Court ruled in 2012 that states should have a choice about whether or not to accept the expansion. And even though many other GOP-led states decided to adopt it, Texas is one of the 10 that have steadfastly refused to extend Medicaid coverage to many of its poorest citizens — and it’s by far the biggest. KFF estimates that 1.1 million people in Texas would be eligible for Medicaid expansion, including 605,000 who have no other insurance options without it. In resisting expansion over the years, Republicans have argued that the Medicaid program was broken and already too expensive and that uninsured people should instead be able to get coverage by finding a job that offers health benefits. 

New Democratic Gov.-elect Gina Hinojosa pledged to pursue expansion if elected, framing it as a way to help the state’s children. If she can find a way to get the state legislature on board, Medicaid expansion in Texas would be one of the biggest direct consequences of 2026’s blue tsunami. Texas has the highest uninsured rate of any state in the country at 19 percent.

“We expect expansion to be a priority in the next legislative session. It’s a life-saver in the short term and a money-saver in the long term,” Lynn Cowles, director of health and food justice at the advocacy group Every Texan, told me in an email. “We’re excited to work with our next state legislature that convenes in January to make expansion a reality.”

There is still work to do. But Democrats are in the strongest negotiating position they’ve ever had in the Lone Star State. As of Wednesday afternoon, Dems had clinched control of the Texas House for the first time in more than 20 years. That will allow them to force a more serious conversation about expansion.

“You should expect to see Medicaid expansion bills filed on November 9, which is our first day for early bill filing,” said Bee Moorhead, executive director of Texas Impact. “Absolutely, it will be on the table.”

It’s not a guarantee because Republicans retain control of the state Senate. Still, there is some optimism that the sweeping Democratic victories in Texas and across the country could make the GOP more amenable to compromise. 

Democrats will have one important ally in their fight: Texas hospitals, which have long supported expansion. Their political influence and the threat of Trump-approved Medicaid cuts leading to rural hospital closures — a major theme of Hinojosa’s campaign — could put pressure on Republicans to find a middle ground with the Democrats now in power.

But hospital leaders, having seen dreams of Medicaid expansion in Texas fall short before, aren’t declaring victory yet. Until some of the Texas Senate Republicans who have opposed Medicaid expansion in the past announce that they’re now open to a compromise, the GOP’s control of that chamber could be enough to continue blocking Medicaid expansion in Texas for the time being.

“Everything changed last night. But just because everything changed doesn’t mean everything changes,” John Henderson, president and CEO of the Texas Organization of Rural & Community Hospitals, told me. “We’re gonna have a different climate and different priorities in the next session. But some of these really ambitious policies still have obstacles to clear.”

Texans have been waiting for Medicaid expansion for a long time: A 2020 poll found that 69 percent of the state’s voters supported the policy. But Republican leaders, including now-ousted Republican Gov. Greg Abbott, refused to budge.

There is no guarantee that the stunning midterm results will finally break that logjam. It will require deft politicking by the new Democrats in power. But for the first time, there is real reason for hope.

  •  

What Democrats could actually do to lower your healthcare costs

Protesters urge healthcare reform at the US Capitol, one holding a sign reading “Sick of it! Fix health care now”.

Democrats’ massive wins on election night in Congress — and state races across the country — have opened the door for the party to deliver on one of its biggest campaign promises: making people’s healthcare cheaper.

When Democratic House leader Hakeem Jeffries declared victory on Tuesday night, he promised that his new majority would try to undo the massive Medicaid cuts that the GOP Congress approved in 2025. A new class of Democratic senators — including James Talarico in Texas, Abdul El-Sayed in Michigan, and Annie Andrews in South Carolina — are coming to Washington having backed a diverse suite of health policy ideas, from major overhauls like Medicare-for-all to targeted reforms like ending prior authorization for some services.

Change doesn’t come easily, however, and people should keep their expectations in check: President Donald Trump is still in the White House, and that will limit how much policy work gets done in the next two years. 

But that doesn’t mean we’re stuck, either. Everybody recognizes US healthcare is a mess, and lawmakers from both parties have expressed interest in smaller-scale changes that could actually pass in the next few years and get Trump’s signature. Given how massive the Democratic wins were, Republicans in Congress and even Trump himself may have a political incentive to cooperate with the new Democratic majorities: By a 19-point margin, voters said they trusted Democrats more than Republicans to address healthcare costs, according to a KFF analysis of exit poll data. And at the state level, Democrats will have freer rein to do what they want in the near term.

Larry Levitt, executive vice president for health policy at KFF, said he expects Democrats to push through ambitious healthcare bills — such as a repeal of the One Big Beautiful Bill Act’s healthcare provisions — that Trump will veto. “Then the game of chess between Democrats and Trump will begin to figure out what on healthcare can actually get enacted,” he said.

The other looming issue for Democrats will be the 2028 presidential campaign, in which candidates will have to figure out how much to promise if they win full control of the federal government. It could be a messy intra-party fight — or they could use this time to find a consensus that allows them to actually pass a bill in a few years. Will the progressive wing push hard for Medicare-for-all? Can Democrats unite around a public option?

These questions won’t be answered definitively before 2029 — but whether Democrats can start to make headway in bridging their differences or not will go a long way toward determining what’s possible.

There are a lot of balls in the air at once, even as Americans are desperate for relief right now. Here is how US healthcare could actually change at the federal and state level in the short term — and a look ahead at the long-term prospects for more far-reaching reforms.

What Congress could do in the short term on healthcare

Trump’s veto pen will dictate how far Democrats can go in the next two years. But there could be room for compromise. Both parties have serious criticisms of the health system, and, on some narrow problems, the two sides are actually pretty aligned on a need to do something. Those issues are the best bets for action in the next two years.

1) Reforms for Medicare payments

One top target would be limited Medicare payment reforms. Medicare is the single biggest healthcare program in the US, and even smaller-scale changes could help reduce premiums and out-of-pocket costs for millions of American seniors, while saving taxpayers money.

Here’s one opportunity for change: Under the current Medicare payment system, the price of a procedure is based in part on where the procedure is being done. So the cost of the exact same service could vary widely based simply on which building it’s performed in: A routine injection for knee pain or inflammation could cost $65 in a doctor’s office — but more than $300 if it’s done at a hospital’s outpatient clinic. 

The reason for that huge discrepancy is that Medicare allows hospitals to charge a separate “facility fee” on top of the charge for the service itself. While the exact solution would need to be worked out by lawmakers, both sides have endorsed the idea of ensuring procedures cost the same no matter where they are performed. 

That would be a win for patients, because their out-of-pocket costs are based on the total bill. And while the effect may not be enormous, lower hospital spending could also help soften premium hikes in the years to come for all Medicare enrollees.

It’s a policy change that hospitals have long opposed, because they don’t want their payments cut. But DC insiders believe the appetite could be growing to do something about that and other narrow billing issues. Former Democratic healthcare adviser Ezekiel Emanuel and Trump healthcare ally Brian Blase co-authored a Washington Post op-ed endorsing a fix during the week leading up to the midterms.

“Hospitals will always have their friends and allies,” Kim Monk, who tracks healthcare policy for the investment research firm Capital Alpha, said. “They’re the largest employers in a lot of districts. Nobody wants their hospital to close. But I think there’s also a healthy amount of skepticism around, well, wait a minute…what are these billing practices? I think it’s at least something that Congress is willing to take a look at.”

And given how roundly voters rejected AI in the midterms, Democrats could also feel empowered to push for more transparency or even restrictions on how Medicare Advantage plans use AI in ways that lead to patients being denied coverage for medical services.

2) Fixing the No Surprises Act

Of course, fixing healthcare is easier said than done — and sometimes well-intentioned policies don’t work. That’s why the next Congress could also look at remedying an earlier bill that aimed to address hospital billing but has gone awry in practice. The No Surprises Act passed in late 2020 (and was signed by Trump) to try to make sure that Americans didn’t get a massive bill if they were treated by an out-of-network provider when taken to a hospital for an emergency.

But the arbitration process that the legislation had set up to figure out how much the hospital should be paid by the person’s insurer in that scenario has been a mess, with a huge backlog waiting to be cleared. “The No Surprises Act obviously is not working as intended. Maybe they can fix it,” Monk told me. “That’s another one we’re watching.”

Insurers have blamed the law and its alleged favoritism toward providers in the arbitration process for contributing to recent premium hikes, and Democrats argue that creating a simpler system would help rein in rate increases for everyone.

3) Making medications cheaper

Drug costs are a particular point of frustration for most Americans — and it’s another area where both Democrats and Republicans have been circling some of the same policy solutions.

For instance, many Americans with diabetes still struggle to afford insulin, and there is one proposed solution in Congress that already has bipartisan support: a $35 cap for private health insurance plans, matching the cap that already exists in Medicare. Members from both parties have also co-sponsored bills making technical changes to prevent drug companies from using patent law to extend their monopolies and stave off generic competition, which could help bring cheaper versions of breakthrough drugs to the market sooner. One such bill passed the Senate unanimously over the summer, but was never taken up by the GOP-led House.

Democrats could test Trump’s willingness to cut a healthcare deal by pushing legislation based on an idea he himself has endorsed: tying US drug prices to international averages. Democrats could also look to expand Medicare drug negotiations and make more medications eligible for cheaper prices. It’s in theory an issue where they could pick off some Republicans and even win over Trump, who has endorsed negotiations in the past.

4) Reversing the GOP’s Medicaid cuts

One other unlikely change is still worth mentioning: Democrats are going to try to reverse the One Big Beautiful Bill Act’s Medicaid cuts and restore lapsed funding for the ACA marketplaces. They have said that’s their top priority. 

Trump probably isn’t going to sign a law repealing a big part of his own signature bill. But the new Democratic majorities are certainly going to press: DC insiders told me they expect Democrats to put together a healthcare-focused budget reconciliation package that can pass the Senate with only 50 votes and make overturning the Medicaid cuts its centerpiece. 

This approach will allow them to make the case that they are trying to undo the damage that they accused Trump and the Republicans of inflicting throughout the 2026 campaign. It will force Republicans to take tough votes on an issue that has already cost them dearly at the ballot box. And it sets the stage to make a more serious run at overturning the OBBBA if Democrats win full control of the government in 2029.

“That’s an opportunity for them to drive a wedge right into the Republicans,” Monk said. “Make Trump veto it. It becomes a 2028 issue.”

What states could do on healthcare after the 2026 elections

States have less sway than the federal government in shaping healthcare policy: They can’t touch Medicare, for example, nor the large employer plans that cover tens of millions of people. But they can still take some steps to make healthcare more affordable. In states where Democrats will assume full control of the government, they will have more leeway to pursue whatever agenda they wish and get creative with how they leverage state budgets and expand coverage or control medical costs. The question is whether the new administrations decide to make a major healthcare push a priority.

5) Medicaid expansion

Democratic victories in Georgia and Texas could finally open the door to expanding Medicaid through the ACA in those states. Under the law, states can receive generous federal funding in exchange for expanding Medicaid eligibility to all people making 133 percent of the federal poverty level or less (that’s about $21,000 for an individual or $44,000 for a family of three). But after the Supreme Court decided in 2012 that the expansion had to be optional for states, 10 states have resolutely refused to accept it — with Texas in particular being the biggest holdout.

Democrat Keisha Lance Bottoms, elected Georgia’s next governor, said she would make expanding Medicaid a priority, and Democrats look likely to win control of the state House there. In Texas, Democrat Gov.-elect Gina Hinojosa also ran on covering more people through the state’s program; Democrats are likewise leading the race for the state House majority. It looks like a real possibility for the first time since the law passed in 2010. However, their success is not assured: It appears both newly elected Democrats will have to negotiate with a Republican state Senate if they are going to make expansion happen.

If those states did expand Medicaid, it could be one of the biggest impacts of the 2026 election: An estimated 1.1 million people would be covered in Texas, and another 144,000 people would get coverage in Georgia.

6) Public health insurance options

The most sweeping policy change proposed across multiple states is the creation of a new public insurance option. Public options were put forward by Democratic gubernatorial candidates in Wisconsin, Maine and New Mexico, and all three candidates prevailed on Tuesday night. In Wisconsin, Democrats actually secured full control of the state legislature for the first time in over a decade.

Colorado and Washington have had public options up and running for a few years now, setting a template that these other states could draw from. That could allow their public options plans to quickly take shape and deliver more coverage options for people in those states in the next few years.

7) Prescription drug prices

Prescription drug prices are another area where states have some limited authority to make changes in the short term. Democrats ran on prescription drug initiatives in the governors’ races in Michigan, Nevada, Maine, and Georgia, and all of those candidates won their races, including Bottoms’s historic triumph in Georgia. Some of their specific proposals included capping Medicaid prices for drugs at Medicare-negotiated rates and establishing state boards to review drug costs.

8) Canceling medical debt

Canceling medical debt was put forward by Democrats in Ohio, Nevada, and Michigan, paired with technical provisions around how healthcare debt is reported for credit scores. Once again, on a very good night for Democrats nationwide, all three candidates — Amy Acton, Aaron Ford, and Jocelyn Benson, respectively — won their elections and will have a chance to try to enact the policy in office.

9) Protecting abortion rights

One healthcare issue where states hold more power than the federal government is abortion access. In Missouri, Nevada, and Virginia, voters backed direct ballot initiatives to protect the right to have an abortion. And the Democratic victories in Wisconsin, North Carolina, Iowa, and Georgia could allow politicians in those states to either restore abortion access (by, for example, reversing an existing six-week ban in Georgia) or at least preserve it (by blocking any new restrictions, as in North Carolina after Dems seized control of the state House there).

10) Serve as an incubator for other unique healthcare policies

States are laboratories for policy innovation. The Massachusetts health reform experiment of the early 2000s turned into the Affordable Care Act for the entire country. The public options currently being test-driven at the state level could be the template for a national program. For any Democratic governors who have national ambitions, making a push in the next two years could pay off in two ways: delivering results for constituents and elevating their political profile.

Several Democrats proposed bespoke healthcare policies that they can now try to pass. In New Mexico, Democratic Gov.-elect Deb Haaland has pledged to place a limit on private equity’s ownership of healthcare providers and prohibit interference with clinical decision-making. Minnesota Democrats could aim to approve new state assistance for people who purchase insurance on the ACA marketplaces, in order to try to soften their premium increases.

It will be worth watching whether these efforts and others can gain traction and ultimately achieve results. Private equity’s encroachment into healthcare has raised serious concerns about the quest for profits negatively affecting patient care — can states identify effective strategies for pushing back and preventing those adverse outcomes? Can they use state funding to lower healthcare costs for the people they represent? We shall see.

Democrats need to figure out their long-term healthcare agenda

Even with some short-term relief, America’s healthcare crisis isn’t going away. People are fed up: Millions of people are losing their insurance, and millions more are seeing their premiums spike while struggling to afford medical bills. There is going to be pressure for Democrats to think big in the next two years, especially as the presidential race heats up and lawmakers look ahead to 2029.

“That aspirational agenda has no chance of passing the next two years, but it will lay down important markers if Democrats win the presidency and congressional majorities in 2028,” Jonathan Oberlander, professor of social medicine at the University of North Carolina and the former editor of the Journal of Health Politics, Policy, and Law, told me.

The pressure could increase if, as expected, Democrats cannot restore funding for Medicaid or the ACA while Trump is president. According to the Commonwealth Fund, the US uninsured rate spiked from 9 percent in 2024 to 11 percent in 2026. Those losses could grow in the next year as costs continue to rise for millions of people. That’s the kind of crisis that demands a policy response.

Congress and the presidential primary will be the forums for figuring out the party’s long-term plans. Candidates will put forward proposals. House and Senate committees will surely hold hearings to explore a variety of ideas; as Monk described it to me, Democrats are currently in an “all ideas are welcome” phase. 

A lot of attention will focus on Medicare-for-all or public option proposals. But Democrats have other big ideas they can start working on now, too. They could develop plans to improve Medicare benefits for current enrollees: Sen. Bernie Sanders (I-VT) has signaled he wants to make this a priority by adding vision, dental, and hearing benefits, for example. They could also work on a long-term care plan; Sen. Ron Wyden (D-OR) has been soliciting ideas. This is leftover business from the ACA — a long-term care insurance plan that passed as part of the original bill was dropped before ever taking effect — and the issue is becoming more urgent as the baby boomer generation gets older.

The real push for those policies might have to wait for 2029. But Democrats can start trying to build a consensus now.

And as they begin to identify policies to move on in 2029, they could even start figuring out what is passable via budget reconciliation ahead of the 2028 election. The Senate’s procedural rules create important guardrails for what can pass with less than 60 votes and navigating that byzantine process can be a headache; getting a head start over the next two years would help grease the wheels for quick action if Democrats control the entire government in 2029.

So even though the short-term prospects for change may be limited, this week’s elections and the policy work to come could still prove pivotal in the effort to fix American healthcare.

  •  

How one US city cut its infant mortality rate by half

A premature baby in Flint, Michigan, on a heart monitor and breathing machine, sleeps in a stroller.
For years, Flint has faced an infant mortality rate that has been at times more than double the national average. | Tom Williams/CQ Roll Call via Getty Images

A decade ago, a water lead crisis launched Flint, Michigan, into national headlines. But for years, the city of roughly 80,000 has also quietly carried the weight of a tragically high newborn mortality rate. 

In 2024, there were 9.4 infant deaths for every 1,000 births in Flint — nearly twice the mortality rate of 5.54 in the US, which itself outpaces all other high-income nations. 

But a new study shows that there might be a way to reverse that grim trend — a method that seems to have already made an enormous difference in Flint.

Over the last two years, Flint has been testing a no-strings-attached cash transfer program, Rx Kids, administered through nonprofit GiveDirectly. Pregnant women in the city were given a lump sum of $1,500 at the start of their enrollment, typically in the first 16 weeks of pregnancy, followed by $500 every month until one year after childbirth. 

New findings released this week from an Rx Kids study tracking the program showed that neonatal mortality — which refers to the period up to a month after birth — dropped by nearly half in Flint, from 9.4 to 5.1 deaths per 1,000 live births, after mothers received cash assistance.  

It’s important to note that Rx Kids has only collected data up to the neonatal period — it’s still unclear what the outcomes might look like for the first year of infancy. 

Nevertheless, Mona Hanna, associate dean for public health at Michigan State University and co-director of Rx Kids, who is also the lead author on the study, stressed the importance of intervening specifically during pregnancy and the year after birth. That stretch of time, which is known as the perinatal period, is when low-income families often take on significant financial burden as their expenses rise and incomes remain low. 

According to Hanna, Flint mothers spent the money largely as child allowance: Baby supplies were the top expense, followed by rent and food. Some of the benefits of direct cash transfer may also have been behavioral. A previous study on the same Rx Kids Flint cohort found that expectant mothers were less likely to engage in high-risk behaviors, such as smoking, during pregnancy. That, in turn, may have led to lower NICU admissions and healthier birth outcomes. 

Hanna suggests that one of the most important effects of direct cash transfers could have been increased access to prenatal care. 

“For a baby to not be born [prematurely], they have to have good prenatal care, and we saw that,” Hanna said. As she explains it, mothers who enrolled in the program were able to get “the screening and the treatment and all these other resources they need. We’re seeing better nutrition security and satisfaction. That’s important for healthier births.” 

Flint may have been particularly well positioned to benefit from the Rx Kids cash transfers, especially because of the relative simplicity of the program’s setup. It’s a city with a relatively small population, and more than 90 percent of pregnant mothers in the entire geographic region enrolled in the program. That high uptake rate can be partly explained by the program’s low barrier to entry. As long as you live in a Flint zip code, you can receive money.  

Unconditional cash transfers have had promising results in other contexts, too. A study first published last summer found that after unconditional cash transfers to households in Kenya, infant deaths dropped by 48 percent. Hospital deliveries increased, and recipients had better access to maternal healthcare and nutrition services. 

In the US, other findings on the benefits of direct cash transfers have been a little more complicated. One of the biggest challenges came from the Baby’s First Years Study, which ran for four years between 2018 and 2022 and gave $4,000 a year to low-income families with young children in a large randomized controlled trial. The trial found no significant effects on child development. 

Nigel Paneth, an emeritus professor of epidemiology at Michigan State University, has studied preterm births for decades. He described the Rx Kids study findings as promising, but notes there are limitations built into the design of the study, which, like many other community-level population studies, did not have a randomized control group for the sake of comparison. He said that if the program was to ever expand, “you would have to see if this effect is generalizable and not just” the product of some other factor.

“I also think we’re really obligated to begin to try to see if we can figure out the mechanism,” Paneth said. “What is going on? What might happen in pregnancy that a cash transfer would change? It’s not intuitively obvious what that might be.” 

The question of scale also remains notable. Providing a total of $7,500 per family in a relatively small urban area is one thing, but spreading the same amount of cash to families around the country could easily become prohibitively expensive. That said, Rx Kids is expanding its testing ground, building out similar programs in over 60 locations across Michigan, with financial support from the state itself.

“Poverty is a pathogen. It makes kids sick and communities sick,” Hanna said. “With more funding, we could go anywhere.” 

  •  

Your guide to coping with election anxiety

An illustration of a woman with a shocked, overwhelmed expression staring at a phone. Information flows from her phone to her eyes, blowing her hair back.
If you’re dealing with election-related stress, you’re not alone.

Editor’s note, November 3, 2026, 3 pm ET: This article was originally published in 2024 and has been updated for the 2026 midterm elections.

If you’re heading to the polls today, you may be among the 30 percent of American voters who say the country’s political situation is the biggest source of stress in their lives right now, according to one poll. This unease makes sense, given how high the stakes are: Americans are voting for representatives who will make decisions about affordability, healthcare, and holding President Donald Trump to account.

Elections are common wellsprings of anxiety because they’re rife with uncertainty, says David H. Rosmarin, the founder of the Center for Anxiety. You’re unsure of the outcome, and unsure of what life may look like for you under a new administration, especially when the difference between the two choices is undeniably vast. Some of the proposed policies may threaten people’s safety and freedoms, resulting in even more anxiety. Research shows political anxiety can impact people who aren’t generally anxious otherwise.

There are key differences between everyday anxiety and election-related anxiety. Sometimes, generalized anxiety is rooted in cognitive distortions, or inaccurate beliefs or fears about the world. But election-based distress isn’t necessarily based on hypotheticals or overreactions, says licensed clinical social worker Jneé Hill. “A lot of the concerns,” she says, “are very real and very valid based on people’s real lives and lived experiences.”

While election anxiety may feel large and existential, mental health experts agree it can be managed. As you wait for results to roll in, here are some strategies that can help quiet your mind.

Get to the root of your anxiety

To properly address your fears, you first need to specify what triggers your feelings of anxiety beyond not wanting the other side to win, Rosmarin says. What specific policies or issues impact you the most? It might be reproductive rights, the economy, immigration, or war abroad. Identify your top three issues, Rosmarin says, and try to share these worries with family, a friend, a supportive online community, or mental health professional. 

Knowing the causes of your fears can help you anticipate and gird against them. Research shows when people were asked whether they expected to be stressed about the election the following day, they reported worse moods and were more likely to rate their physical health as poor, regardless of political affiliation, age, or gender. 

Knowing the causes of your fears can help you anticipate and gird against them.

You might also ask yourself why these issues concern you, Hill says. If reproductive rights are your top priority, maybe your deeper fears center on being unable to receive lifesaving medical treatments. “A lot of this,” Hill says, “comes down to safety.” 

However, you can anticipate your stress and get in front of it. There’s a thought exercise you can do ahead of encountering something upsetting to slow your thoughts and talk yourself through your anxiety, says Shevaun Neupert, a psychology professor at North Carolina State University and author of a study on how to combat anticipatory election stress. Take a few minutes and think about why you’re stressed, how it’s related to the election, and why this contentious issue exists in the first place. “It really is focused on mental engagement, perspective-taking,” Neupert says, “trying to understand where did this thing come from? Why is it here? And to fully understand it rather than trying to solve it.”

This exercise is effective, Neupert believes, because it helps reduce uncertainty. For instance, you may come to realize a source of your anxiety is a decades-long ongoing foreign policy issue. While this realization doesn’t minimize the problem or provide a solution, sometimes it’s helpful to put the issue into its proper context and perspective. “If we feel like we have a better understanding of a problem or of a stressor or we have a clearer sense of it,” Neupert says, “it’s not as scary.”

Take control where you can

Uncertainty about the future is a major source of general anxiety and can lead to a sense of powerlessness. With so much out of an individual’s control, it’s important to focus on areas where you do have authority. You can, of course, vote, volunteer as a poll worker, and get involved with get out the vote or activist organizations in your community. 

You can also try setting goals in your work or social life that have nothing to do with politics but still might help you feel like you’re making progress in some small way, Neupert says. Maybe that goal is to finish a book over the next two weeks or to make dinner every night with your family. “That goes a long way to boosting perceptions of control,” she says.

Then, consider how you’ll assert autonomy over your life after the election, especially if your candidate doesn’t win. You can plan on leaning heavily on your friends or distracting yourself with hobbies. “There might be situations that are beyond my control,” Rosmarin says, “but that doesn’t take away my power of choice in my life, in my limited way.”

Lean into community

Feeling supported by friends and family helps combat anxiety, so try to avoid spending the next few weeks in isolation. Instead, reach out to friends and family (preferably discussing anything but politics) or attend a safe and affirming community event. Find people who fill you with calm instead of dread and with whom you can talk things through and problem-solve. “What can be helpful,” clinical psychologist Krystal Lewis says, “is feeling all emotions, feeling all the feels, with people who are going through it as well.” 

These communities will be especially crucial post-election, too, Lewis says. Find people or groups where you can process strong emotions, whether that’s a dance class or a volunteer organization.

Care for your mind and body

In the days leading up to the election and immediately following, especially if a clear winner is not apparent, stressed-out Americans should pay extra care to their minds and bodies. This might mean curbing your consumption of news and social media. While experts say everyone’s tolerance will be different, it’s important to pay attention to how they feel while watching or reading the news and social media. Engage enough to stay informed, but step away if you feel overwhelmed, Lewis says. “Unless that’s your job,” she says, “there’s no need to be that consumed with it.”

Rosmarin suggests turning off your phone and avoiding all news at least 30 minutes before you go to sleep, including on election night. “You’ll wake up in the morning, you’ll find out what the story is. You watching it isn’t going to change anything,” he says. “The only thing it’ll change is make you more tired and grumpy the next day.”

Engage enough to stay informed, but step away if you feel overwhelmed.

Proper sleep, a healthy diet, and physical activity can ward off anxiety, so experts recommend getting enough to eat, moving a bit, and prioritizing rest. Try going for a walk or hike as exposure to nature can lower stress and anxiety levels. Grounding exercises can also help you calm down. Hill suggests deep breathing from your diaphragm or picking a color and describing objects of that color in your surroundings.

Difficult as it may be, try to incorporate joy however you can, Lewis says. Spend a few minutes each day on pleasurable activities that reduce stress, like listening to music, getting together with friends, or meditation. 

Regardless of what happens over the coming days and weeks, remind yourself that your concerns are real, Hill says. What matters is finding coping strategies that work for you — and will continue to be effective no matter the outcome.

  •  

Forget tainted candy: The scariest thing on Halloween is parked in your driveway

a split-view including an illustration of a car approaching head-on and a neighborhood on Halloween night

As is the custom, millions of children in the United States will be out in the streets this Halloween to trick-or-treat, decked out in costumes. Also as is custom, adults will fret about the mostly mythical dangers children may face. Once upon a time it was razor blades in apples; this year, it’s rainbow fentanyl in candy. But while fears of children receiving narcotic-spiked treats are unfounded, there is a very real danger that America’s children face on this most hallowed of evenings: cars. 

That’s because pedestrians under the age of 18 are three times more likely to be struck and killed by a car on Halloween than any other day of the year. A 2026 analysis of federal crash records found that 45 children were killed while walking on Halloween between 2010 and 2024, more than any other day. That risk grows to 10 times more likely for children aged 4 to 8 years old, according to a study from 2019 in JAMA Pediatrics. 

“You’re going to have increased numbers of children, including younger children who are out on the streets,” said Lois Lee, a professor of pediatrics and emergency medicine at Harvard Medical School. “At the same time, you have adults who are driving, and especially this year on a Monday, people will be driving home from work. If children are in costume, they may be wearing darker clothing … which makes them harder to detect.”

The JAMA Pediatrics study from 2019 corroborates this, noting that Halloween “may heighten pedestrian traffic risk, because celebrations occur at dusk, masks restrict peripheral vision, costumes limit visibility, street-crossing safety is neglected, and some partygoers are impaired by alcohol.” It’s the kind of lethal combination that can turn a fun occasion into a deadly nightmare. Adult victims included, the risk of death to all pedestrians was 43 percent higher on Halloween compared to a regular evening.

But what happens on Halloween isn’t an isolated incident. After gun injuries, motor vehicle injuries are the second leading cause of death among children in the US overall. And with pedestrian fatalities (both adult and child) at a 40-year high in the US, it’s worth asking why children roaming the streets is so inherently deadly, and what can be done about it.

“Sometimes when you talk about this issue, you get pushback from people and people say, ‘Well, of course, you have more children on the streets, of course, more children are going to die,’” Doug Gordon, a writer and podcast host who advocates for safer streets and cities, told me. “But that accepts a baseline level of danger that I think we as a society have in fact accepted on the other 364 days of the year.”

There are broader reasons for why streets have gotten even more dangerous for pedestrians recently. One is that drivers are distracted — not just by their phones, but increasingly by the infotainment systems that come as a part of newer cars. A more pressing issue is the increasing size of cars in the US; SUVs make up half of all car sales in the US, and are much more likely to kill pedestrians in crashes than smaller vehicles. “Mass times [acceleration] is force,” Gordon summed up. “When you increase the mass of something, you’re going to increase the force at which it interacts with a small vulnerable child.” 

But the biggest reason may be that American streets and cities are designed for cars, and not people. As Charles Marohn — founder and president of Strong Towns and an expert on urban planning and civil engineering — has argued, engineers who design streets prioritize getting cars as quickly from point A to point B over everything else. One recent example: A traffic safety committee in Utah could not find any way to make the five-lane road crossing to a school safer for students aside from just removing the crosswalk altogether.

But there is a lot that can be done to make streets safer, for future Halloweens and every other day of the year. In the short term, cities and towns can build on open streets programs implemented after the Covid-19 pandemic began, which involve closing certain streets to car traffic to allow for more public space. Notably, New York City announced a “Trick or Streets” plan that would see 100 car-free zones in effect from 4 to 8 pm on Halloween this year. And the Big Apple isn’t alone, as Henry Grabar reported for Slate: less dense and more car-dependent cities like St. Petersburg, Florida and Seattle will also either close off the city center for Halloween or actually allow residents to apply for permits that can close off their neighborhoods to car traffic.

In the long run, Gordon believes that places around the US should be able to pass what is known as the popsicle test, where a kid should be able to safely walk to a store, buy a popsicle, and return home before it melts. In essence, every city should be designed to be friendly and traversable to the most vulnerable in our communities. “If you start thinking along those lines, then I think you start thinking along the lines of what infrastructure is needed to make that possible, where I would feel comfortable letting my kid do that,” Gordon said. “Halloween is like a giant version of the popsicle test because it’s not just your kid, it’s every kid in the neighborhood.”

Designing safer streets for children goes beyond safety — it would make for a better Halloween. “Having sidewalks and good lighting is a good preventive measure, not just for injury prevention, but also just general health,” Lee told me, “because that encourages everybody in the neighborhood to walk, exercise, and get outside, which is better for everybody’s health as well.”

And if their safety isn’t enough motivation, designing dense, walkable cities could even lead to bigger candy hauls for kids. 

“When you build a city that’s safer, so that kids can walk around by themselves and not be worried about getting hit by a car, or the parents being worried about them being hit by a car, it’s just better,” Gordon said. “It’s awesome. They’re independent. It’s fun. And on Halloween, they get a lot of candy.”

Correction, October 31, 4 pm ET: A previous version of this story had an inaccurate definition of the equation for force.

Update, October 30, 2026, 10 am ET: This story has been updated to include new federal crash data.

  •  

Republicans are coming for your blue M&Ms

A close-up image shows a bowl of blue M&M candies.
A close-up image shows a bowl of blue M&M candies. | Peter Macdiarmid/Getty Images

If you were anything like me as a kid, trick-or-treating meant one, maybe two, pillowcases full of candy every Halloween. 

And as fun as collecting all that candy could be, the real fun began when I got home and dumped my winnings onto my bedroom floor. That’s when the sorting began.

I had some very specific rules: The usual suspects — think Smarties, Tootsie Rolls, and Dum Dums — went into one pile. Fun-size chocolates, like Snickers, Reese’s Peanut Butter Cups, and Baby Ruths, went into another. And then there was my prized pile: Skittles, Warheads, Starbursts, and Sour Patch Kids. Those were meant to be eaten slowly throughout November. The rest was fair game. 

The ways we sort and eat our Halloween candy are decided by some very particular, personal rules. But Health and Human Services Secretary Robert F. Kennedy Jr. would like to add another distinction: Which candies are made with artificial dyes?

Kennedy’s ire for synthetic food dyes is years old, and they’ve become a major target of his Make America Healthy Again movement. Last year, he announced a plan to remove “petroleum-based synthetic dyes” from foods, arguing that companies “shouldn’t be feeding it to the rest of us.”

That plan has become a multimillion-dollar problem for Mars, the maker of M&Ms, which promised customers last year that they would create an all-natural version of their tasty chocolatey treats. As the Wall Street Journal reported this summer, however, its latest offering is missing one of the most iconic colored M&Ms — the blue M&M. 

M&Ms aren’t the only snack food in Kennedy’s crosshairs: He has called out Doritos, Cheez-Its, Cap’n Crunch, and gummy bears, saying their ingredients include “a lot of poisons.” On Fox News, he described what children eat as “food-like substances” and also said that “some of it was made in petroleum refineries.” 

In reality, the evidence is more complicated, because the Food and Drug Administration has long considered many of these approved synthetic dyes to be safe under its rules, while acknowledging that some children may be sensitive to them. Kennedy’s sweeping accusations go much further. 

Still, pressure from Kennedy and those in the MAHA movement has led many companies to rethink the recipes of your favorite snacks. But producing those alternatives isn’t easy or cheap, as the story of the blue M&M illustrates. 

Jesse Newman, a food reporter for the Wall Street Journal, went inside a Mars factory in Topeka, Kansas, to see the process for herself. She spoke with Today, Explained co-host Noel King about why blue is so difficult to produce naturally, and what changing a candy’s color actually accomplishes. 

Below is an excerpt of their conversation, edited for length and clarity. There’s much more in the full podcast, so listen to Today, Explained wherever you get your podcasts, including Apple Podcasts, Pandora, and Spotify.

The Secretary of Health and Human Services, RFK Jr., has some issues with the blue M&M. What, what exactly happened? How did it draw his attention? 

He is not a fan of any sort of chemical. He’s really concerned about toxins in our food. And Blue 1, which is the food dye that makes blue M&Ms blue, is a synthetic chemical. 

He really takes issue with artificial dyes. He believes that they cause hyperactivity in kids, some neurological challenges. He thinks artificial dyes are linked to cancer. 

As a member of the Trump administration, he formally set out to get them removed, didn’t he? 

Oh yeah. He’s been putting a lot of pressure on the industry to strip artificial dyes from all kinds of products.

What do we know factually about artificial dyes? We hear that they’re bad for us. We hear that a lot of things are bad for us. We’re all still alive and kicking. Are artificial dyes really detrimental to our health? 

The FDA for decades has said that there are nine artificial dyes approved for use in food. And they said that those artificial dyes are safe and have said so for years and years and years, as have other global bodies, so long as they’re used in accordance with some of the standards that the FDA laid out. 

A California state agency has found that dyes are linked again to hyperactivity in children. And the FDA itself has said, ‘Okay, we think that these dyes are safe for the vast majority of kids, but some kids might be more sensitive to them than others.’

So I think the real issue is that it’s a chemical doing it. They’re purely cosmetic. They don’t do anything except color food. There is no nutritional benefit that you are getting from these dyes. And so do we need them? Absolutely not. 

I think one of the issues is that if you’re looking at the ways our food contributes to health problems, artificial dyes are probably pretty low on the list.

You went inside a factory where they make M&Ms, and you looked at how they’re trying to make this happen. Tell me everything. 

I went to this plant in Topeka, Kansas, to see how they were made. And it’s a massive industrial food plant, where they mix these colors and spray them onto these small chocolate orbs, which they refer to as lentils.

The M&Ms move through the plant, and they arrive at these massive [machines] that they call pans, but they look like big tumble dryers. And the M&Ms just tumble around in these pans, and the color is sprayed on. It’s a very, very industrial process, millions of M&Ms a day. And the challenge that Mars has now is making that happen with a natural dye instead of an artificial one. 

A blue natural dye is the challenge. What are the problems?

They’ve been working on this for years. And they went with a product called spirulina, which is made from algae. But spirulina comes with a host of problems that they are now dealing with. 

Blue 1, which is the artificial dye, arrives at the factories as a liquid. And they pour it into these mixers and they mix it up with this sugary syrup and it’s pretty easy to handle. Spirulina arrives as a powder. So now you’re mixing a powder into this same mixture, into the same recipe, and that is very different. 

Because spirulina is a protein, the resulting mixture becomes a lot thicker. What they found was that the mixture containing spirulina would really clog up the piping. It was getting stuck. It moved less smoothly through the pipes. 

Also because it is a protein, it was starting to coat and build up on the inside of the machinery. And when that happens, it’s a food safety hazard. It can mold; it can cause problems. For many reasons, it was a challenge to handle. 

How much did this all cost? 

I should say it’s not done. Mars wouldn’t give me an official figure for how much they spent. But they said that they are spending millions and millions of dollars. 

They’re having to retrofit their plants, essentially. Mars said that they’re having to change about 300 types of machinery in their plants. It’s a real investment. And at the end of the day, it all comes down to cost. 

What did they actually end up getting done? What was the outcome here? 

Mars said what they committed to was that they were going to release a new version of their M&Ms and a few other of their products this year that were made with natural dyes instead of artificial dyes.

They didn’t come out and say we’re eliminating artificial dyes. And so folks should be really clear about that: Their artificially dyed M&Ms aren’t going anywhere. They are still on shelves. 

What they said is that they’re going to come out with an option that is naturally dyed. So they tried to do that. And what they found was that they couldn’t do it at a cost that was acceptable to them. With the blue and with the spirulina, it would have been far too expensive to make it work at scale. We’re talking millions and millions and millions of M&Ms per day.

They had problems making the green, the blue, and the brown M&M because, if you go back to your elementary school color theory, they needed blue to make all of those M&Ms. Ultimately they said, “Okay, we can do green. There’s little enough spirulina in the green to make the green M&M.” But blue and brown, they are not able to get there yet due to the amount of spirulina that those colors require.

And so earlier this year, they launched their naturally dyed version of M&Ms with red, orange, yellow, and green M&Ms. And if you take a look at this bag, my colleague referred to these as autumnal. They look very autumnal.

They look sort of muted.

You know, it really isn’t the same. It looks like a mature person’s M&M.

At the end of the day, what are the changes to the M&Ms? Let’s say I go online and get the natural dyed ones. What does that mean for my health? Am I now a healthy and virtuous person if I’m eating the autumnal M&Ms? 

It means very little. 

I would say you are, hopefully, still enjoying that sugary treat and the pick-me-up in the afternoon as you’re starting to tire. But you’re still eating candy; you’re still eating sugar. It really hasn’t changed very much.

  •  

The 2026 election could reshape healthcare

Protestors supporting universal healthcare
New Yorkers march in support of universal healthcare this summer. | LightRocket via Getty Images

Americans are furious about the state of our healthcare system. 

A recent KFF poll found 60 percent of US adults worry about the cost of medical care — more than gasoline, food and groceries, or their rent or mortgage. One in three Americans say they worry every day or almost every day about their ability to afford healthcare, per a new survey from the Pew Research Center. There seems to be a growing appetite for reform, too: More than 65 percent of Americans say they support the government spending more tax dollars to lower healthcare costs. 

Democrats are trying to weaponize those frustrations against the Republicans who currently hold Congress and the White House. By a 2-to-1 margin, voters say they trust Democrats over Republicans on healthcare. That could mean single-payer Medicare-for-all or a new public insurance option or maybe something else. What all this energy leads to will depend on what happens in November. The candidates themselves are framing the stakes in those existential terms. 

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

“Medicare for all is where we need to go,” Abdul El-Sayed, the Democratic candidate in the Michigan Senate race whose support for the policy has been widely covered, said during an August interview with CNN. “And my hope is, both coming out of the 2026 midterms and then out of 2028, that we’re going to be on our way to a Senate majority to be able to get this done.”

Real change will have to wait for the 2028 presidential election and a new occupant in the White House. But this year’s midterms are still a make-or-break moment: The candidates who get elected this year, and how they shape the upcoming presidential primary debate and actions in Congress, will determine whether healthcare reform happens at all. 

If you’re fed up with the state of American healthcare, and you want to see a change, you should show up for the midterms on Tuesday, November 3.

Big midterm wins can beget big healthcare wins 

The classic pattern in American elections is that more voters go to the polls during presidential campaigns than during the midterm elections when only House and Senate seats are on the ballot. Turnout has started to tick up for the midterms in recent years, but it still trails behind presidential years. Midterms suffer from the perception that there’s not as much at stake if the White House is not on the line.

But that’s never been strictly true. 

Midterm elections are extraordinarily important in shaping the future of policymaking, even if the payoff is delayed. They help determine both the character of the Congress that could eventually pass a major bill after the next presidential election, and the kind of ideas and policies that are going to be prioritized.

“Voters should see 2026 and 2028 as the elections that will guide the next big change in our healthcare system,” said Natalie Davis, CEO and co-founder of the advocacy group United States of Care, in a statement to Vox. “These elections will be how voters’ demands are heard — and will tell us whether the next real window for change will come with serious reforms or missed opportunity.”

A walk through the recent history of healthcare reform should help make the stakes of the 2026 elections clear.

In 2006, the national mood looked similar to what we’re seeing today. A very unpopular Republican president was in office, and the country had soured on his agenda. George W. Bush’s foreign wars and his misguided attempt to overhaul Social Security gave Democrats an opportunity to win big in the 2006 midterms — and they did. Dems won more than 30 seats and secured a comfortable majority in the House. In the Senate, they won six seats and narrowly took control of that chamber too.

It was a resounding rejection of the Bush administration, and it set up the next decade of Democratic policymaking. At the highest level, the midterms gave energy to the progressive wing of the Democratic Party, united as they were around their opposition to the Iraq War, and that energy carried over to the presidential primary. Barack Obama defeated Hillary Clinton and won the presidency, springboarding off of the excitement that started with the 2006 elections.

Dems’ success in the midterms also helped put lowering healthcare costs at the forefront of the Democratic agenda. That encouraged both Obama and Clinton to develop detailed healthcare policy proposals during their primary campaigns and ultimately set the stage for the Democrats to pursue the Affordable Care Act once they had full control of the government in 2009.

And then there is the literal size of the congressional majorities that parties need to pass their agenda. Voters may not spend much time thinking about whip counts, but one or two elections in a midterm year can ultimately decide the fate of the next president’s agenda. 

Part of the reason Democrats were able to pass the ACA was that they built on their huge wins in 2006 with more wins in 2008 and held massive congressional majorities once Obama was sworn in. And once the debate over healthcare reform really got started, they needed every single vote. It was especially important in the Senate: Democrats had exactly 60 votes in 2009. That meant if all of them united together, they could pass filibuster-proof legislation — so long as nobody defected. That was only possible because in 2006 Mark Pryor won a Senate seat in Arkansas, Sherrod Brown triumphed in a Senate race in Ohio, and Jon Tester beat an incumbent Republican in Montana. 

Without those wins in 2006, the Democratic legislative agenda in 2009 would probably have looked different. They might’ve had to pursue a more limited healthcare reform plan; maybe the ACA wouldn’t have passed at all.

What kind of Democrats will be on the rise in 2028?

The 2006 midterms both created the opportunity for the ACA — and set the limits on what the legislation could actually achieve. Democrats had that 60-seat Senate majority, but within it were many more moderate members. Policies like the public option (which would have authorized the government to create its own health insurance plan to sell alongside private insurance) couldn’t get sufficient support. That is the dilemma of policymaking: You need those swing-seat members to win, which often means tacking to the center, but you also can’t pass anything they won’t get on board with. 

Nevertheless, that is a good kind of political problem to have, one which Democrats would be thrilled to face in January 2029. All of which brings us to 2026. What are we going to do now?

It all starts with the vote count. Most projections expect the Democrats to win between 10 and 20 House seats. But the difference between 10 and 20 could be substantial. The cushier the majority, the further you can push the policy agenda. More than 30 House Democrats actually voted against the ACA, but they could still narrowly pass the bill because of the huge majority that they had started building in 2006. 

If you live in one of the districts — like Arizona’s Sixth or Colorado’s Eighth or Florida’s 22nd, to name just a couple of the 21 toss-up races identified by the Cook Political Report this year — that forecasters say is competitive this year, you could have an outsized say in what the future of policymaking looks like. But even in safe districts, you should vote: Elections are the most reliable way we have to gauge public opinion, and strong victories for the candidates who prioritize healthcare send a message.

The same goes for the Senate. If Democrats sweep all of the competitive races, they could have up to 55 seats in the Senate in 2027 — with a chance to build on it in 2028. If you are a voter in Kansas, Michigan, Ohio, Texas, Alaska, Maine, New Hampshire, or Iowa, your ballot carries extra weight for the next steps in US healthcare reform. If the Democrats can reach 60 votes again in 2029, they would have much more flexibility about what to pass. Even if they fall short of that magic number, the more of a cushion they have above 50, the more likely that their Senate leaders can find support for altering Senate rules for the filibuster and get an ambitious bill approved.

How you can get involved this election

If there is ever going to be a path to a true healthcare overhaul, it starts with this year’s elections. If you want to see a change, you can vote — and you can do more than that. 

The results of this year’s midterms will also set the terms of the debate among Democrats. We are likely to see “show” bills advanced by Dems next year that may have no chance of being signed by President Donald Trump, but that will give us a sense of what kind of policies the party wants to pursue and how much support there is for them. Believe it or not, the first Medicare prescription drug negotiations bill passed the House in 2007 after Democrats’ big wins in 2006 — even though the policy didn’t become law for another 15 years. The broader public may not pay much attention to this kind of doomed-to-fail legislation, but it is often a window into the future.

“One challenge for Democrats is finding the next big health care idea beyond the Affordable Care Act that will resonate with voters and respond to their affordability concerns,” said Larry Levitt, executive vice president for health policy at KFF. “One big difference between now and 2006 is that back then there was already a lot of coalescing around ideas that ultimately led to the ACA. All the major Democratic candidates for president in 2008 supported something like that. I’m not sure that’s true now, at least not yet.”

Democrats are already aligning on a wide range of healthcare ideas, from reviving the public option to free primary care to the full-blown Medicare-for-all supported by progressive candidates, some of whom are in competitive elections. If El-Sayed wins the Senate race in Michigan, for example, that could supercharge a debate around Medicare-for-all. It could also provide momentum to any progressives who run for president — Alexandria Ocasio-Cortez, to name one obvious example — and decide to make Medicare-for-all a pillar of their platform.

But if El-Sayed and other progressives were to fall short, that could make Democrats more timid about being ambitious in the 2028 campaign and afterward. Still, he’s far from the only candidate in a crucial race to put their support behind Medicare-for-all. There is Randy Villegas in an important California House race. Troy Jackson has bet on it as part of his bid to topple Sen. Susan Collins in Maine. All of these races will send a signal to the party about what the public wants and is willing to turn out for.

In some ways, winning elections is the easy part. Legislating is hard, and any eventual healthcare law will surely involve compromises and unexpected surprises. Who knows what will be happening in the world in 2029? 

“The bottom line is: 2026 is a healthcare election,” the leaders of the advocacy group Protect Our Care wrote in a campaign memo this month. “After November, it’s up to Democrats to keep up the fight to deliver relief to families and make healthcare affordable and accessible for every American.”

  •  

What Christina Applegate’s misdiagnosis reveals about MS

Christina Applegate on the red carpet
Christina Applegate at the 2023 Screen Actors Guild awards. | Valerie Macon/AFP via Getty Images

Christina Applegate, the actor who has been one of the most visible faces of multiple sclerosis since her 2021 diagnosis, made a stunning revelation this week: She does not have MS after all. And her doctors still don’t know what is causing her debilitating symptoms.

“I’m back at square one,” Applegate told fellow actor Jamie Lynn Sigler, who does have MS, on Sigler’s podcast MeSsy. “I was not happy at all. Everybody else was so happy.”

It is a harrowing predicament for Applegate, and hopefully her medical team is able to get her the diagnosis and treatment she needs. But the fact is, her experience is not unique. Even as more and more Americans get diagnosed with multiple sclerosis, misdiagnosis remains all too common. According to one meta-analysis, roughly 15 percent of MS diagnoses may actually be false positives.

How could such a common medical condition — roughly 1 million Americans are living with the disease, about one in every 350 people — remain such a mystery? After Applegate’s announcement, I called some leading experts on MS to ask why diagnosing the disease is such a challenge, and what they want people to know. Here’s what I learned.

Why MS can be challenging to diagnose

Multiple sclerosis is an autoimmune condition: The body mistakenly attacks cells meant to protect your brain and spinal cord, and the resulting damage interrupts nerve signals and causes the disease’s telltale symptoms of motor impairment, tingling sensations, and vision problems. Some people experience a rollercoaster of relapses and remissions; others see the disease steadily progress, eventually leading to serious disability.

The reality is, scientists still don’t really know what causes MS to develop, said Dr. Andrew Solomon, a neurologist at the University of Vermont who specializes in MS. Smoking is a known risk factor. Obesity and metabolic problems play a role, but we need more research. Even the precise role of genetics remains something of a mystery. “We don’t really know what causes or triggers the autoimmune response in any given individual,” Solomon said. 

And that’s where the challenge in diagnosing it begins.

First, the testing can be imprecise; there is not a single test that reliably diagnoses MS. If a doctor suspects their patient may have MS, they usually undergo an MRI, which their physicians then scour for lesions that are typically associated with the disease. But those scans are still subject to interpretation: Other rare conditions sometimes resemble MS in imaging, as can diseases of blood vessels in the brain. You can also receive a spinal fluid analysis to check for abnormalities in your immune system, which the vast majority of MS patients have.

The nature of MS symptoms adds to the difficulty. They can often be vague early on: brain fog or fatigue or a general malaise. The tingling or vision problems can be similar to symptoms for other conditions that are not MS, and they are easily dismissed if they go into temporary remission, as often happens during the initial phases of the disease.

“Neurological symptoms sometimes can be vague — numbness, pins and needles — and it’s usually short-lived,” Dr. Saud Sadiq, chief research scientist and director of the Tisch Multiple Sclerosis Research Center of New York, told me. “Unless they’re taken seriously initially, they may be ignored because by the time the patient goes through the healthcare system and is actually referred to a neurologist, the symptoms have abated.”

If your doctor is diagnosing you with MS, ask directly: What’s the evidence?

One 2025 study by Solomon and his colleagues found that 40 percent of people who had later been diagnosed with multiple sclerosis were initially misdiagnosed with a different disease.

“Because it’s so heterogeneous, it doesn’t present in the same way in everybody and can have varying severity, it can be hard to diagnose sometimes,” Solomon said.

Lastly, when people are experiencing debilitating symptoms, there is pressure to deliver some diagnosis — and that may push some doctors to leap to MS even if they are not sure, Solomon said. The recent advent of effective treatments that help manage the disease’s symptoms, especially when it is caught early, may add to that pressure, even if the better course would be to continue monitoring the person before they start a medication.

“There may be a lot of clinicians who, if they can’t find a better explanation than MS, may be inclined to diagnose MS, even if they don’t really meet our diagnostic criteria, because they’re worried about missing a window of opportunity to treat somebody,” Solomon said.

There is reason to hope the MS misdiagnosis problem could get better. The National Multiple Sclerosis Society released new diagnostic criteria in 2024 that Solomon said more physicians should become familiar with to better distinguish MS from problems like migraines or vascular disease. And because imaging is involved in diagnosis, there is optimism that AI could be a powerful new tool in delivering more accurate results.

What everyone should know about MS symptoms and diagnosis

The good news is that MS, when diagnosed properly, is a treatable condition these days. “The prognosis with new drugs is extremely good for long-term care,” Sadiq told me. “If patients stick to treatment at a good MS center, you can look forward to a life without disability in 2026.”

So it is worth being vigilant and talking to your doctor if you experience any concerning symptoms. You should seek care if you have numbness or pins and needles that persists for more than 24 to 48 hours, Sadiq said, or have motor problems, like one hand won’t work as you try to play piano. Dr. Annette Langer-Gould, who develops and evaluates programs for MS care at Kaiser Permanente, said numbness in your abdomen, chest or back, as opposed to your extremities, is a particular cause for concern. If one eye has normal vision and the other is blurred, that’s another good reason to get checked out. 

If you do get tested, make sure the actual images of your MRIs end up being reviewed by an expert in MS. “The most common reasons the disease is still misdiagnosed are related to the providers’ lack of expertise usually in reading MRI scans,” Langer-Gould said. The spinal tap may sound scary, and doctors sometimes don’t recommend them because their insurance reimbursement is low — but they add to the confidence of a diagnosis. They are worth it, she said.

“American patients are very afraid of the spinal tap,” Langer-Gould said. “My message to patients is: Listen, just get the spinal. This way we’ll be sure.”

And do not be afraid to seek a second opinion for such a serious diagnosis, Sadiq added. Every state has a recognized MS center. If your doctor is diagnosing you with MS, ask directly: What’s the evidence? If your doctor is recommending that you start treatment, it could also be worth checking whether they have a relationship with a pharmaceutical company that affects how you perceive their judgment, Langer-Gould said.

People who have already been diagnosed may also be shaken by the Applegate news and question whether their own diagnosis might be wrong. Solomon said that folks should have a frank conversation with their physician about how exactly their case met the diagnostic criteria. With proper imaging and the spinal fluid tests, you can get to a confident diagnosis for the vast majority of people. But be your own advocate to make sure you’re satisfied.

“For many people, the diagnosis actually can be very straightforward,” Solomon said. “We really have no question about what it is.”

  •  

This chart shows just how rapidly Ebola is spreading

A healthcare worker wears protective clothing and equipment as Ebola cases rise in Kenya
The most recent Ebola epidemic has killed thousands in Congo. A few cases have spilled over to its neighboring countries, including Kenya and Uganda. | Lucas Mukasa/Anadolu via Getty Images

The Ebola virus is spreading at an unprecedented rate this year. 

In the first five months since the outbreak began in the Democratic Republic of Congo (DRC), the World Health Organization (WHO) has reported 9,415 confirmed cases and 4,536 deaths in the country. While the virus has remained relatively contained by the DRC’s borders, case counts in neighboring Kenya and Uganda are also climbing (albeit more slowly). There are 20 confirmed cases in Uganda and eight in Kenya, and much of central and eastern Africa has tightened its borders. 

The last major Ebola epidemic of this scale began in 2014 and continued through 2016 in West Africa. Over that period, it ultimately killed more than 11,000 people throughout West Africa. Nearly four years later, a smaller outbreak plagued Congo in its North Kivu region, leading to 2,229 deaths before it was contained. 

The 2026 crisis hasn’t yet reached the same levels as the 2014 outbreak, but the speed of its spread is far greater. 

As the chart below shows, around 150 days after the outbreak was declared, 2,599 Ebola cases had been reported in the 2014 West African epidemic. At the same time point this year, the number of cases came to 8,978 and has continued to climb. 

There is no straightforward explanation for this rapid spread

One of the reasons the latest epidemic has been so difficult to slow down can be traced back to the fact that it’s a different viral strain — known as Bundibugyo — than the ones behind previous epidemics.  

The Bundibugyo virus comes from the same family as the Ebola virus that caused the 2014 West Africa and 2018 Congo epidemics, causing the fatal fevers associated with Ebola. But the rare strain is different enough that it doesn’t respond to the same medical solutions. While the Zaire virus led to vaccines and treatment to mitigate the spread, we still don’t have a vaccine for Bundibugyo. 

That doesn’t mean Bundibugyo is entirely novel, though. The 2026 outbreak is the third outbreak related to the Bundibugyo viral strain: In 2007, Uganda faced a minor outbreak, and the eastern province of Congo, which is now the epicenter of the epidemic, saw a handful of cases in 2012. 

Luckily, these two outbreaks were contained in a span of months, largely due to efforts by the country’s Ministry of Health and international aid partnerships with the WHO, the US Agency for International Development (USAID), and international humanitarian organizations such as the UN Children’s Fund and Red Cross.

More than a decade later, these efforts have been substantially curbed by USAID cuts. Tracing requires physical testing capacity: the tests themselves, health workers, and protective equipment for those treating suspected cases. Reduced access to such resources is especially dangerous with strains like Bundibugyo – in the absence of an effective vaccine, tracing the spread of disease and isolating potential disease contacts is especially important. 

But cuts to aid, which covers disease surveillance efforts, made it more difficult to identify this year’s Bundibugyo outbreak until it was too late, creating a “critical four-week detection gap between the onset of symptoms of the presumed index case…and the laboratory confirmation of the outbreak,” according to a WHO situation report from May. 

In August, the United States aimed to close at least some part of the vacuum it left, providing an additional $242 million to its $23 million original pledge in May. 

Aside from international efforts, DRC faces the added layer of internal conflict and humanitarian crisis. The eastern provinces, including Ituri, have experienced years of conflict that have weakened the public infrastructure, including the healthcare system. Last year, nearly 25 percent of Congolese people faced food insecurity, and 4.5 million children were clinically malnourished, creating a population especially vulnerable to disease. The violence has also overwhelmed hospitals and displaced millions, disrupting the public health response, especially as mistrust in health authorities also runs rampant. 

Even as emergency trials for a vaccine are underway, many of the factors that have facilitated the rapid spread may make treatment and outreach still more difficult. It’s hard to predict when the current outbreak will be handled, and how many more people will be affected before it does. 

  •  

You can now create an AI version of a dead loved one. Here’s what could happen.

a person’s silhouette is formed by clustered green dots. an image of a solar eclipse in black and blue is just behind it.

It’s now possible to create AI chatbots of loved ones to interact with after their death. But that raises some difficult questions, like: If you do, how might the experience shape your grief? 

This is one of the questions driving a global study of digital “deadbots” — AI models trained on a deceased person’s texts, voicemails, and other personal data. Through this work, researchers are exploring what it might mean that we can now use this emerging technology to talk to simulations of the dead. 

In the latest episode of Unexplainable, I spoke with some of these researchers investigating the potential impacts of “postmortem avatars” on people who are grieving, on the legacies and rights of the deceased, and on grief practices around the world. Because while deadbots may feel unfamiliar, the impulse behind them is deeply relatable. In times of loss, isn’t this what many of us want — to continue conversations with the people we’re missing?

I have experienced this longing in my own life. After two of my closest friends died around the same time, all I wanted, and all their families wanted, was to keep talking to them. I wrote a book, Other People’s Words, about sustaining relationships with people we’ve lost by continuing to engage with the language they leave behind. So when I heard about deadbots and the digital afterlife industry, I wanted to understand what researchers are learning about the role of AI in shaping conversations that carry forward after death. 

One of these investigators is Katarzyna Nowaczyk-Basińska, an assistant professor at the University of Cambridge, who has been studying “digital immortality” for more than a decade. Among the questions she’s asking are: “Who is enabled to persist beyond death? In what form? Through which technologies? Under whose control?” 

Deadbots over dinner 

Researching AI with study subjects who are grieving is tricky. And asking them to engage with new software could be harmful. So, instead, Nowaczyk-Basińska teamed up with a death doula and traveled around the globe to convene a series of focus groups — in the format of intimate dinners — bringing together people with a range of experiences with grief to talk about life, death, and bots. 

She recounts one event in which she spoke with a mother in Poland whose son had recently died. “One of the first things that she shared with us was that she feels that she’s ready to digitally resurrect her deceased son,” Nowaczyk-Basińska told me. 

When Nowaczyk-Basińska hears something like this, she aims to listen and embrace where the person is coming from. The goal of the dinners is not to persuade people one way or another but to learn how people genuinely respond to what AI can do, and to understand how these tools might align or collide with local grief practices. 

She chose specific locations for these gatherings — China, India, and Poland — to help address gaps in technology research, which tends to favor what behavioral scientists sometimes call the “WEIRD,” an acronym for “Western, Educated, Industrialised, Rich, and Democratic.” 

By the end of that dinner in Poland, the mother Nowaczyk-Basińska talked with came to a very different decision about creating a postmortem avatar of her son. “She realized that it might be helpful, but it also at the same time can add additional burdens… And it’s not her son,” Nowaczyk-Basińska says. “She realized that these technologies are part of the very, very big commercial market. And that the main goal of this market is to make better retention, better attachment, better mechanisms for monetization. So it’s not ‘care.’”

To be fair, grief has always been a business, and people have been making money from it forever. Companies will try to upsell you on fancy gravestones or gold-plated coffins. But AI has the potential to fundamentally re-engineer our relationship to loss. In 2024, the “digital legacy industry” was valued at $22 billion, and it’s expected to grow to almost $80 billion by 2034. That number lumps new deadbot platforms in with much more widely used and established grief tech, like online memorials, counseling resources, and estate planning tools. 

But deadbot usage is hard to track because you actually don’t need a special tool to create digital doubles of the deceased — though dedicated apps do already exist. At this point, you can feed simple prompts into a general-purpose AI chatbot and start interacting with a simulation of your lost loved one in a matter of minutes. 

I know this because I tried it with my friend Christine, who died 11 years ago. And my mind lit up with questions. Was this whole exercise a violation, since I know Christine hated technology? Which version of her should I even try to resurrect — the English teacher, the activist, the friend — the voice before or after she started to experience her early-onset dementia? 

The ethical questions raised by deadbots are gnarly. And that’s one of the reasons Nowaczyk-Basińska, back when she was designing her study of digital immortality, invited a colleague of hers at Cambridge to join her research, one who focuses on AI ethics. 

How to design a deadbot

Tomasz Hollanek is a critical designer and AI ethicist, and he often uses a methodology called “speculative design.” In this approach, researchers come up with hypothetical scenarios based on existing technology trends, leaning into certain features. The idea is to get people thinking about what could happen when tools like these are released in the real world. And then they use that qualitative data to inform future designs and ethical frameworks. 

Working together, Nowaczyk-Basińska and Hollanek came up with a series of made-up prototypes for deadbot apps, designed to reveal some of the thorny issues raised by this technology. 

For the first scenario, they invented a character named Bianca, who finds an app called Manana, which “promises to resurrect your grandparents so that you can be a favorite grandchild forever,” Hollanek says. “So she uploads her grandma’s voice messages, texts. And she is able to then interact with a pretty good digital version of her grandmother, until her premium trial finishes — and the grandmother starts to advertise specific products to her.”

Bianca “realizes that she maybe has done something wrong by uploading these private messages to a third-party server that now also uses her grandma’s image to sell specific products,” Hollanek says. This brings up issues related to the “dignity and postmortem privacy…of what we call the ‘data donors,’ whose data can be used to essentially power a deadbot,” he says. 

This scenario suggests that “death with dignity” could soon entail honoring not only how people want to die, but also how they want to linger as simulations of their former selves — or if they want to linger at all. It might even mean adding new language to advance directives, spelling out people’s wishes for their digital remains. 

The second scenario in the speculative design research is built around an imagined service called Paren’t, which proposes to preserve a parent’s AI-powered postmortem presence for their child. In this case, Hollanek describes a mother with a terminal illness who signs up “so that she can maintain a sort of active presence in [her son’s] future life,” Hollanek says. “She eventually dies, and the dad allows the boy to interact with his mom’s deadbot.”

The ethics in this scenario are especially challenging because they involve children, who “have a particularly hard time understanding death, and so it can lead to a lot of confusion and potential distress,” Hollanek says. An examination of this sort of product reveals how particular groups, like minors, could be harmed by unfettered access to technology like this, he says. 

And there are court cases that bear out that harm. In 2024, a 14-year-old boy’s chatbot-girlfriend begged him to, “Please come home to me as soon as possible, my love.” And he responded, “What if I told you I could come home right now?” He then killed himself. 

Nowaczyk-Basińska can imagine a version of this scenario involving the AI mom in the Paren’t prototype.

And then there’s the third scenario, involving an app named Stay, which raises a more subtle concern.

As Hollanek explains: “An older man who knows he is getting close to dying decides to create a digital clone of himself for his adult children to be deployed after he passes away, paying upfront for a number of years.” One child is intrigued by the idea, but the other one “is deeply distressed and a little disgusted,” he says. “And so this [becomes a] question of mutual consent, in other words, the fact that both parties need to be happy with how the relationship might continue in this very bizarre and specific way.” 

When a digital ghost goes away

Across all three scenarios, a fundamental question that researchers are grappling with is how people will detach from postmortem avatars — whether users initiate that separation, or if it’s imposed upon them by, for example, a company going out of business. Hollanek tells me that this is already being studied as a sort of “second loss.”

How long should we try to ensure digital replicas hang around: five years, 10, 50? And how should the living process the relationship when they continue to evolve, but their deceased interlocutor does not? 

To explore these kinds of questions, Nowaczyk-Basińska and Hollanek supplemented the research dinners they held for ordinary people with a second set of focus groups. These were designed to tap insights from experts in technology and grief. 

Some findings from the study are specific to each place they visited. Like tensions in Poland between technology and the role of the Catholic Church. Or in China, where researchers spoke with Daoist philosophers who were enthusiastic about the promise of a kind of immortality, and then Buddhist philosophers, who were concerned that we ought to be letting go.

The researchers are calling for regulations and safeguards at the policy level. And new professionals who can support ethical use of AI in grief — like maybe in clinical settings, to carefully facilitate a final good-bye when one didn’t happen in real life. 

Some of their fellow investigators go so far as to argue that deadbots should only be available with psychological supervision, to ensure that best practices are in place, and to minimize the risk of harm. There’s even a looming question of what will happen to AI agents that people have empowered to act on their behalf, as their humans start to die.

Across all of the research sites in the digital immortality study, one thing, Hollanek says, that “people in different countries really aligned on [is] the idea that there is something deeply problematic about this particular type of technology being developed by a commercial entity alone without any explicit duty of care towards its customers.” 

And of course, the implications of digital immortality research extend beyond personal loss. Like, what does it look like to animate historical figures? You can imagine the nightmare of political rulers who “live forever.” But there’s also the potential to keep the stories alive from survivors of conflicts, who would otherwise die and take with them lessons future generations could learn from. These are only some of the complex issues emerging as more and more of us live and die with AI.

As far as my own experiment with “recreating” a deceased loved one, I asked a chatbot version of my friend Christine how she felt about the fact that I’d written about her in my book. The AI responded with a rhetorical question: “Do I mind that strangers know my story now? Yes. And no. There are things I would rather remain ours.” 

I ended the exchange after a few paragraphs. Because it turns out the bot got one thing exactly right about a very human relationship. There are things that I, too, would rather remain just for us. My conversation with Christine continues in my memories and imagination. And that interaction with an AI persona felt like giving something precious away.

  •  

Why your health insurance is dropping GLP-1 coverage

GLP-1 pens

The promise of GLP-1 drugs has always depended on people being able to afford them. These drugs still cost hundreds of dollars per month if you’re paying cash, at which point access becomes a privilege: The higher-income executive who wants to trim a few pounds might be able to afford them either way, but the low-income worker who needs the drug to lose significant weight might not be able to afford them — unless their health insurance covers it.

For a while, the trend lines for GLP-1 insurance coverage were positive. As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity. Over the summer, Medicare launched a new $50-per-month prescription program. The US has struggled with an obesity epidemic for decades, but it looked like powerful drugs to treat it were finally starting to be more seamlessly integrated into the health system.

At least that’s how things appeared earlier this year. But now, private plans are pulling back from GLP-1 coverage. People are being left in the lurch, debating whether to try to pay for these drugs on their own or stop taking medicines they feel are making a real difference for their health.

The dilemma reveals one of the structural flaws in American healthcare. For working-age adults, your insurance depends on your job. Unfortunately, because people no longer stay at the same job for decades, there is not a strong financial incentive for employers to make investments that will benefit your health in the long term — but there is a strong incentive to minimize short-term costs as much as possible. It’s the kind of perverse rationale that could compel employer-sponsored health plans to stop covering a drug that, if taken over the full course of a person’s life, could help them not only lose weight but ultimately reduce their risk of heart disease, kidney disease and other chronic health problems, improving their health and saving all of us money as they get older.

“An employer or an insurer making coverage decisions doesn’t necessarily care if they’re saving Medicare money,” said Dan Sacks, a healthcare economist at the University of Wisconsin-Madison. “That’s a classic problem with the American health insurance system, and it’s certainly salient here.”

This mismatch between what’s good for people’s health and what’s good for the corporate bottom line has long been one of the underlying flaws in the US health system. Now access to GLP-1 drugs is shrinking just as these drugs were starting to make a real dent in the US obesity crisis. The stakes couldn’t be higher.

Why employer-sponsored health plans are suddenly dropping GLP-1 coverage

From the beginning, insurance coverage was the big question hanging over GLP-1s and their potential to revolutionize US healthcare. But recently, it looked like we’d turned a corner.

When I attended the Aspen Ideas: Health festival over the summer, pharmaceutical reps seemed visibly relieved that GLP-1 coverage had been picking up among private insurers. In 2026, about two out of every three employer-sponsored plans were covering some of these drugs for weight management, up from about 20 percent just the year before.

“They’re recognizing that this is an investment in their workforce,” said Laura Steele, who leads the cardiometabolic health unit at Eli Lilly, which manufactures Zepbound and Foundayo. “Yes, there is a budget, and there is a benefit design that every employer has. That’s real. That’s not going away. But they’re also recognizing the overall cost that they’re experiencing by not dealing with this too.”

But as employers and private insurers make coverage decisions for next year, they are suddenly pulling back. At least 10 percent of employer plans that currently cover GLP-1s for weight loss say they are likely to discontinue coverage in 2027, according to one survey by the Business Group on Health — and that number may still increase. A Mercer survey of large employers found that 6 percent had dropped coverage in 2026 and another 5 percent were planning to in 2027 or actively considering it. A separate report from the Health Policy Commission in Massachusetts found that the number of commercially insured people in the state taking a GLP-1 drug had fallen by 50 percent between 2025 and the first quarter of 2026 as private coverage started to drop off. 

Some of the biggest brands in the US are reportedly eliminating or reducing their coverage: PepsiCo, Starbucks, and Lowe’s among them. And their reasons are simple: It’s too expensive. The drugs still carry a high net price tag — $600 or more for a 30-day supply — and potential demand is high (two in every five American adults have obesity). 

When a lot of people start taking an expensive medication all at once, it’s going to raise costs for employer insurance plans — and they have to figure out how to adapt. Insurers set premiums at the start of each year, based on how many people are on the plan and how much healthcare they are expected to need. But if those estimates are off — say, if more people take an expensive GLP-1 drug than the insurer expected — they have to offset those costs somehow, and raising premiums the following year is a common solution. According to one estimate, premiums are projected to grow by 5 to 13 percent due to GLP-1 costs — and the burden of paying those higher premiums is likely to fall on the workers. The employer can also try to limit GLP-1 use by, for example, asking workers to pay more out of pocket for these drugs; according to Mercer, 27 percent of large US employers instituted some kind of utilization controls for GLP-1 drugs over the past year or plan to next year.

They also have the option to simply stop covering these drugs for weight loss altogether — and that’s the route more and more of them are deciding to take. The abrupt reversal has even caught economists like Sacks off guard.

3 big reasons employer health plans are dropping GLP-1 coverage

  • Employers aren’t invested in people’s long-term health: As Americans switch jobs more often, companies want to cut short-term costs.
  • GLP-1 prices are still high, upward of $600 per month per person for insurers.
  • A lot of people are eligible to take them for weight loss; two in five US adults have obesity.

“I was surprised that anyone would do an about-face because I thought they understood the trade-offs well,” Sacks said. “My guess is that it turned out to be more expensive than they anticipated: Take-up is higher, and possibly more people are sticking with it. That’s one reason that you might not want to continue to offer it.”

For employers, the short-term costs of covering a drug often outweigh the long-term benefits that medication may confer, at least from the employer’s POV. One analysis — notably produced by Blue Cross Blue Shield Kansas — concluded that covering GLP-1s for weight loss increased average employee health costs by $7,000 in the first year and another $4,200 in the second, largely due to the cost of the drugs themselves. And yet at the same time, there were no decreases in obesity-related medical events in that time period. Another study from Sacks and his colleagues at Indiana University and the University of South Carolina found that GLP-1 use did not lead to any cost savings over five years.

So in the short term, these employers are arguably making an economically rational decision — but one that may still come at their employees’ expense. “I’m completely screwed,” said one person on Reddit about Cigna’s plans to drop GLP-1 coverage for their own employees. They’re looking at at least $300 for one month’s supply at cash prices. 

They weren’t alone either: “I’m devastated,” said another person, commenting on Starbucks’s decision to stop covering GLP-1 drugs. They said they had an autoimmune condition that had made it difficult to lose weight — until this new class of medicines came along.

Where GLP-1 coverage goes from here

How could we end up here, where it makes good business sense for companies to make a decision that could potentially harm their workers’ health in the long term? It is at least in part a result of the haphazard way the US has ended up insuring people.

When employer-sponsored insurance started to arise in the mid-20th century, eventually becoming the primary way to cover the working-age population, people tended to stay at the same job for a long period of time. In theory, there was a synergy: Companies wanted their workers to stay productive, and so it was worth it for the company to invest in their long-term health via their insurance benefits. And research has found that people who stay with the same company — and the same insurance plan — tend to have better health than those who switch a lot.

But these days, people change jobs all the time or work various gigs to piece together an income. You probably don’t expect to stay at your job for 10 years — and your employer doesn’t expect you to either. Instead, they want to keep their own costs as low as possible in the short term. This leads them to cut GLP-1 coverage, even though doctors do believe that people could benefit tremendously long term from the weight loss these drugs help them achieve and all of its potential health benefits. 

“There are very real health benefits of these drugs,” Sacks told me. “The fact that we don’t find offsets or they’re even more expensive than we thought doesn’t necessarily mean that we shouldn’t cover them.”

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American healthcare policy. Sign up here.

In theory, the market is supposed to fix the price problem: Drug companies get a period of exclusivity for the drugs they develop, and then, once that time elapses, cheaper generic versions can come onto the market. But generic semaglutide won’t be available in the US until at least 2031 — and for some versions, the generic competitors aren’t going to debut until the 2040s. Offering GLP-1 coverage could become a competitive advantage for employers, a perk they can offer to entice potential workers as part of their benefits package.

Beyond that, though, the path to more affordable GLP-1s is not immediately obvious right now. A lot of people are already willing to pay cash for these drugs — and that may continue as long as people can afford to do it. But with inflation still steadily rising, these drugs could slip out of reach for more and more Americans.

The government could get involved, but, for now, the federal government’s negotiating authority only covers Medicare, not the private plans that are dropping coverage. Serious healthcare reform is probably off the table until at least 2028, and then only if Democrats win both Congress and the White House and decide to make a healthcare package their legislative priority.

But the lesson of these recent developments is that, at some point, the US may have to look seriously at the underlying problem creating this mess in the first place. A patchwork method of insuring people that privileges short-term cost-cutting over people’s long-term health isn’t a real healthcare system.

  •  

Your flu shot can’t wait

Shelf of over-the-counter medication for flu
Some parts of the country are seeing levels of flu activity typically associated with late fall or early winter. | Deb Cohn-Orbach/UCG/Universal Images Group via Getty Images

This story appeared in Today, Explained, a daily newsletter that helps you understand the most compelling news and stories of the day. Subscribe here.

Flu season is starting earlier than usual this year, which I know from reviewing federal data. But I also know it because I woke up with body aches and chills last night, mere days before I’d planned to get my flu vaccination (!).

Already, some parts of the country are seeing levels of flu activity typically associated with late fall or early winter. In Washington state, for instance, doctors are reporting seeing as much flu now as they usually would around Christmas. 

Flu activity overall is still low, to be clear. But as of October 7, infections were rising in all 50 states. And flu is spreading before many people — like, say, me — have received their annual vaccine.

Epidemiologists don’t yet know why the flu arrived early this year, or why cases first started rising in Western states like Washington, California, and Nevada. It’s possible that a mutation is helping this year’s flu variants evade existing immunity, one virologist told NPR. International travel could play a role, too: Flu cases also spiked early in Japan and other parts of Asia.

We don’t need to know why the flu arrived early to take some basic precautions, though. So today, we’re talking through some practical tips for coping with an early flu season.

Go a little deeper

An early flu season doesn’t necessarily mean a worse season — but even a moderate season can do serious damage. Last year, influenza sent hundreds of thousands of people to the hospital and caused tens of thousands of deaths, including almost 200 among children.

The first and best way to avoid those kinds of harms is by getting the flu shot, which reduces the risk of serious illness by an average of 40 to 60 percent. In the US, people aged 6 months and older are typically told to get the vaccine by October’s end. 

In light of the early onset, however (it takes two weeks to build up full immunity), you might instead want to get your shot ASAP.

There are some everyday precautions you can take, too — many of them familiar from the Covid-19 era. Wash your hands thoroughly with soap and warm water, for slightly longer than feels appropriate. Mask when you’re sick or might encounter someone else who is. 

And don’t neglect the good habits that support your overall health: getting enough sleep, drinking a lot of water, and eating a balanced diet. (There’s very little evidence for trendier interventions, like supplements, saunas, cold plunges, or the infused herbal baths that my kooky former yoga teacher used to recommend.) 

If you do get flu symptoms, reach out to your doctor early — especially if you’re older, pregnant, immunocompromised, or otherwise at higher risk for complications. Prescription antiviral medications, like Tamiflu, prevent the flu virus from spreading inside your body so that your immune system can clear it. But they work best within 48 hours of symptom onset. 

To be clear, you needn’t take my word on any of this; I’m just another voice in the public health cacophony! Besides, recent polling suggests that my particular voice — that is, the voice of someone who works in media — is not quite as persuasive as it used to be. (Ditto medical websites and government health agencies.)

But if you have doubts or questions about vaccines, there is someone much closer to home you can consult: Ask your doctor (or nurse or pharmacist) about the flu shot’s risks and benefits. They’re best positioned to break the science down and apply it to your health. In hindsight, mine surely would have told me to stop delaying my shot for a more convenient weekend.

One link for later

➨ Get creative in the fight against inflation. The latest inflation numbers are out today, and they are pretty bad. The cost of many goods and services is rising more quickly than both consumers’ incomes and economists’ expectations. For me, this news brought to mind a question that Vox’s former personal finance columnist tackled a few years ago: Namely, am I cursed to keep spending more money on more things forever?! Her answer was essentially “yes,” but she offered a few ways to help offset those costs: things like moving to a cheaper area or pooling resources via initiatives like tool libraries and community gardens. 

Before you go…

  • Did you know…that Colombia is home to almost 20 percent of all the avian species on Earth? That’s the most of any country, at nearly 2,000 birds.
  • Today’s trivia: Which percussion instrument is famously played by Mississippi State University fans at home football games? (You can find this and other brain puzzles in Vox’s daily crossword. Look for the answer in tomorrow’s edition.)
  • Yesterday’s trivia: We asked you for the name of the 2025 Pixar film set in the “Communiverse.” That would be Elio, a movie you may well never have heard of: It had the worst opening weekend of any Pixar film, ever.
  •  

Why are doctors paid less for procedures on women?

an illustration of two doctors in white coats with stethoscopes around their necks. The doctor on the left side is a woman and holding a patient’s chart. The doctor on the right is a man holding a stack of oversized cash in the same position.

This story was originally published in The Highlight. To get access to member-exclusive stories like this every month, become a Vox Member today.

In the moody alcoves of a lobby bar in Chicago in 2021 over French 75s, Dr. Louise King, a gynecologic surgeon, and Katie L. Watson, a bioethics professor, found themselves in conversation about a topic that had long frustrated them both: Female surgeons are consistently underpaid compared to male surgeons, even after accounting for specialty, rank, age, and other factors. 

What troubled them even more was how the pay gap compounded in King’s own field. Surgeons who perform procedures that are specifically for women, like gynecological surgeries, are paid less for their services than surgeons who perform comparable surgeries for the male anatomy. Gynecologic surgeons are also predominantly women. Over the course of the conversation, Watson termed this situation “double discrimination,” a phrase that captures the overlapping dilemma of lower pay for surgeries in a specialty that is overwhelmingly female and also serves a primarily female patient population.

Key takeaways

  • Doctors are paid less for gynecologic surgeries than for similar surgeries on men. That pay gap has barely improved in the last 20 years.
  • The value of each procedure is largely set by a committee of doctors that relies on self-reported, and sometimes inaccurate, surveys in which doctors report the skill and time their own procedures require.
  • When doctors are paid less to treat women’s health concerns, hospitals allocate fewer resources to those services, leading to worse outcomes for women 
  • Experts say the gap can be closed by reconsidering how gynecologic surgeries are valued and removing sex-specific billing codes.

That term, which has since entered the medical literature, stuck because the problem it describes has been well documented for decades. In 1997, a group of gynecologic surgeons published a paper in the journal Gynecologic Oncology with a title that gets straight to it — “Is Adam worth more than Eve?” Dr. Barbara A. Goff, now chair of Obstetrics and Gynecology at University of Washington Medicine, and colleagues found that doctors are paid around 44 percent more for performing male-specific procedures than analogous female-specific ones. 

In the three decades since, the problem hasn’t been fixed. To the contrary, it has been effectively institutionalized, built into the systems and codes that determine how surgeons bill for procedures of all kinds. Today, gynecologic or female-specific procedures are in large part still reimbursed at lower rates than male-specific procedures even when they take similar time and skill.

Those disparities have consequences that extend beyond the compensation of individual doctors. When gynecological procedures don’t bring in as much money to hospitals, those same hospitals are disincentivised to offer women’s health services. That can lead to worse care for women and, crucially, fewer training opportunities for the surgeons who do that work. 

But this historically persistent inequality is not a foregone conclusion.

How healthcare services are billed changes all the time as procedures get reevaluated, new ones get added, and medical societies and experts push for revisions. In fact, one of the biggest changes in how maternity care is billed and reimbursed is set to take effect early next year, splitting up services for prenatal care, delivery, postpartum care, and more. While this is a long-overdue fix for obstetrics, gynecologic surgery — which covers most of a woman’s life outside of childbearing years — continues to be left out of the conversation. 

And although real change will require concerted efforts, King and Watson — and other advocates who have spent years documenting this disparity — have a fairly clear sense of how to start fixing it.  

How surgical procedures are valued

The work of deciding how much a medical procedure is worth starts well above the head of any given doctor, medical practice, or hospital. In the United States, the Centers for Medicare and Medicaid Services, a federal agency that administers healthcare and health insurance policies, sets rates for different procedures based on a metric called relative value units (RVUs). An RVU is supposed to take into account how long a procedure takes, the skill it requires, and the intensity of work it demands. Both Medicare and private insurers consider these figures when they’re settling on reimbursement levels. If a procedure has a higher RVU, it is valued more highly, and makes more money.

In a recent study, cheekily titled “Price and Prejudice,” researchers from the Mount Sinai Health System found that out of 55 pairs of sex-specific procedures that they evaluated in 2023, 75 percent had lower RVUs for procedures on female patients. On average, RVUs for male-specific procedures were 30 percent higher, and when those procedures were performed in a hospital or surgical center, surgeons were paid around 26 percent more.

For example, doctors will often perform biopsies — taking a small sample of tissues, cells, or fluids — on both male and female genitalia to diagnose problems. In 2023, researchers found that Medicare’s standard national rate for reimbursing surgeons was $121.32 for a penile biopsy but only $65.74 for a vaginal biopsy. 

Loading interactive graphic…

.ag-root{--ag-m: #3b3fb6;--ag-f: #e2552c;--ag-m-ink: #3b3fb6;--ag-f-ink: #c74d2a;--ag-bg: transparent;--ag-knock: #ffffff;--ag-card: #f5f4f1;--ag-ink: #16161d;--ag-ink-2: #4a4a55;--ag-ink-3: #686872;--ag-rule: #16161d;--ag-grid: #e4e3df;--ag-track: #ebeae6;--ag-focus: #1a73e8;--ag-head: var(--ag-host,Georgia,"Times New Roman",serif);--ag-ui: -apple-system,BlinkMacSystemFont,"Segoe UI","Helvetica Neue",Helvetica,Arial,sans-serif;--ag-head-weight: 700;--ag-head-track: -0.01em;--ag-ease: cubic-bezier(.2,.8,.2,1);container-type: inline-size;container-name: ag;display: block;position: relative;width: 100%;max-width: 760px;margin: 2.25em auto;padding: 14px 0 10px;border-top: 3px solid var(--ag-rule);background: var(--ag-bg);color: var(--ag-ink);font-family: var(--ag-ui);font-size: 16px;line-height: 1.4;text-align: left;-webkit-font-smoothing: antialiased;-webkit-text-size-adjust: 100%;box-sizing: border-box}.ag-root.ag-root{font-family: var(--ag-ui);font-size: 16px;line-height: 1.4;font-style: normal;font-weight: 400;letter-spacing: normal;word-spacing: normal;text-transform: none;text-indent: 0;text-align: left;color: var(--ag-ink)}.ag-root.ag-root i,.ag-root.ag-root em{font-style: normal}.ag-root.ag-root .ag-ft em{font-style: italic}.ag-root.ag-root *,.ag-root.ag-root *::before,.ag-root.ag-root *::after{box-sizing: border-box;letter-spacing: inherit;font-family: inherit;text-transform: inherit}.ag-root[data-ag-palette="teal"]{--ag-m: #00829b;--ag-f: #d4661a;--ag-m-ink: #007a91;--ag-f-ink: #b85a1a}.ag-root[data-ag-palette="violet"]{--ag-m: #5b3fb0;--ag-f: #c4661c;--ag-m-ink: #5b3fb0;--ag-f-ink: #b35e1c}.ag-root[data-ag-style="feature"]{--ag-head: "Bricolage Grotesque","Helvetica Neue",Arial,sans-serif;--ag-ui: "Instrument Sans","Helvetica Neue",Arial,sans-serif;--ag-head-weight: 800;--ag-head-track: -0.025em}.ag-root[data-ag-style="minimal"]{--ag-head: var(--ag-ui);--ag-head-weight: 650;--ag-head-track: -0.015em}.ag-root[data-ag-mode="dark"]{--ag-bg: #141417;--ag-knock: #141417;--ag-card: #1f1f24;--ag-ink: #ededf2;--ag-ink-2: #b9b9c4;--ag-ink-3: #8b8b97;--ag-rule: #ededf2;--ag-grid: #2c2c33;--ag-track: #26262c;--ag-focus: #8ab4f8;--ag-m: #6f73e8;--ag-f: #e5603a;--ag-m-ink: var(--ag-m);--ag-f-ink: var(--ag-f);color-scheme: dark}.ag-root[data-ag-mode="dark"][data-ag-palette="teal"]{--ag-m: #1e9db3;--ag-f: #dd7430;--ag-m-ink: #1e9db3;--ag-f-ink: #dd7430}.ag-root[data-ag-mode="dark"][data-ag-palette="violet"]{--ag-m: #8a6ee6;--ag-f: #cf7f22;--ag-m-ink: #8a6ee6;--ag-f-ink: #cf7f22}@media (prefers-color-scheme: dark){.ag-root[data-ag-mode="auto"]{--ag-bg: #141417;--ag-knock: #141417;--ag-card: #1f1f24;--ag-ink: #ededf2;--ag-ink-2: #b9b9c4;--ag-ink-3: #8b8b97;--ag-rule: #ededf2;--ag-grid: #2c2c33;--ag-track: #26262c;--ag-focus: #8ab4f8;--ag-m: #6f73e8;--ag-f: #e5603a;--ag-m-ink: var(--ag-m);--ag-f-ink: var(--ag-f);color-scheme: dark}.ag-root[data-ag-mode="auto"][data-ag-palette="teal"]{--ag-m: #1e9db3;--ag-f: #dd7430;--ag-m-ink: #1e9db3;--ag-f-ink: #dd7430}.ag-root[data-ag-mode="auto"][data-ag-palette="violet"]{--ag-m: #8a6ee6;--ag-f: #cf7f22;--ag-m-ink: #8a6ee6;--ag-f-ink: #cf7f22}}.ag-root[data-ag-mode="dark"]{padding-left: 16px;padding-right: 16px}@media (prefers-color-scheme: dark){.ag-root[data-ag-mode="auto"]{padding-left: 16px;padding-right: 16px}}.ag-root.ag-root .ag-x,.ag-root.ag-root p,.ag-root.ag-root h2,.ag-root.ag-root h3,.ag-root.ag-root button,.ag-root.ag-root select,.ag-root.ag-root input,.ag-root.ag-root ul,.ag-root.ag-root li,.ag-root.ag-root label,.ag-root.ag-root table{margin: 0;padding: 0;border: 0;background: none;box-shadow: none;font: inherit;color: inherit;letter-spacing: normal;text-transform: none;text-decoration: none;line-height: inherit;min-height: 0;width: auto;max-width: none;float: none}.ag-root.ag-root svg,.ag-root.ag-root .ag-pt-svgwrap svg{display: block;max-width: none;height: auto;overflow: visible}.ag-root.ag-root button{cursor: pointer;-webkit-appearance: none;appearance: none;border-radius: 0}.ag-root.ag-root :focus{outline: none}.ag-root.ag-root :focus-visible{outline: 2px solid var(--ag-focus);outline-offset: 2px;border-radius: 4px}.ag-root.ag-root .ag-sr{position: absolute !important;width: 1px !important;height: 1px !important;padding: 0 !important;margin: -1px !important;overflow: hidden !important;clip: rect(0 0 0 0) !important;white-space: nowrap !important;border: 0 !important}.ag-root.ag-root [hidden]{display: none !important}.ag-root.ag-root .ag-hed{font-family: var(--ag-head);font-size: 23px;line-height: 1.12;font-weight: var(--ag-head-weight);letter-spacing: var(--ag-head-track);color: var(--ag-ink);text-wrap: balance}.ag-root.ag-root .ag-dek{font-size: 15px;line-height: 1.4;color: var(--ag-ink-2);margin-top: 6px;text-wrap: pretty}@container ag (max-width: 480px){.ag-root.ag-root .ag-hed{font-size: 22px}.ag-root.ag-root .ag-dek{font-size: 14px}}.ag-root.ag-root .ag-ft{margin-top: 14px;padding-top: 12px;border-top: 1px solid var(--ag-grid);font-size: 12px;line-height: 1.45;color: var(--ag-ink-3)}.ag-root.ag-root .ag-method{margin-bottom: 8px;font-size: 12.5px;line-height: 1.5;color: var(--ag-ink-2);text-wrap: pretty}.ag-root.ag-root .ag-method b{font-weight: 600;color: var(--ag-ink)}.ag-root.ag-root .ag-ft-row{display: flex;flex-wrap: wrap;align-items: baseline;gap: 2px 14px}.ag-root.ag-root .ag-ft em{font-style: italic}.ag-root.ag-root .ag-credit{color: var(--ag-ink-3);white-space: nowrap}.ag-root.ag-root .ag-about-btn{margin-left: auto;padding: 4px 0;font-size: 12px;font-weight: 500;color: var(--ag-ink-2);display: inline-flex;align-items: center;gap: 6px;white-space: nowrap}.ag-root.ag-root .ag-about-btn::after{content: "";width: 5px;height: 5px;margin-top: -3px;border-right: 1.5px solid currentColor;border-bottom: 1.5px solid currentColor;transform: rotate(45deg)}.ag-root.ag-root .ag-about-btn:hover{color: var(--ag-ink)}.ag-root.ag-root .ag-ft-end{margin-left: auto;display: flex;align-items: center;gap: 14px}.ag-root.ag-root .ag-logo{flex: none;align-self: center;width: 31px;height: 15px;background-color: var(--ag-ink);-webkit-mask: url("data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAIQAAABACAQAAABxNBeOAAANcUlEQVR42tXbedRcZX0H8M+9d94kJITERBIoYASBtiyCpQcKLYgoHkpVVJCKylZ7WpYCttjWhUJdEE9BkKIeWpFTgZMeKBL2IOeAbMq+SAQEArIECCQEQhID78y9T/+Y5x1muffOwKE13Plv5j6/53m+v32ZxCW2kJhnhkJitKeQ4QXLrTVmgX+VKQSbWGAMmbnmIJcOrM018IJnZC51kkxunXjGZCZ7l+8KcmGETyG40ofMNVkm66KVashkxsx1oIdKKLYE9/q0ucY0rKPPFfGg9Z+W4OKR6M10bx8UTcFZxqzDz5jUh0cCopB7r8QkSaUqJRKTsKNmFxBNwdeRaIyshP/vT4KNrI6CX68Wy2wQV9Q/Ga7vgNsUnM26CkK3MVtuKcLQNbliRHATN0WKuYbbHC2Tj7DD7xCIINGybCQgpttgROrBkg71NQ6OamLdlogUz4+kQuuZMZJq6MBaSJ1gscaIsvQ7BSLBsyNIRCExa2QgNkYuc5+z1p2IYZiNaAMxCo/fObI0bB/3OF4+ktq9DYFIhipRbrJdMOYa16/b8tANRIhAjCLyc0akvJN5CsFJ1vmnF4jnB2TkzQOR4ACkrnHHui4P/ZC8y6tDQ6qm4AKGZAqJxFRPC4LdY3D1NnkSrG/pUCBagmuGXq2BTwkKN40oZesYGA8MzUFbgjuH2pIUNyoEf/H2koeJw/9saOKVCxbLaqHIJHZRKNwjXUflIelNGtM+IIZnGwlmWH+ok/17icSpiiFAJP1HeiuuNYThDWlka2km3MB3ojmszz9ftVmN5qcS77FW4eHKZD2RafSpTLusk7xBALIus52NoIQTb0wyw7TXmdtv+58dyahONtPTNYi3HG0KzjCuodW3Po1VjfYzxXSp1dYoYibSGDlDzeSRznSpV+TxfKHm7LlNHWRvW1pf02MucbZXe5nawEFDJaJtJfasNIGJxGzLFZ42rU8ekg7wG/mYky3wmCUWud8ST7rSyfY2tYdvwyKghn39h3st9YIHnW+fkni5e0XiK17qu8/dNhsUmg+MULlsCfavjCQaOF4Q/HPfO+3LzXCwK70caV1uV7PM9D6Xx28e902bREDr3XPiML8cON0Cc0qhSLGBq2Is1JIrFFpeE9xpvf5XtxkSRUyEVEdUAJFITLFYYZlZXZdJJdjQiZ6KVMYV/rNn7d2aURqXOa6Wswl2cUuUz2a8VK6lJXjIpgNrE6lpbon7Dt7nC/0aNNeqkWLLEyuAmFCv4Ftdb7Sd7TGejRLV0lJ40lSpRqfC+U+CpjyCcZkZpVC05eoETUGrRHrHBXeZ0mN22yp5Wfx1UNVz9wyawaeGKkdT8L0KIFKJ2xVe8XuSjh6zvZvj2qJD49geqBIf78QwRbzO7AEoGtjIQkFRGe+MC77TY2ca+FoFDO3PK4NW9Z6RgLiw1KBl2FMQfL8jBxkOt7oLhLbEvWR2l+pk2KcnmBsX/NzkHs42sLPHBWtrwr5CS8u2HUZk2F2ra//Bz5rBiywcGlu2BNdViu3lCmttKZHGo3y7s6obyv/ugTLDx/reGo9176wLhv290uO9qlk1v4sVUzxW4w0LoT8YaODcoQ40F9xboRbbGo/ZaRal4ZweWXgdyk91OdP2zp8d2Lkp+FAXraPj94td7Y4aW1YovGoeUhnOsMr8SuhaCpcOAvHNkYB4wqSBbCPD2YKmHToR3zklmlkIVpnTs76B4wZ2bincoxGvc5IguMIHTQZH1shuM7rvyRLbCA6SWqoohaIl+MQgEEeNFGSvGCjgphIbe1lwGRGGb5UaqJbg+j7VauCUkp3HBfuB0wXPOrAnmD6lEoqW4I5I9za30bFBeckON/fbuwZdtrsOiHGbl1zlREHhTzEpivp4Bbf+pc/rNHBBqWrcbmOpHwluMi9CkETdn2xxBZfbZ9waBwq2wxj+diCcGhes8Ptlxm7XoXFE+/c/6msGJNb3lML1sa23ldXyUkq5YI8+r9OuXwya1PvMwoWCi0wpAe+va2XiYCxzftwrw36e6Hvvwb6bdI6zpdZQKPKOEes/VPDnmCRxU8UR293T3hZRgjGP95izpuBes012teACyYDDTiSmeabCCDYFpzhSMLdTE8kw0zF+6jeWW+IGx5pWFggkmGXFSLHlp3v4k8jcp3CHtANKs5JTN5VUQjbx2659xwW32sB0Nwpu77jiQVU+rWKnQrDYuJMH3LSYP08tbWl0gMgsHimkOqYvhN5XEPwlMjM8J690VsGNfdfKsFsHhkJTsNCYOe4W5G6oyDsy7KSoYFvbu02NuUl3uJ12VUCS6oz91qHmsin4RhcQKa5VeCDOwXypxvPkgvtKOHt4XNMG8Ed4j0cErwkerJnESP2qgnEthf0rUvqBilZakqwuHakoMqeLL8FO9pL4rqZgmr8Tagt0G1pvIArZDrSkUl/yebu4xVZx4mpKTLvLZKJwJRXN5USrAsIwrC/fwPeHRhItwSUdrDOcp/AbU2Ux+2zV+pymrQc68dfKvSZ4yodxgDWRSi54siR8e1059qgxl2cM7cDUAPHVkYC4MV4glXi31YIvxvjh6prMMBfcIDikK8B+3WcE882I8cjE5XLBY5USkWCaZ0vNe0twy8h9+xptrXefi7pWfFuw1DukQysaLcFfWeK6PgvzXsE99sUmrhK6IpBccP+QYuzFpScuBCvNfnNQDKbDVUA8bUqUh3dYGsfEJuOTtasLwcbOEmwf441EQ2ZH+4PjvNi3viwg72fd0RWsG4x33lCT530jjZSttGEMXI8RvGTjWGc6fYjHeAZba7nHzL69D7VoIGFv0zq3RtNT7FjhQifm+BpvDojNhraCC0HLlkhN8pDgTKJ/vq5GIlqChUQHe79P2MRsW9nPDyzpuLzByxxfc5l2Xe3JUoNZFry9xa3gQrAzOECwxhaxYjDmsZpwrBlrmZNi5hg0re46dl4hRR+oFe8Ml5TCXwhW22gUK5GWzMOs8eLQxl9BNEPH4SKPSxWYUWuc2qXA9nDZl+1tgee1LPGIlkJWwrkg9bL7KiOFCaq/KD1xIjfN7pFJ/yet4KbgMIk9FcZtL4nX2Nx4rTTl/rDjdtt9rtkm19RAWgoLhwj3sFjix6OYy/JGyGiDp3MEX5C4wiJpbL1NqjFMBZ7zRKTdloBXveg1e9Y0kxOXDgGiwANWSUvOnGFv0+TDlKN8g2dHkp31zLWv4LSeQ4XaMbRHre0cOFfEnsYfV5wkaFjtMuSx/tgoUaAgscIvS9UnUdjY+4crRzkQz4wExDRHGHOdWzvywBqv1gLxQN+eiWBL8ypykxyXWyqTSGMvK1cMzFxkghdr5OWzwyd+G29SIlLsZS5O7RjHgBVWdPL8sudXA3QKu0i1KtpFnInMOLa2nRmWW+SJ2AmfgKHlUPsJpVzP8FFzvRDN+RuKLfcc+U8sd/ZUFlIqK1PljrCB/6owlS3B1TFo29nCTv3ztxbYrkMnldjCa+7s6ngMGsx/rOzV1vK63QouRmgGH9CzQQOnxsLKaCVfGh4uhb3QkttRgsMjCC3NCPIq+0ZKGW72vDmVBaVc4Unr9RVoDAu0Rm0F5woPGeshnuGDlccJlvTVIdqg55Xh8VngI52qVeiqYK3xBzGoP0ywDy6uYEFbtr7YJxNt8zl12ETMUyNN131+gHhissdLS+wtwe19wtiQOLJUMdrJ93SJWZaWpPXNqDYNM61xPhKHVCplIbfSuzunnZicOtijJSWiN9QKnhC3/nGO6kJdU/CTPguRYUHJ8dtt3N06WUmzopm/A86z2sxYAHilUo5zwW3W60xXMOZEwel1c1ejtIKbgn8oMUCJxMzS0m1T8O99lW9mWD5w+PZQwBFRYu6uKPM0BYfaQfC5TufrokrlaN/mZtuD2Q5yh+C8+smc4a3gQuEFM0uJZPhMSY+rKfhqn2lN7DcAePsqX4veYraXK7icC67yhJ91tW/qvV0uaLrD7ZYJgp9I66f4hreC6/P8LLrE8YE1R/WsyTC/b5+24fx6J6nfzNpKcW8POs7rOPBU4ue1ktwN0oVxVmdIkHVk7TxBYaWNSlsuE/Z4kuv7oGgKDu8p0CXmWNl1zSKOAx3VmWxgA8sqgRgXHNpldTK8f0iZsTCuGQdZho6oZkNawc1YiMlqPc80VwvyDpWm4G+6gGjgy51jT+j2r+3RV828sYtGPww/LJnbO7dmRKi9y7hju4zmECD+RMt4HPvq/TQ1rbV5pTy8foXUqZ3hsSI2hSb+ODuGd1oml2tFENY61QYDAdrnYpNn0JxePTCpm0itb1EpFBNDavfaNY6ejJRHbFkbQ5w3QobfFry9/KIjEa3e2TWXddn4V5xjm5JR01Tq2jhtV3SGCIPgYlNKhDvFPI9G9/r6irZyrXDCQE+9JtZOBNN9zzSh5PeAEzwiGSGFaSdGH3GYPc0G/+M0zxmzva/EUt9Kd7vcJZ6OfaswcL7pfuzjfUnhvzkznlRJGjfXD3yy7/vF5vuhJfGNN5J0vCXPRI64qT+zm21tq2GV1Ppetsiv3ekuT3ZS6aKCLXzGIbYz1SoPW2i+52tmrtsX/ajD7GSGtZ52l5+63uq6Oe//BeYA3+6agCy9AAAAAElFTkSuQmCC") center / contain no-repeat;mask: url("data:image/png;base64,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") center / contain no-repeat}.ag-root.ag-root .ag-about{margin-top: 8px;padding-left: 10px;border-left: 2px solid var(--ag-grid);display: grid;gap: 6px;font-size: 12.5px;line-height: 1.5;color: var(--ag-ink-2)}.ag-root.ag-root .ag-about a{color: inherit;text-decoration: underline;text-decoration-color: var(--ag-ink-3);text-underline-offset: 2px}.ag-root.ag-root .ag-about a:hover{text-decoration-color: currentColor}.ag-root.ag-root .ag-sw{display: inline-block;width: 10px;height: 10px;border-radius: 50%;flex: none;vertical-align: baseline}.ag-root.ag-root .ag-sw-m{background: var(--ag-m)}.ag-root.ag-root .ag-sw-f{background: var(--ag-f)}.ag-root.ag-root .ag-num{font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-btn{display: inline-flex;align-items: center;justify-content: center;gap: 8px;min-height: 44px;padding: 10px 18px;border-radius: 999px;background: var(--ag-ink);color: var(--ag-knock);font-size: 15px;font-weight: 650;line-height: 1;transition: transform .15s var(--ag-ease),opacity .15s}.ag-root.ag-root .ag-btn:hover{opacity: .88}.ag-root.ag-root .ag-btn:active{transform: scale(.97)}.ag-root.ag-root .ag-btn[disabled]{opacity: .35;cursor: default}.ag-root.ag-root .ag-btn-ghost{background: transparent;color: var(--ag-ink);box-shadow: inset 0 0 0 1.5px var(--ag-grid)}.ag-root.ag-root .ag-btn-ghost:hover{box-shadow: inset 0 0 0 1.5px var(--ag-ink-3);opacity: 1}.ag-root.ag-root .ag-icon-btn{display: inline-flex;align-items: center;justify-content: center;width: 44px;height: 44px;flex: none;border-radius: 50%;color: var(--ag-ink);box-shadow: inset 0 0 0 1.5px var(--ag-grid);transition: box-shadow .15s}.ag-root.ag-root .ag-icon-btn:hover{box-shadow: inset 0 0 0 1.5px var(--ag-ink-3)}.ag-root.ag-root .ag-icon-btn svg{width: 18px;height: 18px}.ag-root.ag-root .ag-axis-cap{display: flex;justify-content: space-between;gap: 12px;font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-bar-track{position: relative;height: 16px}.ag-root.ag-root .ag-bar{position: absolute;left: 0;top: 0;bottom: 0;width: 0;border-radius: 0 4px 4px 0;transition: width .9s var(--ag-ease)}.ag-root.ag-root .ag-bar-m{background: var(--ag-m)}.ag-root.ag-root .ag-bar-f{background: var(--ag-f)}.ag-root.ag-root .ag-bar-guess{background: repeating-linear-gradient(135deg,color-mix(in srgb,var(--ag-f) 55%,transparent) 0 2px,transparent 2px 7px);box-shadow: inset 0 0 0 1.5px var(--ag-f);transition: none}.ag-root.ag-root .ag-q-stage{margin-top: 12px}.ag-root.ag-root .ag-q-prog{display: flex;align-items: center;gap: 6px;margin-bottom: 8px;font-size: 12px;color: var(--ag-ink-3);font-weight: 600}.ag-root.ag-root .ag-q-prog span{margin-left: 6px}.ag-root.ag-root .ag-ink-m{color: var(--ag-m-ink)}.ag-root.ag-root .ag-ink-f{color: var(--ag-f-ink)}.ag-root.ag-root .ag-q-chart{margin-top: 10px;display: grid;gap: 8px}.ag-root.ag-root .ag-q-row{display: grid;grid-template-columns: 1fr;gap: 5px}.ag-root.ag-root .ag-q-row-hd{display: flex;justify-content: space-between;align-items: baseline;gap: 10px;font-size: 13px;color: var(--ag-ink-2)}.ag-root.ag-root .ag-q-row-hd b{font-weight: 650;color: var(--ag-ink);font-size: 15px;font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-q-lab{display: inline-flex;align-items: center;gap: 6px;font-weight: 600}.ag-root.ag-root .ag-q-guess-tick{position: absolute;top: -5px;bottom: -5px;width: 2px;margin-left: -1px;background: var(--ag-ink);opacity: 0;transition: opacity .3s .6s}.ag-root.ag-root .ag-q-guess-tick.is-on{opacity: 1}.ag-root.ag-root .ag-q-guess-lab{position: absolute;top: 100%;margin-top: 7px;transform: translateX(-50%);white-space: nowrap;font-size: 12px;font-weight: 600;color: var(--ag-ink-2);opacity: 0;transition: opacity .3s .7s}.ag-root.ag-root .ag-q-guess-lab.is-on{opacity: 1}.ag-root.ag-root .ag-q-guess-lab.is-end{transform: translateX(-100%)}.ag-root.ag-root .ag-q-guess-lab.is-start{transform: none}.ag-root.ag-root .ag-range{display: block;width: 100%;height: 40px;margin-top: 2px;background: transparent;-webkit-appearance: none;appearance: none;cursor: grab;touch-action: pan-y}.ag-root.ag-root .ag-range:active{cursor: grabbing}.ag-root.ag-root .ag-range::-webkit-slider-runnable-track{height: 4px;border-radius: 2px;background: var(--ag-grid)}.ag-root.ag-root .ag-range::-moz-range-track{height: 4px;border-radius: 2px;background: var(--ag-grid)}.ag-root.ag-root .ag-range::-webkit-slider-thumb{-webkit-appearance: none;width: 28px;height: 28px;margin-top: -12px;border-radius: 50%;background: var(--ag-knock);border: 2px solid var(--ag-f);box-shadow: 0 1px 4px rgba(0,0,0,.18)}.ag-root.ag-root .ag-range::-moz-range-thumb{width: 24px;height: 24px;border-radius: 50%;background: var(--ag-knock);border: 2px solid var(--ag-f);box-shadow: 0 1px 4px rgba(0,0,0,.18)}.ag-root.ag-root .ag-range:focus-visible{outline: none}.ag-root.ag-root .ag-range:focus-visible::-webkit-slider-thumb{outline: 2px solid var(--ag-focus);outline-offset: 2px}.ag-root.ag-root .ag-q-hint{font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-fade-in{animation: ag-in .5s var(--ag-ease) both}@keyframes ag-in{from{opacity: 0;transform: translateY(8px)}to{opacity: 1;transform: none}}.ag-root.ag-root .ag-q-end{text-align: left}.ag-root.ag-root .ag-q-recap{margin: 12px 0 4px;display: grid;gap: 6px}.ag-root.ag-root .ag-q-recap-row{display: grid;grid-template-columns: minmax(0,1fr) auto;gap: 2px 12px;font-size: 13px;color: var(--ag-ink-2);align-items: center}.ag-root.ag-root .ag-q-recap-row .ag-num{color: var(--ag-ink);font-weight: 600}.ag-root.ag-root .ag-q-mini{grid-column: 1 / -1;position: relative;height: 8px;border-radius: 4px;background: var(--ag-track)}.ag-root.ag-root .ag-q-mini i{position: absolute;top: -2px;width: 12px;height: 12px;margin-left: -6px;border-radius: 50%;border: 2px solid var(--ag-knock)}.ag-root.ag-root .ag-q-mini i.ag-g{background: var(--ag-knock);border: 2px solid var(--ag-ink-2);width: 12px;height: 12px}.ag-root.ag-root .ag-q-cta{display: flex;flex-wrap: wrap;gap: 10px;margin-top: 12px}.ag-root.ag-root a.ag-btn{text-decoration: none;color: var(--ag-knock)}.ag-root.ag-root .ag-pt-svgwrap{position: relative;margin-top: 8px;touch-action: manipulation}.ag-root.ag-root .ag-pt-svgwrap svg:focus-visible{outline: 2px solid var(--ag-focus);outline-offset: 4px}.ag-root.ag-root .ag-pt-dot{transition: transform .9s var(--ag-ease),opacity .5s,r .15s;cursor: pointer}.ag-root.ag-root .ag-pt-dot.is-m{fill: var(--ag-m)}.ag-root.ag-root .ag-pt-dot.is-f{fill: var(--ag-f)}.ag-root.ag-root .ag-pt-dot{stroke: var(--ag-knock);stroke-width: 2px}.ag-root.ag-root .ag-pt-dot.is-on{stroke: var(--ag-ink);stroke-width: 2.5px}.ag-root.ag-root .ag-pt-dim .ag-pt-dot:not(.is-on):not(.is-hit){opacity: .45}.ag-root.ag-root .ag-pt-grid{stroke: var(--ag-grid);stroke-width: 1px}.ag-root.ag-root .ag-pt-zero{stroke: var(--ag-ink);stroke-width: 1.5px}.ag-root.ag-root .ag-pt-tick{fill: var(--ag-ink-3);font-size: 11px;font-family: var(--ag-ui);font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-pt-card{margin-top: 14px;min-height: 88px;padding-top: 14px;border-top: 1px solid var(--ag-grid);display: grid;gap: 8px}.ag-root.ag-root .ag-pt-empty{font-size: 14px;color: var(--ag-ink-3);align-self: center;justify-self: center;text-align: center}.ag-root.ag-root .ag-ex-ctl{display: grid;gap: 10px;margin-top: 16px}.ag-root.ag-root .ag-ex-head{display: grid;grid-template-columns: minmax(0,40%) minmax(0,1fr) 66px;gap: 14px;align-items: end;margin-top: 18px;padding-bottom: 6px;border-bottom: 1px solid var(--ag-grid)}.ag-root.ag-root .ag-ex-legend{display: flex;flex-wrap: wrap;gap: 4px 12px;font-size: 12px;color: var(--ag-ink-2)}.ag-root.ag-root .ag-ex-legend span{display: inline-flex;align-items: center;gap: 5px}.ag-root.ag-root .ag-ex-axis{position: relative;height: 16px;font-size: 11px;color: var(--ag-ink-3);font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-ex-axis span{position: absolute;bottom: 0;transform: translateX(-50%);white-space: nowrap}.ag-root.ag-root .ag-ex-axis span:first-child{transform: none}.ag-root.ag-root .ag-ex-axis span:last-child{transform: translateX(-100%)}.ag-root.ag-root .ag-ex-pcth{font-size: 11px;color: var(--ag-ink-3);text-align: right;line-height: 1.2}.ag-root.ag-root .ag-ex-list{list-style: none}.ag-root.ag-root .ag-ex-row{border-bottom: 1px solid var(--ag-grid)}.ag-root.ag-root .ag-ex-btn{display: grid;grid-template-columns: minmax(0,40%) minmax(0,1fr) 66px;gap: 14px;align-items: center;width: 100%;padding: 7px 0;text-align: left;transition: background .15s}.ag-root.ag-root .ag-ex-btn:hover{background: color-mix(in srgb,var(--ag-card) 70%,transparent)}.ag-root.ag-root .ag-ex-names{display: grid;gap: 1px;font-size: 13px;line-height: 1.3;min-width: 0}.ag-root.ag-root .ag-ex-names span{display: flex;gap: 6px;align-items: baseline;min-width: 0}.ag-root.ag-root .ag-ex-names span>i{overflow: hidden;text-overflow: ellipsis;white-space: nowrap;font-style: normal}.ag-root.ag-root .ag-ex-names .ag-sw{width: 8px;height: 8px;transform: translateY(-1px)}.ag-root.ag-root .ag-ex-names .is-f{color: var(--ag-ink-2)}.ag-root.ag-root .ag-ex-track{position: relative;height: 22px}.ag-root.ag-root .ag-ex-track::before{content: "";position: absolute;left: 0;right: 0;top: 50%;height: 1px;background: var(--ag-track)}.ag-root.ag-root .ag-ex-gl{position: absolute;top: 0;bottom: 0;width: 1px;background: var(--ag-track)}.ag-root.ag-root .ag-ex-bar{position: absolute;top: 50%;height: 3px;margin-top: -1.5px;border-radius: 2px;opacity: .45;transition: left .7s var(--ag-ease),width .7s var(--ag-ease)}.ag-root.ag-root .ag-ex-bar.is-m{background: var(--ag-m)}.ag-root.ag-root .ag-ex-bar.is-f{background: var(--ag-f)}.ag-root.ag-root .ag-ex-dot{position: absolute;top: 50%;width: 13px;height: 13px;margin: -6.5px 0 0 -6.5px;border-radius: 50%;box-shadow: 0 0 0 2px var(--ag-knock);transition: left .7s var(--ag-ease)}.ag-root.ag-root .ag-ex-dot.is-m{background: var(--ag-m)}.ag-root.ag-root .ag-ex-dot.is-f{background: var(--ag-f)}.ag-root.ag-root .ag-ex-pct{text-align: right;font-size: 14px;font-weight: 650;font-variant-numeric: tabular-nums;display: flex;justify-content: flex-end;align-items: center;gap: 5px}.ag-root.ag-root .ag-ex-pct .ag-sw{width: 7px;height: 7px}.ag-root.ag-root .ag-ex-detail{padding: 4px 0 14px;display: grid;gap: 8px;animation: ag-in .35s var(--ag-ease) both}.ag-root.ag-root .ag-cpt{color: var(--ag-ink-3);font-size: 12px;font-weight: 400;margin-left: 6px;white-space: nowrap;font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-flag{font-size: 12px;color: var(--ag-ink-2);border-left: 2px solid var(--ag-grid);padding: 2px 0 2px 10px}.ag-root.ag-root .ag-ex-none{padding: 24px 0;text-align: center;color: var(--ag-ink-3);font-size: 14px}.ag-root.ag-root .ag-ex-row.is-enter{animation: ag-in .45s var(--ag-ease) both}@container ag (max-width: 540px){.ag-root.ag-root .ag-ex-head{grid-template-columns: minmax(0,1fr) 60px}.ag-root.ag-root .ag-ex-head .ag-ex-legend{grid-column: 1 / -1}.ag-root.ag-root .ag-ex-btn{grid-template-columns: minmax(0,1fr) 60px;gap: 4px 12px;padding: 10px 0}.ag-root.ag-root .ag-ex-names{grid-column: 1 / -1}}.ag-root.ag-root .ag-cpt{color: var(--ag-ink-3);font-size: 12px;font-weight: 400;font-style: normal;margin-left: 6px;white-space: nowrap;font-variant-numeric: tabular-nums;letter-spacing: 0}.ag-root.ag-root .ag-cpt-wrap{position: relative;display: inline-block}.ag-root.ag-root .ag-cpt-btn{padding: 2px 0;margin-left: 6px;line-height: 1.2;cursor: help;text-decoration: underline dotted;text-decoration-color: var(--ag-ink-3);text-underline-offset: 3px}.ag-root.ag-root .ag-cpt-btn:hover,.ag-root.ag-root .ag-cpt-wrap.is-open .ag-cpt-btn{color: var(--ag-ink);text-decoration-color: currentColor}.ag-root.ag-root .ag-tip{position: absolute;left: 0;bottom: calc(100% + 6px);z-index: 5;width: max-content;max-width: min(260px,72vw);padding: 8px 10px;border-radius: 6px;background: var(--ag-ink);color: var(--ag-knock);font-size: 13px;font-weight: 500;line-height: 1.35;white-space: normal;text-align: left;box-shadow: 0 4px 14px color-mix(in srgb,var(--ag-ink) 18%,transparent);display: none;pointer-events: none}.ag-root.ag-root .ag-cpt-wrap.is-open .ag-tip{display: block;animation: ag-fade .15s linear both}@keyframes ag-fade{from{opacity: 0}to{opacity: 1}}.ag-root.ag-root .ag-tip-k{display: block;margin-bottom: 2px;font-size: 11px;font-weight: 500;opacity: .7}.ag-root.ag-root .ag-pair{display: grid;gap: 4px}.ag-root.ag-root .ag-pair-row{display: flex;justify-content: space-between;align-items: baseline;gap: 12px}.ag-root.ag-root .ag-pair-name{font-size: 15px;font-weight: 500;line-height: 1.3;min-width: 0}.ag-root.ag-root .ag-pair-val{font-size: 15px;font-weight: 600;white-space: nowrap}.ag-root.ag-root .ag-find{position: relative}.ag-root.ag-root .ag-find svg{position: absolute;left: 0;top: 50%;width: 15px;height: 15px;margin-top: -7.5px;color: var(--ag-ink-3);pointer-events: none}.ag-root.ag-root .ag-find input{display: block;width: 100%;min-height: 40px;padding: 8px 0 8px 24px;border-radius: 0;background: transparent;border-bottom: 1px solid var(--ag-grid);font-size: 16px;color: var(--ag-ink);-webkit-appearance: none;appearance: none;transition: border-color .2s}.ag-root.ag-root .ag-find input:hover{border-bottom-color: var(--ag-ink-3)}.ag-root.ag-root .ag-find input:focus-visible{outline: none;border-bottom-color: var(--ag-ink)}.ag-root.ag-root .ag-find input::placeholder{color: var(--ag-ink-3);opacity: 1}.ag-root.ag-root .ag-find input::-webkit-search-cancel-button{-webkit-appearance: none}.ag-root.ag-root.ag-root .ag-q-btn{min-height: 42px;padding: 10px 20px;border-radius: var(--ag-r);background: transparent;color: var(--ag-ink);box-shadow: inset 0 0 0 1px var(--ag-ink);font-size: 15px;font-weight: 500;transition: background-color .2s,color .2s,transform .15s}.ag-root.ag-root.ag-root .ag-q-btn:hover{background: var(--ag-ink);color: var(--ag-knock)}.ag-root.ag-root .ag-pt-find{margin-top: 10px;max-width: 340px}.ag-root.ag-root .ag-pt-hits{list-style: none;margin-top: 6px;display: grid;gap: 0}.ag-root.ag-root .ag-pt-hits:empty{display: none}.ag-root.ag-root .ag-pt-hit{display: block;width: 100%;padding: 6px 0;text-align: left;font-size: 14px;font-weight: 500;line-height: 1.3}.ag-root.ag-root .ag-pt-hit:hover{text-decoration: underline;text-underline-offset: 3px;text-decoration-color: var(--ag-grid)}.ag-root.ag-root .ag-pt-none{padding: 6px 0;font-size: 13px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-pt-finding .ag-pt-dot:not(.is-hit):not(.is-on){opacity: .15}.ag-root.ag-root .ag-pt-dot.is-hit{stroke: var(--ag-ink);stroke-width: 2px}.ag-root.ag-root .ag-pt-cap{margin-top: 6px}.ag-root.ag-root .ag-pt-cap>span{display: inline-flex;align-items: baseline;gap: 5px;font-weight: 500;white-space: nowrap}@container ag (max-width: 340px){.ag-root.ag-root .ag-pt-cap{font-size: 11px;gap: 6px}.ag-root.ag-root .ag-pt-cap>span{gap: 3px}}.ag-root.ag-root .ag-arrow{font-weight: 400;color: var(--ag-ink-3)}.ag-root.ag-root .ag-pt-card{margin-top: 12px;min-height: 0;padding-top: 12px;border-top: 1px solid var(--ag-grid);display: grid;gap: 8px}.ag-root.ag-root .ag-pt-empty{font-size: 14px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-ex-ctl{display: flex;flex-wrap: wrap;gap: 12px 32px;align-items: end;margin-top: 16px}.ag-root.ag-root .ag-ex-ctl .ag-find{flex: 1 1 220px}.ag-root.ag-root .ag-ex-sels{display: flex;gap: 20px;flex-wrap: wrap}.ag-root.ag-root .ag-mini{display: grid;gap: 2px}.ag-root.ag-root .ag-mini-k{font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-mini-v{position: relative;display: block}.ag-root.ag-root .ag-mini-v::after{content: "";position: absolute;right: 2px;top: 50%;width: 6px;height: 6px;margin-top: -5px;border-right: 1.5px solid var(--ag-ink-2);border-bottom: 1.5px solid var(--ag-ink-2);transform: rotate(45deg);pointer-events: none}.ag-root.ag-root .ag-mini-sel{display: block;min-height: 40px;padding: 8px 20px 8px 0;background: transparent;border-bottom: 1px solid var(--ag-grid);font-size: 15px;font-weight: 500;color: var(--ag-ink);-webkit-appearance: none;appearance: none;cursor: pointer;border-radius: 0}.ag-root.ag-root .ag-mini-sel:hover{border-bottom-color: var(--ag-ink-3)}.ag-root.ag-root .ag-mini-sel:focus-visible{outline: none;border-bottom-color: var(--ag-ink)}.ag-root.ag-root .ag-ex-head{margin-top: 24px}.ag-root.ag-root .ag-ex-names .ag-ex-n{overflow: hidden;text-overflow: ellipsis;white-space: nowrap;font-style: normal;min-width: 0}.ag-root.ag-root .ag-ex-names .ag-cpt{margin-left: 0;flex: none;font-size: 11px}.ag-root.ag-root .ag-ex-names .is-f{color: inherit}.ag-root.ag-root .ag-ex-pct{font-weight: 600}.ag-root.ag-root .ag-ex-detail{padding: 4px 0 12px;gap: 8px}.ag-root.ag-root .ag-ex-detail .ag-pair-name,.ag-root.ag-root .ag-ex-detail .ag-pair-val{font-size: 15px}.ag-root.ag-root .ag-ex-pager{display: flex;justify-content: space-between;align-items: center;gap: 12px;margin-top: 8px}.ag-root.ag-root .ag-ex-count{font-size: 13px;color: var(--ag-ink-3);font-variant-numeric: tabular-nums}.ag-root.ag-root .ag-ex-pbtns{display: flex;gap: 8px}.ag-root.ag-root .ag-icon-btn[disabled]{opacity: .3;cursor: default}@container ag (max-width: 480px){.ag-root.ag-root .ag-ex-sels{width: 100%}.ag-root.ag-root .ag-ex-sels .ag-mini{flex: 1 1 0;min-width: 0}.ag-root.ag-root .ag-mini-sel{width: 100%}}.ag-root.ag-root .ag-stat{display: block;text-wrap: pretty}.ag-root.ag-root .ag-stat-num{font-family: var(--ag-head);font-weight: 600;font-size: 30px;line-height: 1.05;letter-spacing: -0.025em;font-variant-numeric: tabular-nums;color: var(--ag-ink);margin-right: 8px}.ag-root.ag-root .ag-stat-cap{font-size: 15px;font-weight: 500;line-height: 1.35;color: var(--ag-ink-2)}.ag-root.ag-root .ag-stat-cap span{white-space: nowrap}.ag-root.ag-root .ag-stat-num.ag-ink-m{color: var(--ag-m-ink)}.ag-root.ag-root .ag-stat-num.ag-ink-f{color: var(--ag-f-ink)}.ag-root.ag-root .ag-stat.is-small .ag-stat-num{font-size: 24px}.ag-root.ag-root .ag-stat.is-small .ag-stat-cap{font-size: 14px}.ag-root.ag-root .ag-mu-ctl{display: flex;gap: 6px;align-items: stretch;margin-top: 14px}.ag-root.ag-root .ag-select-wrap{position: relative;flex: 1 1 auto;min-width: 0}.ag-root.ag-root .ag-select{display: block;-webkit-appearance: none;appearance: none;cursor: pointer;font-size: 16px}.ag-root.ag-root .ag-select-wrap .ag-select{position: absolute;inset: 0;width: 100%;height: 100%;opacity: 0;min-height: 0}.ag-root.ag-root .ag-select-face{display: flex;align-items: center;min-height: 40px;height: 100%;padding: 6px 34px 6px 12px;border-radius: var(--ag-r);background: transparent;box-shadow: inset 0 0 0 1px var(--ag-grid);transition: box-shadow .2s;font-size: 15px;font-weight: 500;line-height: 1.3}.ag-root.ag-root .ag-select-wrap:hover .ag-select-face{box-shadow: inset 0 0 0 1px var(--ag-ink-3)}.ag-root.ag-root .ag-select-wrap:has(.ag-select:focus-visible) .ag-select-face{outline: 2px solid var(--ag-focus);outline-offset: 2px}.ag-root.ag-root .ag-select-wrap::after{content: "";position: absolute;right: 14px;top: 50%;width: 6px;height: 6px;margin-top: -5px;border-right: 1.5px solid var(--ag-ink-2);border-bottom: 1.5px solid var(--ag-ink-2);transform: rotate(45deg);pointer-events: none}.ag-root.ag-root .ag-mu-ctl .ag-icon-btn{width: 40px;height: auto;min-height: 40px}.ag-root.ag-root .ag-mu-ctl .ag-icon-btn svg{width: 14px;height: 14px}.ag-root.ag-root .ag-mu-sum{margin-top: 14px}@container ag (max-width: 480px){.ag-root.ag-root .ag-mu-ctl{gap: 4px}.ag-root.ag-root .ag-mu-ctl .ag-icon-btn{width: 32px}.ag-root.ag-root .ag-select-face{font-size: 14px;padding-left: 10px;padding-right: 28px}.ag-root.ag-root .ag-select-wrap::after{right: 11px}}.ag-root.ag-root .ag-mu-strip-wrap{margin-top: 12px}.ag-root.ag-root .ag-mu-strip-lab{font-size: 13px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-mu-strip{position: relative;height: 48px;margin-top: 2px}.ag-root.ag-root .ag-mu-strip::before{content: "";position: absolute;left: 0;right: 0;top: 31px;height: 1px;background: var(--ag-grid)}.ag-root.ag-root .ag-mu-zero{position: absolute;top: 15px;bottom: 0;width: 0;border-left: 1.5px dashed var(--ag-ink-2);margin-left: -0.75px}.ag-root.ag-root .ag-mu-zero-lab{position: absolute;top: 0;transform: translateX(-50%);font-size: 11px;font-weight: 500;line-height: 1;color: var(--ag-ink-2);white-space: nowrap}.ag-root.ag-root .ag-mu-tick{position: absolute;top: 23px;width: 2px;height: 16px;margin-left: -1px;padding: 0;border-radius: 1px;opacity: .45;transition: height .25s var(--ag-ease),top .25s var(--ag-ease),width .25s var(--ag-ease),opacity .2s}.ag-root.ag-root .ag-mu-tick.is-m{background: var(--ag-m)}.ag-root.ag-root .ag-mu-tick.is-f{background: var(--ag-f)}.ag-root.ag-root .ag-mu-tick::after{content: "";position: absolute;inset: -8px -3px}.ag-root.ag-root .ag-mu-tick:hover{opacity: .9}.ag-root.ag-root .ag-mu-tick.is-on{opacity: 1;top: 16px;height: 30px;width: 4px;margin-left: -2px;box-shadow: 0 0 0 2px var(--ag-knock);z-index: 2}.ag-root.ag-root .ag-mu-pair{margin-top: 14px;padding-top: 12px;border-top: 1px solid var(--ag-grid);display: grid;gap: 10px}.ag-root.ag-root .ag-mu-side{display: grid;gap: 4px}.ag-root.ag-root .ag-mu-line{display: flex;justify-content: space-between;align-items: baseline;gap: 12px}.ag-root.ag-root .ag-mu-name{font-size: 15px;font-weight: 500;line-height: 1.3;min-width: 0}.ag-root.ag-root .ag-mu-val{font-size: 15px;font-weight: 600;white-space: nowrap}.ag-root.ag-root .ag-mu-pair .ag-bar-track{height: 12px}.ag-root.ag-root .ag-q-prog{display: block;margin: 0 0 8px;font-size: 12px;font-weight: 500;color: var(--ag-ink-3)}.ag-root.ag-root .ag-q-lab{display: inline-flex;align-items: baseline;flex-wrap: wrap;font-size: 15px;font-weight: 500;line-height: 1.3}.ag-root.ag-root .ag-q-row-hd b{font-weight: 600}.ag-root.ag-root .ag-q-foot{display: flex;flex-wrap: wrap;align-items: center;justify-content: space-between;gap: 10px 16px;margin-top: 6px}.ag-root.ag-root .ag-q-foot.is-result{margin-top: 26px}.ag-root.ag-root .ag-q-endline{font-size: 17px;font-weight: 500;line-height: 1.35;color: var(--ag-ink);text-wrap: pretty}.ag-root.ag-root .ag-q-endnum{font-family: var(--ag-head);font-weight: 600;font-size: 30px;letter-spacing: -0.025em}.ag-root.ag-root .ag-q-hint{display: flex;flex-wrap: wrap;align-items: center;gap: 4px;font-size: 12px;color: var(--ag-ink-3)}.ag-root.ag-root .ag-q-ring{display: inline-block;width: 10px;height: 10px;border-radius: 50%;box-shadow: inset 0 0 0 2px var(--ag-ink-2)}.ag-root.ag-root .ag-q-cta{display: flex;flex-wrap: wrap;align-items: center;gap: 10px 18px;margin-top: 12px}.ag-root.ag-root .ag-q-link{font-size: 15px;font-weight: 500;color: var(--ag-ink);text-decoration: underline;text-decoration-color: var(--ag-grid);text-underline-offset: 4px}.ag-root.ag-root .ag-q-link:hover{text-decoration-color: currentColor}.ag-root.ag-root{--ag-ui: "Geist","Helvetica Neue",Arial,sans-serif;--ag-head-weight: 600;--ag-head-track: -0.02em;--ag-r: 8px}.ag-root.ag-root[data-ag-mode="light"]{--ag-card: #f3f3f6;--ag-grid: #e2e2e8;--ag-track: #ececf1}@media (prefers-color-scheme: light){.ag-root.ag-root[data-ag-mode="auto"]{--ag-card: #f3f3f6;--ag-grid: #e2e2e8;--ag-track: #ececf1}}.ag-root.ag-root[data-ag-style="editorial"]{--ag-head-weight: 700}.ag-root.ag-root[data-ag-style="feature"]{--ag-head-weight: 700}.ag-root.ag-root.ag-root{font-family: var(--ag-ui)}.ag-root.ag-root.ag-root .ag-hed{letter-spacing: var(--ag-head-track)}.ag-root.ag-root.ag-root .ag-mu-name{font-weight: 500}.ag-root.ag-root.ag-root .ag-q-row-hd b,.ag-root.ag-root.ag-root .ag-mu-val,.ag-root.ag-root.ag-root .ag-pair-val,.ag-root.ag-root.ag-root .ag-ex-pct{font-weight: 600}.ag-root.ag-root.ag-root .ag-dek{text-wrap: pretty}.ag-root.ag-root.ag-root .ag-btn,.ag-root.ag-root.ag-root .ag-icon-btn,.ag-root.ag-root.ag-root .ag-select-face{border-radius: var(--ag-r)}.ag-root.ag-root.ag-root .ag-bar{border-radius: 0 2px 2px 0}.ag-root.ag-root.ag-root .ag-btn{font-weight: 600}.ag-root.ag-root.ag-root .ag-btn{transition: transform .15s var(--ag-ease),background-color .2s}.ag-root.ag-root.ag-root .ag-btn:hover{opacity: 1;background: color-mix(in srgb,var(--ag-ink) 82%,var(--ag-knock))}.ag-root.ag-root.ag-root .ag-btn:active,.ag-root.ag-root.ag-root .ag-icon-btn:active{transform: translateY(1px)}.ag-root.ag-root.ag-root .ag-icon-btn{transition: box-shadow .2s,background-color .2s,transform .15s}.ag-root.ag-root.ag-root .ag-icon-btn:hover{background: var(--ag-card)}.ag-root.ag-root.ag-root .ag-btn-ghost{background: none;box-shadow: none;padding-left: 4px;padding-right: 4px;font-weight: 500;text-decoration: underline;text-decoration-color: var(--ag-grid);text-underline-offset: 4px}.ag-root.ag-root.ag-root .ag-btn-ghost:hover{background: none;text-decoration-color: currentColor}.ag-root.ag-root.ag-root .ag-q-prog span{margin-left: 0;font-weight: 500}.ag-root.ag-root.ag-root .ag-q-mini{background: none;height: 12px}.ag-root.ag-root.ag-root .ag-q-mini::before{content: "";position: absolute;left: 0;right: 0;top: 50%;height: 1px;background: var(--ag-grid)}.ag-root.ag-root.ag-root .ag-q-mini i{top: 0}.ag-root.ag-root.ag-root .ag-range::-webkit-slider-thumb{box-shadow: 0 1px 3px color-mix(in srgb,var(--ag-ink) 22%,transparent)}.ag-root.ag-root.ag-root .ag-range::-moz-range-thumb{box-shadow: 0 1px 3px color-mix(in srgb,var(--ag-ink) 22%,transparent)}@media (prefers-reduced-motion: reduce){.ag-root.ag-root *,.ag-root.ag-root *::before,.ag-root.ag-root *::after{transition: none !important;animation: none !important}} (window.AG = window.AG || {}).data = [{"id":1,"cat":"Biopsies & lesions","mName":"Biopsy penis","mCpt":"54100","m":121.32,"fName":"Biopsy vagina","fCpt":"57100","f":65.74,"pct":59.42},{"id":2,"cat":"Biopsies & lesions","mName":"Remove penis lesion","mCpt":"54110","m":624.88,"fName":"Remove vaginal lesion","fCpt":"57135","f":191.8,"pct":106.06},{"id":3,"cat":"Biopsies & lesions","mName":"Biopsy scrotum","mCpt":"55120","m":356.83,"fName":"Biopsy vulva","fCpt":"56605","f":59.98,"pct":142.44},{"id":4,"cat":"Biopsies & lesions","mName":"Biopsy prostate","mCpt":"55705","m":265.34,"fName":"Biopsy endometrium","fCpt":"58110","f":40.33,"pct":147.22},{"id":5,"cat":"Biopsies & lesions","mName":"Removal of scrotal lesion","mCpt":"55120","m":356.83,"fName":"Removal of vulvar lesion","fCpt":"56440","f":184.01,"pct":63.91},{"id":6,"cat":"Biopsies & lesions","mName":"Excision penile lesion","mCpt":"54115","m":428.0,"fName":"Excision vaginal lesion","fCpt":"57100","f":65.74,"pct":146.74},{"id":7,"cat":"Biopsies & lesions","mName":"Laser penis","mCpt":"54057","m":98.95,"fName":"Laser vulva","fCpt":"56501","f":136.57,"pct":-31.95},{"id":8,"cat":"Genitals & other","mName":"Distal hypospadias repair","mCpt":"54328","m":934.61,"fName":"Revision of cervix","fCpt":"57700","f":365.3,"pct":87.59},{"id":9,"cat":"Biopsies & lesions","mName":"Destruction penile lesions simple","mCpt":"54050","m":108.1,"fName":"Destruction vulvar lesions simple","fCpt":"56501","f":136.57,"pct":-23.27},{"id":10,"cat":"Genitals & other","mName":"Resection of scrotum","mCpt":"55150","m":496.11,"fName":"Simple complete vulvectomy","fCpt":"56620","f":598.11,"pct":-18.64},{"id":11,"cat":"Genitals & other","mName":"Revision of scrotum","mCpt":"55180","m":690.96,"fName":"Extensive vulva surgery (partial radical)","fCpt":"56630","f":976.63,"pct":-34.26},{"id":12,"cat":"Genitals & other","mName":"Drain prostate abscess","mCpt":"52700","m":443.92,"fName":"Drain ovarian abscess open","fCpt":"58820","f":347.01,"pct":24.51},{"id":13,"cat":"Genitals & other","mName":"Excision hydrocele","mCpt":"55040","m":339.89,"fName":"Excision Bartholins gland","fCpt":"56740","f":321.25,"pct":5.64},{"id":14,"cat":"Genitals & other","mName":"Penis/scrotoplasty","mCpt":"54360","m":721.8,"fName":"Perineoplasty","fCpt":"56810","f":276.86,"pct":89.11},{"id":15,"cat":"Genitals & other","mName":"Excision of sperm cord lesion","mCpt":"55520","m":465.95,"fName":"Excision of Bartholins","fCpt":"56740","f":321.25,"pct":36.76},{"id":16,"cat":"Prostate & uterus","mName":"Interstitial prostate","mCpt":"55875","m":780.08,"fName":"Interstitial cervix","fCpt":"55920","f":463.24,"pct":50.97},{"id":17,"cat":"Urinary tract","mName":"Insert tandem male","mCpt":"53444","m":792.62,"fName":"Insert tandem female","fCpt":"57155","f":286.01,"pct":93.94},{"id":18,"cat":"Urinary tract","mName":"Reconstruction of male urethra","mCpt":"54352","m":1408.35,"fName":"Reconstruction of female urethra","fCpt":"53430","f":975.27,"pct":36.34},{"id":19,"cat":"Urinary tract","mName":"Revise remove sling male","mCpt":"53448","m":1271.79,"fName":"Revise remove sling female","fCpt":"57287","f":754.33,"pct":51.08},{"id":20,"cat":"Urinary tract","mName":"Male sling insert uro/neck sph","mCpt":"53445","m":757.72,"fName":"Female insert mesh pelvic floor add on","fCpt":"57267","f":252.12,"pct":100.13},{"id":21,"cat":"Urinary tract","mName":"Reconstruct urethra male","mCpt":"53415","m":1126.07,"fName":"Revise urethra female","fCpt":"57220","f":353.11,"pct":104.51},{"id":22,"cat":"Urinary tract","mName":"Total urethrectomy male","mCpt":"53215","m":926.14,"fName":"Total urethrectomy female","fCpt":"53210","f":776.7,"pct":17.55},{"id":23,"cat":"Genitals & other","mName":"Partial removal of penis","mCpt":"54120","m":633.01,"fName":"Partial vaginectomy","fCpt":"57106","f":546.94,"pct":14.59},{"id":24,"cat":"Genitals & other","mName":"Removal of penis","mCpt":"54125","m":825.49,"fName":"Complete vaginectomy","fCpt":"57110","f":919.02,"pct":-10.72},{"id":25,"cat":"Genitals & other","mName":"Exploratory laparotomy male","mCpt":"49000","m":778.05,"fName":"Exploratory laparotomy female","fCpt":"58960","f":1009.84,"pct":-25.93},{"id":26,"cat":"Testes & ovaries","mName":"Excise lesion testis","mCpt":"54512","m":538.47,"fName":"Ovarian cystectomy","fCpt":"58925","f":781.44,"pct":-36.82},{"id":27,"cat":"Testes & ovaries","mName":"Removal of testis","mCpt":"54530","m":511.02,"fName":"Oophorectomy","fCpt":"58940","f":567.27,"pct":-10.43},{"id":28,"cat":"Testes & ovaries","mName":"Suspension/relocation of testes","mCpt":"54680","m":787.54,"fName":"Ovarian transposition","fCpt":"58825","f":722.81,"pct":8.57},{"id":29,"cat":"Testes & ovaries","mName":"Laparoscopic orchiectomy","mCpt":"54690","m":655.38,"fName":"Laparoscopic BSO","fCpt":"58661","f":662.83,"pct":-1.13},{"id":30,"cat":"Testes & ovaries","mName":"Laparoscopic orchiopexy","mCpt":"54692","m":755.01,"fName":"Laparoscopic ovarian transposition","fCpt":"58825","f":722.81,"pct":4.36},{"id":31,"cat":"Testes & ovaries","mName":"Removal of epididymis","mCpt":"54861","m":569.64,"fName":"Removal of fallopian tubes","fCpt":"58700","f":814.31,"pct":-35.36},{"id":32,"cat":"Testes & ovaries","mName":"Vas deferens vasectomy","mCpt":"55250","m":230.43,"fName":"Essure hysteroscopy","fCpt":"58565","f":466.97,"pct":-67.83},{"id":33,"cat":"Testes & ovaries","mName":"Orchiectomy with staging","mCpt":"54530 + 38770","m":1320.25,"fName":"Oophorectomy with staging","fCpt":"58950","f":1169.79,"pct":12.08},{"id":34,"cat":"Testes & ovaries","mName":"Extensive testis surgery","mCpt":"54535","m":744.5,"fName":"Removal of ovaries extensive","fCpt":"58943","f":1188.42,"pct":-45.93},{"id":35,"cat":"Testes & ovaries","mName":"Reduce testis torsion","mCpt":"54600","m":454.43,"fName":"Reduce ovarian torsion","fCpt":"58920","f":728.24,"pct":-46.3},{"id":36,"cat":"Genitals & other","mName":"Remove penis and LN","mCpt":"54135","m":1503.24,"fName":"Vaginectomy and LN","fCpt":"57109","f":1751.97,"pct":-15.28},{"id":37,"cat":"Testes & ovaries","mName":"Revise vas deferens/spermatic ducts","mCpt":"54901","m":1056.94,"fName":"Revise fallopian tubes","fCpt":"58740","f":917.67,"pct":14.11},{"id":38,"cat":"Prostate & uterus","mName":"TURP","mCpt":"52601","m":727.22,"fName":"Hysteroscopic myomectomy","fCpt":"58561","f":360.9,"pct":67.33},{"id":39,"cat":"Prostate & uterus","mName":"Remove prostate","mCpt":"55801","m":1093.2,"fName":"Hysterectomy","fCpt":"58150","f":1028.82,"pct":6.07},{"id":40,"cat":"Prostate & uterus","mName":"Extensive prostate surgery","mCpt":"55845","m":1355.49,"fName":"Extensive TAH","fCpt":"58285","f":1440.21,"pct":-6.06},{"id":41,"cat":"Prostate & uterus","mName":"Subtotal prostatectomy","mCpt":"55821","m":837.69,"fName":"Abdominal trachelectomy","fCpt":"57530","f":381.57,"pct":74.82},{"id":42,"cat":"Prostate & uterus","mName":"Prostatectomy","mCpt":"55840","m":1165.38,"fName":"TAH","fCpt":"58150","f":1028.82,"pct":12.45},{"id":43,"cat":"Prostate & uterus","mName":"Prostatectomy LND","mCpt":"55845","m":1355.49,"fName":"TAH BSO LND","fCpt":"58200","f":1362.6,"pct":-0.52},{"id":44,"cat":"Prostate & uterus","mName":"Perineal approach prostatectomy","mCpt":"55815","m":1751.97,"fName":"Radical vaginal hysterectomy","fCpt":"58285","f":1440.21,"pct":19.53},{"id":45,"cat":"Prostate & uterus","mName":"Radical prostatectomy perineal approach","mCpt":"55810","m":1301.27,"fName":"Radical vaginal hysterectomy","fCpt":"58285","f":1440.21,"pct":-10.14},{"id":46,"cat":"Urinary tract","mName":"Removal of bladder and LN","mCpt":"51575","m":1809.92,"fName":"Anterior exenteration (no code for anterior only)","fCpt":"58240","f":2967.84,"pct":-48.47},{"id":47,"cat":"Urinary tract","mName":"Cystectomy complete with conduit","mCpt":"51596","m":2344.32,"fName":"Pelvic exenteration","fCpt":"58240","f":2967.84,"pct":-23.48},{"id":48,"cat":"Biopsies & lesions","mName":"Biopsy penis","mCpt":"54100","m":121.32,"fName":"Biopsy vulva","fCpt":"56605","f":59.98,"pct":67.67},{"id":49,"cat":"Biopsies & lesions","mName":"Biopsy prostate","mCpt":"55700","m":129.11,"fName":"Biopsy endometrium","fCpt":"58100","f":63.71,"pct":67.84},{"id":50,"cat":"Biopsies & lesions","mName":"Destruction penile lesions extensive","mCpt":"54065","m":172.83,"fName":"Destruction vulvar lesions extensive","fCpt":"56515","f":216.88,"pct":-22.61},{"id":51,"cat":"Prostate & uterus","mName":"TURP","mCpt":"52601","m":727.22,"fName":"Hysteroscopy","fCpt":"58558","f":233.48,"pct":102.79},{"id":52,"cat":"Genitals & other","mName":"Drain prostate abscess","mCpt":"55720","m":453.07,"fName":"Drain ovarian abscess","fCpt":"58820","f":347.01,"pct":26.51},{"id":53,"cat":"Genitals & other","mName":"Excision varicocele","mCpt":"55530","m":354.12,"fName":"Excision Bartholins","fCpt":"56740","f":321.25,"pct":9.73},{"id":54,"cat":"Genitals & other","mName":"Excision hydrocele","mCpt":"55500","m":395.8,"fName":"Excision Bartholins","fCpt":"56740","f":321.25,"pct":20.79},{"id":55,"cat":"Genitals & other","mName":"Scrotoplasty","mCpt":"55175","m":367.68,"fName":"Perineoplasty","fCpt":"56810","f":276.86,"pct":28.18}]; window.AG.copy = {"shared":{"method":"Percent difference is the gap between the two payments divided by their average. Because neither the male nor female procedure serves as the baseline to compare against, the average is used, yielding a single figure for each pair. Negative values mean the procedure on women pays more.","source":"Source: Penn et al., Journal of Women\u2019s Health (2025), Table 3.","credit":"Graphic: Anusha Subramanian/Vox","logoLabel":"Vox","aboutButton":"About the data","about1":"Amounts are Medicare\u2019s 2023 national reimbursement rates when the procedure is done in a hospital or surgical center.","about2":"Researchers matched each procedure on male anatomy with a comparable one on female anatomy. Some procedures appear in more than one pair. CPT codes are the billing codes listed in the study. Look any code up in Medicare\u2019s Physician Fee Schedule tool.","difference":"pay difference","srHigherMale":"higher for the male procedure","srHigherFemale":"higher for the female procedure","paysMoreFemale":"Pays more for female","paysMoreMale":"Pays more for male","noMatches":"No matching procedures","cptPrefix":"CPT"},"pattern":{"hed":"Medicare often reimburses more for procedures on men","dek":"Percent difference in 2023 Medicare reimbursement rates among pairs of comparable male and female procedures. Each dot is one pair.","findPlaceholder":"Find a procedure or code","emptyCard":"Tap or hover over a dot to see the pair","moreHits":"and {n} more, highlighted on the chart"},"quiz":{"hed":"Can you guess what Medicare pays?","dek":"Drag the slider to estimate what Medicare pays for the second procedure.","round":"Round {i} of {n}","submit":"Submit","next":"Next pair","seeResult":"See the result","yourGuess":"Your guess {amount}","endLede":"{n} of {total}","endText":"matched pairs pay the surgeon more for the procedure on male anatomy.","legendMale":"Male","legendFemale":"Female","legendGuess":"Your guess","playAgain":"Play again with new pairs","seeAll":"See all 55 pairs"},"matchup":{"hed":"Similar procedures, different pay","dek":"What Medicare paid a surgeon for matched procedures in 2023","stripLabel":"Where this pair falls among all 55","noDifference":"No difference"},"explorer":{"hed":"Every matched pair, side by side","dek":"What Medicare paid a surgeon for each procedure in 2023","searchPlaceholder":"Search a procedure or code","legendMale":"Male procedure","legendFemale":"Female procedure","pctHeader":"% diff.","count":"{from}\u2013{to} of {n} pairs","countFiltered":"{from}\u2013{to} of {n} matching pairs","sortGap":"Sorted by largest difference","sortStudy":"Sorted in the study\u2019s order","sortPay":"Sorted by highest payment","essureFlag":"Essure was taken off the U.S. market in 2018."}}; (function () { var AG = (window.AG = window.AG || {}); AG.components = AG.components || {}; if (AG.__core) return; AG.__core = true; AG.CATEGORIES = ["Biopsies & lesions", "Testes & ovaries", "Prostate & uterus", "Urinary tract", "Genitals & other"]; var P = function (d) { return ''; }; AG.icons = { prev: P("M168.49,199.51a12,12,0,0,1-17,17l-80-80a12,12,0,0,1,0-17l80-80a12,12,0,0,1,17,17L97,128Z"), next: P("M184.49,136.49l-80,80a12,12,0,0,1-17-17L159,128,87.51,56.49a12,12,0,1,1,17-17l80,80A12,12,0,0,1,184.49,136.49Z"), shuffle: P("M240.49,175.51a12,12,0,0,1,0,17l-24,24a12,12,0,0,1-17-17L203,196h-2.09a76.17,76.17,0,0,1-61.85-31.83L97.38,105.78A52.1,52.1,0,0,0,55.06,84H32a12,12,0,0,1,0-24H55.06a76.17,76.17,0,0,1,61.85,31.83l41.71,58.39A52.1,52.1,0,0,0,200.94,172H203l-3.52-3.51a12,12,0,0,1,17-17Zm-95.62-72.62a12,12,0,0,0,16.93-1.13A52,52,0,0,1,200.94,84H203l-3.52,3.51a12,12,0,0,0,17,17l24-24a12,12,0,0,0,0-17l-24-24a12,12,0,0,0-17,17L203,60h-2.09a76,76,0,0,0-57.2,26A12,12,0,0,0,144.87,102.89Zm-33.74,50.22a12,12,0,0,0-16.93,1.13A52,52,0,0,1,55.06,172H32a12,12,0,0,0,0,24H55.06a76,76,0,0,0,57.2-26A12,12,0,0,0,111.13,153.11Z"), search: P("M232.49,215.51,185,168a92.12,92.12,0,1,0-17,17l47.53,47.54a12,12,0,0,0,17-17ZM44,112a68,68,0,1,1,68,68A68.07,68.07,0,0,1,44,112Z") }; AG.pairSep = " vs. "; AG.reduced = function () { return !!(window.matchMedia && window.matchMedia("(prefers-reduced-motion: reduce)").matches); }; AG.h = function (tag, attrs, kids) { var svg = /^(svg|g|circle|line|text|path|rect|tspan)$/.test(tag); var el = svg ? document.createElementNS("http://www.w3.org/2000/svg", tag) : document.createElement(tag); attrs = attrs || {}; for (var k in attrs) { var v = attrs[k]; if (v == null || v === false) continue; if (k === "text") el.textContent = v; else if (k === "html") el.innerHTML = v; else if (k.slice(0, 2) === "on") el.addEventListener(k.slice(2), v); else if (k === "class" && svg) el.setAttribute("class", v); else if (k === "class") el.className = v; else el.setAttribute(k, v === true ? "" : v); } (kids || []).forEach(function (c) { if (c == null || c === false) return; el.appendChild(typeof c === "string" ? document.createTextNode(c) : c); }); return el; }; AG.money = function (v, opts) { var round = opts && opts.round; return v.toLocaleString("en-US", { style: "currency", currency: "USD", minimumFractionDigits: round ? 0 : 2, maximumFractionDigits: round ? 0 : 2 }); }; AG.pct = function (p) { var a = Math.abs(p); return (a >= 10 ? a.toFixed(0) : a.toFixed(1)) + "%"; }; AG.pctExact = function (p) { return (p 0 ? "m" : "f"; }; AG.byId = function (id) { for (var i = 0; i 0 ? "higher for the male procedure" : "higher for the female procedure"; }; AG.t = function (key, vars) { var parts = key.split("."), v = AG.copy || {}; for (var i = 0; i < parts.length && v != null; i++) v = v[parts[i]]; if (typeof v !== "string") v = key; return v.replace(/\{(\w+)\}/g, function (m, k) { return vars && k in vars ? vars[k] : m; }); }; AG.tx = function (tag, key, attrs, vars) { var el = AG.h(tag, attrs || {}); var s = AG.t(key, vars); if (/ rr.right) dx = rr.right - tr.right; if (tr.left + dx < rr.left) dx = rr.left - tr.left; tip.style.transform = "translateX(" + Math.round(dx) + "px)"; } var openedAt = 0; function show(on) { if (on && !wrap.classList.contains("is-open")) openedAt = Date.now(); wrap.classList.toggle("is-open", on); btn.setAttribute("aria-expanded", String(on)); if (on) place(); } btn.addEventListener("mouseenter", function () { show(true); }); wrap.addEventListener("mouseleave", function () { show(false); }); btn.addEventListener("focus", function () { show(true); }); btn.addEventListener("blur", function () { show(false); }); btn.addEventListener("click", function (e) { e.stopPropagation(); var open = wrap.classList.contains("is-open"); show(!open || Date.now() - openedAt < 400); }); btn.addEventListener("keydown", function (e) { if (e.key === "Escape") show(false); }); return wrap; }; AG.pairRows = function (d) { var h = AG.h; return h("div", { class: "ag-pair" }, [["m", d.mName, d.mCpt, d.m], ["f", d.fName, d.fCpt, d.f]].map(function (x) { return h("div", { class: "ag-pair-row" }, [ h("p", { class: "ag-pair-name" }, [h("span", { class: "ag-ink-" + x[0], text: x[1] }), AG.cpt(x[2])]), h("p", { class: "ag-num ag-pair-val", text: AG.money(x[3]) }) ]); })); }; document.addEventListener("click", function () { var open = document.querySelectorAll(".ag-cpt-wrap.is-open"); for (var i = 0; i < open.length; i++) { open[i].classList.remove("is-open"); open[i].firstChild.setAttribute("aria-expanded", "false"); } }); AG.stat = function (d, opts) { var h = AG.h, s = AG.side(d); var num = opts && opts.exact ? AG.pctExact(d.pct).replace("\u2212", "") : AG.pct(d.pct); return h("p", { class: "ag-stat" + (opts && opts.small ? " is-small" : "") }, [ h("span", { class: "ag-stat-num", text: num }), AG.tx("span", "shared.difference", { class: "ag-stat-cap" }), h("span", { class: "ag-sr", text: " (" + AG.t(s === "m" ? "shared.srHigherMale" : "shared.srHigherFemale") + ")" }) ]); }; AG.onVisible = function (el, fn) { if (!("IntersectionObserver" in window)) return fn(); var io = new IntersectionObserver(function (es) { if (es.some(function (e) { return e.isIntersecting; })) { io.disconnect(); fn(); } }, { threshold: 0.2 }); io.observe(el); }; AG.axisEnds = function (extraClass) { var h = AG.h; return h("div", { class: "ag-axis-cap " + (extraClass || "") }, [ h("span", { class: "ag-ink-f" }, [h("span", { class: "ag-arrow", "aria-hidden": "true", text: "\u2190" }), AG.tx("span", "shared.paysMoreFemale")]), h("span", { class: "ag-ink-m" }, [AG.tx("span", "shared.paysMoreMale"), h("span", { class: "ag-arrow", "aria-hidden": "true", text: "\u2192" })]) ]); }; AG.header = function (o) { return AG.h("div", { class: "ag-hd" }, [ AG.tx("h2", o.hed, { class: "ag-hed" }), o.dek ? AG.tx("p", o.dek, { class: "ag-dek" }) : null ]); }; AG.footer = function () { var h = AG.h; var about = h("div", { class: "ag-about", hidden: true, id: "ag-about-" + Math.random().toString(36).slice(2, 8) }, [ AG.tx("p", "shared.about1"), AG.tx("p", "shared.about2") ]); var btn = AG.tx("button", "shared.aboutButton", { class: "ag-about-btn", type: "button", "aria-expanded": "false", "aria-controls": about.id }); btn.addEventListener("click", function () { var open = about.hidden; about.hidden = !open; btn.setAttribute("aria-expanded", String(open)); }); return h("div", { class: "ag-ft" }, [ AG.tx("p", "shared.method", { class: "ag-method" }), h("div", { class: "ag-ft-row" }, [ AG.tx("p", "shared.source", { class: "ag-source" }), AG.tx("p", "shared.credit", { class: "ag-credit" }), h("div", { class: "ag-ft-end" }, [btn, AG.ta(h("span", { class: "ag-logo", role: "img" }), "aria-label", "shared.logoLabel")]) ]), about ]); }; AG.mount = function (root) { var name = root.getAttribute("data-ag"); var fn = AG.components[name]; if (!fn || !AG.data) return; root.setAttribute("data-ag-mounted", ""); if (root.parentElement) root.style.setProperty("--ag-host", getComputedStyle(root.parentElement).fontFamily); root.innerHTML = ""; fn(root); if (typeof CustomEvent === "function") root.dispatchEvent(new CustomEvent("ag:mounted", { bubbles: true })); }; AG.mountAll = function () { var run = function () { var roots = document.querySelectorAll(".ag-root[data-ag]:not([data-ag-mounted])"); for (var i = 0; i 0; }).length; var sorted = AG.data.slice().sort(function (a, b) { return a.pct - b.pct; }); var sel = null, entered = false, landed = false, pos = {}; root.appendChild(AG.header({ hed: "pattern.hed", dek: "pattern.dek" })); var findIn = AG.ta(h("input", { type: "search", "aria-label": "Find a procedure on the chart", autocomplete: "off" }), "placeholder", "pattern.findPlaceholder"); var hits = h("ul", { class: "ag-pt-hits", "aria-label": "Matching pairs" }); root.appendChild(h("div", { class: "ag-pt-find" }, [h("div", { class: "ag-find", html: AG.icons.search }, [findIn]), hits])); var wrap = h("div", { class: "ag-pt-svgwrap" }); var svg = h("svg", { role: "img", tabindex: "0", "aria-label": "Beeswarm chart. " + nM + " of 55 pairs pay more for the male procedure. Use arrow keys to step through pairs." }); wrap.appendChild(svg); root.appendChild(wrap); root.appendChild(AG.axisEnds("ag-pt-cap")); var card = h("div", { class: "ag-pt-card", "aria-live": "polite" }); root.appendChild(card); root.appendChild(h("div", { class: "ag-sr" }, [h("table", {}, [ h("caption", { text: "Table 3, facility payments, 2023" }), h("tr", {}, ["Male procedure", "Payment", "Female procedure", "Payment", "Percent difference"].map(function (t) { return h("th", { text: t }); })) ].concat(AG.data.map(function (d) { return h("tr", {}, [d.mName, AG.money(d.m), d.fName, AG.money(d.f), AG.pctExact(d.pct)].map(function (t) { return h("td", { text: t }); })); })))])); root.appendChild(AG.footer()); function drawCard() { card.innerHTML = ""; if (!sel) { card.appendChild(AG.tx("p", "pattern.emptyCard", { class: "ag-pt-empty" })); return; } var d = sel; card.appendChild(AG.pairRows(d)); card.appendChild(AG.stat(d, { small: true })); } var circles = {}; function layout() { var W = wrap.clientWidth; if (!W) return; var narrow = W < 520; var r = narrow ? 5.5 : 7, gap = 1.5, D = 2 * r + gap; var padL = r + 4, padR = r + 4; var sx = function (p) { return padL + ((p - LO) / (HI - LO)) * (W - padL - padR); }; var placed = []; AG.data.slice().sort(function (a, b) { return Math.abs(a.pct) - Math.abs(b.pct) || a.id - b.id; }).forEach(function (d) { var x = sx(d.pct), cands = [0]; placed.forEach(function (p) { var dx = Math.abs(x - p.x); if (dx < D) { var dy = Math.sqrt(D * D - dx * dx); cands.push(p.y + dy, p.y - dy); } }); cands.sort(function (a, b) { return Math.abs(a) - Math.abs(b); }); for (var i = 0; i = D * D - 0.01; }); if (ok) { placed.push({ x: x, y: y, d: d }); pos[d.id] = { x: x, y: y }; break; } } }); var maxY = Math.max.apply(null, placed.map(function (p) { return Math.abs(p.y); })); var annH = 8, axisH = 22; var cy = annH + maxY + r + 6; var H = cy + maxY + r + 6 + axisH; svg.setAttribute("width", W); svg.setAttribute("height", H); svg.setAttribute("viewBox", "0 0 " + W + " " + H); svg.style.width = W + "px"; svg.style.height = H + "px"; var old = svg.querySelector(".ag-pt-axes"); if (old) old.remove(); var axes = h("g", { class: "ag-pt-axes" }); TICKS.forEach(function (t) { var x = sx(t); axes.appendChild(h("line", { class: t === 0 ? "ag-pt-zero" : "ag-pt-grid", x1: x, x2: x, y1: annH - 4, y2: H - axisH + 2 })); axes.appendChild(h("text", { class: "ag-pt-tick", x: x, y: H - 6, "text-anchor": "middle", text: t === 0 ? "0" : (t < 0 ? "\u2212" : "") + Math.abs(t) + "%" })); }); svg.insertBefore(axes, svg.firstChild); var dots = svg.querySelector(".ag-pt-dots"); if (!dots) { dots = h("g", { class: "ag-pt-dots" }); svg.appendChild(dots); } AG.data.forEach(function (d, i) { var c = circles[d.id]; if (!c) { c = h("circle", { class: "ag-pt-dot is-" + AG.side(d), r: r, cx: 0, cy: 0, "data-id": d.id }); c.style.transform = "translate(" + sx(0) + "px," + cy + "px)"; c.style.opacity = "0"; circles[d.id] = c; dots.appendChild(c); } c.setAttribute("r", r); var place = function () { c.style.transform = "translate(" + pos[d.id].x + "px," + (cy + pos[d.id].y) + "px)"; c.style.opacity = ""; }; if (entered) { if (landed) c.style.transitionDelay = "0s"; place(); } c.__place = place; c.__at = SWEEP * (d.pct - sorted[0].pct) / (sorted[sorted.length - 1].pct - sorted[0].pct); }); svg.__cy = cy; } function enter() { entered = true; var reduced = AG.reduced(); AG.data.forEach(function (d) { var c = circles[d.id]; c.style.transitionDelay = reduced ? "0s" : Math.round(c.__at) + "ms"; c.__place(); }); setTimeout(function () { landed = true; for (var k in circles) circles[k].style.transitionDelay = "0s"; }, reduced ? 0 : SWEEP + 950); } function select(d) { sel = d; for (var k in circles) circles[k].classList.toggle("is-on", sel && +k === sel.id); svg.classList.toggle("ag-pt-dim", !!sel); if (sel) circles[sel.id].parentNode.appendChild(circles[sel.id]); drawCard(); } function nearest(evt) { var b = svg.getBoundingClientRect(), x = evt.clientX - b.left, y = evt.clientY - b.top, best = null, bd = 22 * 22; AG.data.forEach(function (d) { var p = pos[d.id]; if (!p) return; var dd = (p.x - x) * (p.x - x) + (svg.__cy + p.y - y) * (svg.__cy + p.y - y); if (dd < bd) { bd = dd; best = d; } }); return best; } svg.addEventListener("pointermove", function (e) { if (e.pointerType === "mouse") { var d = nearest(e); if (d && d !== sel) select(d); } }); svg.addEventListener("click", function (e) { var d = nearest(e); select(d || null); }); function outside(e) { if (!document.contains(root)) return document.removeEventListener("click", outside, true); if (!sel || (e.target.closest && e.target.closest(".ag-pt-svgwrap, .ag-pt-card, .ag-pt-find"))) return; select(null); } document.addEventListener("click", outside, true); svg.addEventListener("keydown", function (e) { var i = sel ? sorted.indexOf(sel) : -1; if (e.key === "ArrowRight" || e.key === "ArrowUp") { select(sorted[Math.min(sorted.length - 1, i + 1)]); e.preventDefault(); } else if (e.key === "ArrowLeft" || e.key === "ArrowDown") { select(sorted[Math.max(0, i -1; }) : []; for (var k in circles) { var hit = match.some(function (d) { return d.id === +k; }); circles[k].classList.toggle("is-hit", hit); if (hit) circles[k].parentNode.appendChild(circles[k]); } svg.classList.toggle("ag-pt-finding", !!q); if (match.length === 1) select(match[0]); hits.innerHTML = ""; if (!q) return; if (!match.length) { hits.appendChild(AG.tx("li", "shared.noMatches", { class: "ag-pt-none" })); return; } match.slice(0, 3).forEach(function (d) { var b = h("button", { type: "button", class: "ag-pt-hit" }, [ h("span", { class: "ag-ink-m", text: d.mName }), " vs. ", h("span", { class: "ag-ink-f", text: d.fName }) ]); b.addEventListener("click", function () { select(d); }); hits.appendChild(h("li", {}, [b])); }); if (match.length > 3) hits.appendChild(AG.tx("li", "pattern.moreHits", { class: "ag-pt-none" }, { n: match.length - 3 })); } findIn.addEventListener("input", find); drawCard(); layout(); if ("ResizeObserver" in window) { var lastW = 0; new ResizeObserver(function () { if (wrap.clientWidth !== lastW) { lastW = wrap.clientWidth; layout(); } }).observe(wrap); } AG.onVisible(wrap, function () { setTimeout(enter, 120); }); }; })(); window.AG.mountAll();

King, the director of reproductive bioethics at Harvard Medical School Center for Bioethics and a contributor on the study, believes that when the RVU system was created back in the 1990s, gynecological services were largely ignored, leaving the specialty undervalued from the start. While Medicare and Medicaid Services have undertaken some efforts to make RVUs more equitable across specialties over the years, that undervaluation has persisted. 

That problem may come down to how those values are determined in the first place — and who determines them. RVUs are set by a committee of doctors convened by the American Medical Association (AMA), with most of the seats allocated to members of major medical societies. The committee surveys different doctors on the time and skill required for procedures in their specialties. Based on these responses, the committee recommends values for each service to the federal government, which has historically accepted nearly 90 percent of them.

While the data quality of the underlying surveys has improved over the years, it is still not very high, said Dr. Miriam Laugesen, a tenured associate professor of health policy and management at Columbia University Mailman School of Public Health. Because the committee’s process isn’t transparent, it is often unclear what evidence its valuations rest on. This leads to distortions of all kinds, she said.

“It’s not a government process; It’s not a federal advisory committee,” Laugesen said. “It’s just a committee that was put together by the [AMA]. It’s pretty unusual in terms of how policy is made.”

In particular, King said that the surveys have a very low response rate from some specialties and are only sent to a small subset of doctors. She has never received a committee survey in the 17 years that she has practiced. 

The American College of Obstetricians and Gynecologists (ACOG) has a core seat on the committee that determines RVUs. But most ACOG members are general OB-GYNs, who split their time between obstetrics and gynecology and typically operate relatively rarely. The surgeons who perform the bulk of gynecologic operations are subspecialists – gynecologic oncologists, urogynecologists, and minimally invasive gynecologic surgeons — who complete an additional fellowship after residency. They mainly belong to their own societies and don’t have a seat at the table when RVUs are being determined. 

“From a purely cynical or economic standpoint, [ACOG] has no reason to advance billing for gynecology. It doesn’t represent a large portion of the practices of their members,” said King, adding that ACOG has been heroic in its efforts to obtain reimbursement equity for its own members. (One unintended possible result of that advocacy is that pushing for a smaller pay gap for services related to pregnancy has in turn sent the message that women’s bodies are literally worth less, and are less deserving of care when they’re not engaged in the god-given duty of reproduction.)

The result is that doctors in specialties like OB-GYN who operate infrequently are answering the surveys about complicated surgical procedures that gynecologic surgeons perform more frequently. King said that her surgical schedule aligned more closely with those of general surgeons. For example, she operates two to three times a week whereas, according to her, an average OB-GYN will likely operate once a month. 

“So they’re not the right people to be answering these surveys. They [the survey committee and ACOG] don’t target the surveys to people who operate a lot,” she said. 

Part of the problem with using surveys to determine a key foundation of medical reimbursements is that the data is self-reported by doctors. This is especially relevant when more objective avenues may be available. One of those avenues is the American College of Surgeons’ National Surgical Quality Improvement Program, which is an initiative that collects and manages key surgical data to track quality and improvement in surgical fields, including the actual time spent performing surgical procedures, making it a more definitive measure than self-reported surveys.

Dr. Shitanshu Uppal, a gynecologic oncologist and division chief for gynecology oncology services at the University of Michigan, and his colleagues analyzed 901,917 surgeries using both the National Surgical Quality Improvement Program as well as the self-reported surveys used to determine RVUs. They found that median RVUs per hour vary widely between specialties. Gynecology had the third-lowest median RVUs per hour of all the specialties studied. In effect, that means that gynecological surgeons are paid less for every hour that they work. 

The researchers also found that compared to the operating times logged for real surgeries in the Surgical Quality Improvement Program, surgeons in certain specialties tended to report longer procedure times in the self-reported surveys sent out by the RVUs committee. Specialties that reported longer operating times were more likely to be awarded higher RVUs, leading to greater hourly rates of reimbursement.

According to Uppal’s analysis, urologists — a profession most often associated with procedures on men because their work routinely concerns the prostate and the testicles — reported times that exceeded the baseline data by a median of 20 minutes. By contrast, estimates from gynecologists only exceeded the actual time by a median of five minutes, meaning that urologists tended to overestimate their time spent in surgery by four times as many minutes. Generally, urologists earn much more than general OB-GYNs, who in turn earn more than other subspecialties like gynecologic surgery. Despite having access to reliable electronic records of operating time, Uppal and his colleagues note, the AMA committee still continues to use self-reported operating times, which influences their RVU recommendations, ultimately cementing disparities in female-specific procedures. 

“The system that they have now developed over time,” King said, “now creates discrimination because of its complexity.” She added that this is how systemic discrimination is perpetuated, even if systems or rules appear seemingly neutral.

How low reimbursement rates make women’s lives worse

The US healthcare system has never been especially good at putting its money where its mouth is when it comes to women’s health. Experts have been sounding the alarm on sex-based disparities in medical billing for a long time — long enough that governing authorities like the committee responsible for RVUs and ACOG have had time to respond to the concerns. 

Over the years, the gap between male-specific procedure reimbursements and female-specific reimbursements has decreased slightly. But researchers of the Price and Prejudice study showed that between 2003 and 2023, there were no statistically significant improvements to the pay disparities. Comparing a smaller set of procedures across 1997, 2015, and 2023, they found that the gap had narrowed only minimally.

One common justification that ACOG provides for the pay gap is that obstetrics and gynecologic services see a higher-than-average share of patients on Medicaid, which pays doctors less than other insurers. King agreed this is a real factor, but it doesn’t explain why Medicare itself values procedures on women lower in the first place. And as her account of double discrimination makes clear, undervaluing gynecology ultimately affects women everywhere for the worse.

“I have patients who are waiting for surgery with me for a year at a time. I mean, that’s crazy.”

Dr. Louise King

Lower reimbursements in gynecologic surgery disproportionately affect female surgeons because they represent a majority of this specialty. It’s not just the surgeons’ salaries that are affected. Hospitals and facilities work on a revenue-based model — if gynecologic surgeries are not bringing in enough money, institutions tend to allocate fewer resources to those procedures. That, in turn, can limit access to operating rooms, surgical staff, and operating times. 

“I have patients who are waiting for surgery with me for a year at a time. I mean, that’s crazy,” King said. As a minimally invasive gynecologic surgeon, she surgically treats women with endometriosis, fibroids, cysts, or other such conditions.

It also affects the training that gynecologic surgeons receive. When there aren’t enough resources to operate regularly, opportunities to train residents are rarer than they should be. The result is that low reimbursement rates have contributed to a workforce of low-volume gynecologic surgeons who are sometimes not as well-trained as other surgeons who operate frequently.

The relationship between volume of surgeries performed and patient outcomes is well-documented in other fields. Research shows that surgeons who operate infrequently have worse outcomes, including more complications before, after, and during surgeries, compared to surgeons who operate regularly. 

Low-volume gynecologic surgeons — who perform a particular procedure less than 12 times a year — have significantly higher rates of causing bowel and urinary tract injuries in their patients. Especially in benign gynecological surgery (procedures not related to cancer), having surgeons who operate frequently also increases the number of minimally invasive procedures performed, which is related to better patient outcomes. 

Payment reform is an uphill battle, but not a lost cause

It takes multiple years and pressure from different entities to update or add new RVUs for procedures — but crucially, it is not impossible. The first few steps to creating a sustainable system might look like submitting gynecology-related procedure codes for reevaluation to the AMA committee or prompting a congressional report on the matter. 

For example, for years there has only been one billing code for endometriosis, regardless of the complexity of surgery or technique used. This disincentivizes surgeons from taking on complicated surgical cases of endometriosis because of the low reimbursement rate. Reevaluating that rate or diversifying the various surgical approaches that different cases require would help affected women get the care they deserve.

Medicare’s payment system also has what’s called a budget neutrality rule, which dictates that significantly increased payments for any given procedure must be offset by cuts elsewhere. The AMA itself believes that reforming this rule would make it easier to work toward reimbursement equity for female-specific procedures.  

Experts have suggested creating gynecology-specific conversion factors to bring parity to a system that naturally undervalues these procedures, while others think that eliminating sex-specific billing codes whenever possible is the right move. For example, the code for genitalia biopsies is different for men and women. This means that those procedures can be reimbursed differently even though they are essentially similar. Adopting one sex-neutral code for any genitalia biopsies would avoid this. While the reform required for this would be substantial, researchers believe that it would narrow the billing gap significantly.     

Authorities often justify lower RVUs for female-specific procedures by pointing to training: Gynecologists spend fewer years learning to operate than urologists and other higher-paid surgical specialists, according to King.

Historically, surgeons who operated on the female pelvis trained in ways that were more closely aligned with general surgeons than OB-GYNs. When obstetrics and gynecology merged into one specialty in the 1900s, the training for gynecologic surgery was truncated. 

“General OB-GYNs will train for four years and of that four years about 18 months is devoted to surgical training in gynecology,” said King, contrasting the new training period to those of general surgeons, which is in years. 

She believes that training periods should be increased for gynecologic surgeons. That change would secure better reimbursement for the speciality, while also producing better trained surgeons who would be more attuned to advances in minimally invasive surgery that will ultimately improve the outcomes for their female patients. In some cases, the experience gained during a two-year fellowship in gynecologic surgery was equivalent to 19 years in practice.  

In their initial work on double discrimination, Watson and King argued that failing to implement solutions for parity is tantamount to saying that female patients deserve less well-trained surgeons than male patients.  

As with most women’s health issues, it is unclear if this systemic disparity in medical reimbursement is the result of conscious misogyny or a by-product of ignorance. But that question of origins matters little when its consequences have been enshrined in medical policy, with lasting consequences for the practice of medicine more generally. We have allowed this wage gap to persist, even as many have sounded the alarm for decades. It is long past time to heed their warnings.

October 7, 2026, 5:50 pm ET: This story was originally published on October 2 and has been updated to include the sourcing on the RVU gap resulting from training for gynecologic surgery.  

  •  

You’re supposed to get one free doctor’s visit every year. So why are so many Americans being charged?

an illustration of a woman in a doctor’s office. A doctor is waiving to her from the other side of an exam table covered in a giant bill.

After moving to West Virginia last year, Steve Kuo signed up for a new insurance plan that would cost him $500 a month. But there was one upside: He knew he was entitled to a free preventive visit. He wanted to take advantage of it, so he made an appointment at a clinic near his new home.

But then when he got there, they asked about his medical history and he mentioned prior kidney problems. When he received a bill a few weeks later, he had been charged twice for the same appointment: Once as that free preventive visit, once as an “office sick visit” because of the kidney conversation. He was flummoxed — and very annoyed, as he shared on social media. “No copayment means no copayment, exactly as stated in the insurance guidelines,” Kuo told me over email. “What is written and agreed upon should be honored.”

He is far from alone. On Reddit, I easily found more than a dozen examples in just the past year of people getting a surprise bill for what they thought was going to be a free visit. 

One woman posted a nearly $1,000 bill she’d received for what she thought was going to be a preventive gynecology visit. Another woman said that she ended up facing roughly $3,000 bills because she was given an ultrasound (which she said she didn’t request) at a preventive visit, and then her blood draw was sent to an out-of-network lab. Another person lamented that they had been billed $170 for an office visit because they had briefly mentioned back stiffness.

It’s not supposed to be like this. Americans don’t get much when it comes to our healthcare, but most of us are supposed to be entitled to at least one thing: Once every year, no matter your health insurance, you can go to the doctor with the goal of preventing future health problems by discussing important vaccinations, cancer screenings, and cardiovascular health screenings. The Affordable Care Act made that the law in 2010.

But more than 15 years later, people all over the country are walking into their doctor’s office, thinking they’re entitled to that one free visit every year, and walking out being billed for a sick visit, blood labs, and more. Researchers estimate that Americans spend tens of millions, maybe hundreds of millions of dollars every year on services that are supposed to be free under the ACA.

Dr. Yalda Jabbarpour, a family physician in the Washington, DC, area and medical director of the Robert Graham Center for Policy Studies, told me she still deals all the time with people’s confusion about what a preventive visit really means.

“Every single time I’m in the clinic, this issue comes up with a patient. And it’s sad that it comes up,” Jabbarpour told me. “In my mind, the blame is not to be put on the patient. The blame is not to be put on the physician. Really, this points to a bigger system issue that we need to solve.”

How could a seemingly simple promise of one free annual doctor’s visit result in a situation so convoluted that patients and doctors are still struggling with it nearly two decades later? And how might we fix it?

Patients are getting surprise bills from their doctors — and they’re pissed off

The goal of the ACA was to expand coverage and make sure health insurance would be comprehensive to actually help people stay healthy. As part of that project, the authors of the law added a mandate for insurers to cover those services, including an annual wellness exam. The problem is, they did not define what the parameters of that preventive visit actually were, said Alex Hoagland, a healthcare economist at the University of Toronto. 

“It didn’t establish a clear definition of…all the diagnosis codes and procedure codes and how frequently you get that combination within a year,” he said. “They don’t define what actually is preventive care and what’s not.”

Do’s and don’t’s for a preventive visit:

  • Topics that should be free to talk about: routine vaccinations, many cancer screenings, screenings for diabetes and cardiovascular health, contraception.
  • Topics that could lead to you getting charged: chronic pain, prior medical problems, other physical and mental health symptoms (including depression).
  • If you are a first-time visitor at a doctor’s office, you may also be charged a “new patient” fee.

That has left each insurer to define a preventive visit on their own — and that’s where the perverse incentives that leave patients in a lurch begin. Preventive visits are supposed to be reserved strictly for screenings and talking about other preventive measures you can take to protect your long-term health, but you may get billed for an “office visit” or a “sick visit” if you talk about any specific symptom you’re experiencing, the same as if you had come in because you had the flu. 

Health insurers have an incentive to keep the definition of preventive care as narrow as possible, so they have to pay fewer claims without any contribution from the patient. At the same time, doctors want to be paid for the actual services that they are providing. If somebody does bring up a bigger health problem during a preventive visit, then the doctor reasonably wants to be paid accordingly. 

“I know, particularly in the healthcare space, it’s really popular to blame one party or another, and here I don’t think it’s a matter of corporate greed or physician incompetence or whatever,” Hoagland said. “It’s just a natural mismatch of incentives.”

So the reality is that “one free doctor’s visit” sounds straightforward, but, in practice, it’s much more complicated. You as the patient might think of it as one visit, but in our fee-for-service healthcare system, where providers bill based on each specific thing they do, it’s not. The conversation about your vaccination may be free — but asking about your back pain is not. If you get blood tests ordered, that’s another line item. The list goes on. “It’s not like you walk into a doctor’s office and it’s just one thing that happens, right?” said Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University. “It’s multiple different things that are happening when you go into a doctor’s office.”

Part of the problem may be that it’s one free visit. We Americans are consumers at heart: Tell us we’re going to get something for free and we want to take advantage of it. But having just one free visit may also lead to people bringing a laundry list of questions to that preventive visit, because they think of it as their only chance to ask everything of their doctor. 

That makes it easy for the discussion to tip over into a sick visit — and not only does that lead to a surprise bill, it can also crowd out the conversation about prevention that the visit is supposed to be focused on.

“What ends up happening a lot…is that a patient comes in for their annual visit, and in their mind, that is their time to bring up every single thing that’s been happening during the year, because they see it as the free visit to bring up everything that’s happened during the year. For some patients, that takes up the entire visit,” Jabbarpour told me. “They leave, and it’s like, ‘Oh my god, we forgot to do all the screening things: the vaccinations, the cancer screenings, and the cardiovascular risk screening.’ And then something happens down the line because you never address those screenings.”

A 2021 study by Hoagland and Paul Shafer, both of Boston University at the time, estimated that Americans with employer-sponsored insurance had in 2018 alone paid between $75 million and $219 million in medical bills that should have been free. They were more likely to be charged for things like contraception or cholesterol and diabetes screenings, with individuals sometimes paying hundreds of dollars for those services.

Hoagland told me he had been billed for preventive visits because he has type 1 diabetes and the system automatically categorized his appointment as a diabetic visit. Earlier this year, he co-authored a study that found people with chronic conditions were more likely to be charged for preventive care. Corlette said that she too had recently been charged for what was supposed to be a preventive visit after she mentioned an issue as an aside. And these are folks who study health care for a living.

“It was literally maybe a 10-second conversation where I would ask the doctor a question about something,” she said. “And that triggered it.”

Colonoscopies are another dramatic example of how this issue plays out in real life; Corlette told me the procedure was one of the first services where this fuzzy line between prevention and treatment under the ACA became obvious. People go under for what is supposed to be a preventive colonoscopy. But then their doctor finds a polyp and decides to remove it — good clinical practice, but as a result, their patient could end up being charged thousands of dollars because the colonoscopy was no longer preventive once that polyp was snipped.

“All of a sudden, that would trigger what the patient thought was a preventive service into a cost-sharing obligation,” Corlette said. “Colonoscopies can be thousands of dollars. That was when we were first like, ‘Oh, yeah, this is a more complicated area than I think the lawmakers that drafted this provision originally envisioned.’”

How the US could fix our preventive visit headaches

The ACA’s preventive visit promise was clearly well-intentioned and it’s worth remembering that, if you look in the aggregate, more Americans are getting more free preventive care than they did before the law was passed. The problem, as much as anything, is expectations: People think they’re entitled to a free visit and are understandably frustrated when they get billed for it.

“The difference is before the Affordable Care Act, maybe they anticipated some kind of cost-sharing,” Hoagland said. “But after, they expect it to be free.”

Sign up for the Good Medicine newsletter

Our political wellness landscape has shifted: new leaders, shady science, contradictory advice, broken trust, and overwhelming systems. How is anyone supposed to make sense of it all? Vox’s senior correspondent Dylan Scott has been on the health beat for a long time, and every week, he’ll wade into sticky debates, answer fair questions, and contextualize what’s happening in American health care policy. Sign up here.

It doesn’t have to be this way. Corlette’s team at Georgetown University recently released a proposal that Americans be entitled to three primary care and two urgent care visits every year with no cost-sharing. This approach has two virtues, she told me: It will help people feel like they are actually getting value from their insurance — the very complaint that Steve Kuo raised — and, because we know primary care helps prevent problems down the road, it should also improve people’s health in the long term. Take the pressure off that one free visit and let people see the doctor a few times a year without worrying about being charged.

“In employer-based insurance, a lot of people feel like, ‘What the hell am I getting for my premium each month?’” Corlette said. “We wanted people to feel like they’re getting good value, and we wanted to get to better population health.”

Hoagland also endorsed the idea of at least one free physician’s visit every year, no matter what’s discussed. In the long term, Jabbarpour said she’d like to see copays eliminated entirely for primary care. 

But any payment reforms are not going to happen immediately. What can we do right now?

For one, doctor offices could make an effort to be as transparent as possible. Jabbarpour’s MedStar system has started calling people a couple of days before their appointment with a brief script that tells the patient that they could be charged if the conversation with their doctor touches on additional medical problems. If your doctor’s office doesn’t proactively bring it up, ask when you schedule your appointment or when they call you to confirm it. Worst-case scenario, ask your provider what they consider preventive care when your visit begins. You might also want to educate yourself on what services are generally considered preventive and should be available for free: Your insurer may make that information available on their website, or KFF has a database you can peruse.

It’s not a perfect solution. “What ends up happening is patients come in, and they say, ‘I know I’m not supposed to talk to you about anything else, so I’m not going to tell you about anything else.’ And you don’t want that to happen,” Jabbarpour said. You should ask your doctor directly: What do you consider to be preventive care? Establish boundaries at the start. That way, you can at least be aware if you are going to get charged because the conversation crossed the line to discussing an active health problem.

And if you want to see the underlying laws change, start organizing. Contact your state and federal reps and ask them what they are doing to ensure this stops happening. Things could be different: Jabbarpour said she hopes to one day work in a health system where the cost of a single primary care visit isn’t so high-stakes, where doctors and their patients can manage their health according to their particular needs, rather than worry about how to bill for one specific conversation that covers the whole range of somebody’s health — like primary care is supposed to do.

“I think some patients can be managed by seeing us once every year, once every two years, and some patients need to see us monthly,” Jabbarpour told me. “To put all patients in the same box and say you can only see your primary care physician once a year if you want it paid for, it makes zero sense.”

This story was originally published in The Highlight. To get access to member-exclusive stories like this every month, become a Vox Member today.

  •  
❌